(11) EP 1 693 448 A1

(12)

# **EUROPEAN PATENT APPLICATION**

published in accordance with Art. 158(3) EPC

(43) Date of publication: 23.08.2006 Bulletin 2006/34

(21) Application number: 03751478.3

(22) Date of filing: 14.10.2003

(51) Int Cl.:

(86) International application number: **PCT/JP2003/013123** 

(87) International publication number:
 WO 2005/035754 (21.04.2005 Gazette 2005/16)

(84) Designated Contracting States:

AT BE BG CH CY CZ DE DK EE ES FI FR GB GR
HU IE IT LI LU MC NL PT RO SE SI SK TR

(71) Applicant: CHUGAI SEIYAKU KABUSHIKI KAISHA Tokyo, 115-8543 (JP)

(72) Inventors:

 HATTORI, Kunihiro, CHUGAI SEIYAKU KABUSHIKI KAISHA Gotenba-shi, Shizuoka 412-8513 (JP)

 KOJIMA, Tetsuo, CHUGAI SEIYAKU KABUSHIKI KAISHA Gotenba-shi, Shizuoka 412-8513 (JP)

 MIYAZAKI, Taro, CHUGAI SEIYAKU KABUSHIKI KAISHA Gotenba-shi, Shizuoka 412-8513 (JP)

 SOEDA, Tetsuhiro, CHUGAI SEIYAKU KABUSHIKI KAISHA Gotenba-shi, Shizuoka 412-8513 (JP)  SENOO, Chiaki, CHUGAI SEIYAKU KABUSHIKI KAISHA Gotenba-shi, Shizuoka 412-8513 (JP)

NATORI, Osamu,
 CHUGAI SEIYAKU KABUSHIKI KAISHA
 Gotenba-shi,
 Shizuoka 412-8513 (JP)

 KASUTANI, Keiko, CHUGAI SEIYAKU KABUSHIKI KAISHA Gotenba-shi, Shizuoka 412-8513 (JP)

 ISHII, Shinya, CHUGAI SEIYAKU KABUSHIKI KAISHA Gotenba-shi, Shizuoka 412-8513 (JP)

(74) Representative: Vossius & Partner Siebertstrasse 4 81675 München (DE)

## (54) DOUBLE SPECIFIC ANTIBODIES SUBSTITUTING FOR FUNCTIONAL PROTEIN

(57) The present inventors succeeded in separating bispecific antibodies that functionally substitute for ligands of type I interferon receptors comprising two types of molecules: AR1 chain and AR2 chain. Furthermore, the present inventors succeeded in producing bispecific antibodies that substitute for the enzyme reaction-accel-

erating function of blood coagulation factor VIII/activated blood coagulation factor VIII, which bind to both blood coagulation factor IX/activated blood coagulation factor IX and blood coagulation factor X.

### Description

### Technical Field

[0001] The present invention relates to bispecific antibodies that substitute for functional proteins. More specifically, the present invention relates to bispecific antibodies that functionally substitute for ligands of hetero-receptors, bispecific antibodies that substitute for the cofactors which enhance enzymatic reaction, and pharmaceutical compositions comprising the antibodies as an active ingredient.

## Background Art

30

35

40

45

50

55

[0002] Antibodies have received much attention as a medicine because of their high stability in blood and low antigenicity. Of these are bispecific antibodies that can simultaneously recognize two types of antigens. Bispecific antibodies have been proposed for some time; however, only antibodies that simply connect two types of antigens, such as those for retargeting NK cells, macrophages, and T cells (see Non-Patent Document 8), have been reported. For example, MDX-210, which is currently under clinical study, is a bispecific antibody that merely retargets FcγRI-expressing monocytes and such to HER-2/neu-expressing cancer cells. Thus, so far there are no examples that utilize a bispecific antibody as an alternative means to substitute for an *in vivo* functional protein.

**[0003]** One example of an *in vivo* functional protein is the ligand of a receptor. Examples of such ligands are interleukin (IL)-2, 3, 4, 5, 6, 7, 9, 10, 11, 12, 13, and 15, erythropoietin (EPO), growth hormone (GH), granulocyte colony-stimulating factor (G-CSF), thrombopoietin (TPO), granulocyte-macrophage colony-stimulating factor (GM-CSF), interferon (IFN- $\alpha$ , IFN- $\beta$ , IFN- $\gamma$  etc.), ciliary neurotrophic factor (CNTF), leukemia inhibitory factor (LIF), Oncostatin M, Cardiotrophin-1 (CT-1), and tumor necrosis factor (TNF).

**[0004]** In these receptors, it is thought that the distance and/or angle of the receptor molecules forming dimers or multimers change upon ligand binding, thus enabling these receptors to transmit signals into cells. In other words, a suitable anti-receptor antibody may become an antibody that can mimic ligand-mediated receptor dimerization or multimerization.

**[0005]** Monoclonal antibodies that show a ligand-substituting effect towards homodimer-comprising TPO receptors (MPL) (see Patent Document 1 and Non-Patent Document 1), EPO receptors, and GH receptors have already been reported. Respectively, these antibodies are thought to have an effect of recovering thrombocyte count at the time of thrombopenia, an effect of increasing red blood cell count at the time of anemia, and a growth-enhancing effect on dwarfism. Thus, their applications in medicine are expected.

**[0006]** However, in the case of a heterodimer-forming receptor, which requires the formation of a complex of two or several types of receptor molecules, its ligand function cannot be expected to be substituted by general antibodies. The above-mentioned bispecific antibodies which can recognize two types of receptor molecules with their two arms are thought to be suitable for this purpose, however, no reports have been made.

**[0007]** Another example of an *in vivo* functional protein is a cofactor. Examples of cofactors are tissue factor (TF), blood coagulation factor V (F.V), activated blood coagulation factor V (F.Va), blood coagulation factor VIII (F.VIII), activated blood coagulation factor VIII (F.VIIIa), thrombomodulin (TM), protein S (PS), protein Z (PZ), heparin, complement C4b, complement regulatory factor H, membrane cofactor protein (MCP), and complement receptor 1 (CR1).

**[0008]** Of these, F.VIII/F.VIIIa is a cofactor required for sufficient activity expression of F.IXa. Scheiflinger F. *et al.* discovered that a certain anti-F.IX/F.IXa antibody acts to promote the activation of F.X by F.IXa in a chromogenic assay (see Patent Document 2). However, in an assay that examines the ability for coagulation recovery in F.VIII-deficient plasma, the coagulation recovery ability was observed only when F.IXa was added exogenously, but not if this antibody was used alone.

**[0009]** F.VIIIa has been known to interact not only with F.IXa but also with F.X (see Non-Patent Documents 6 and 7). In this respect, the antibody of Scheiflinger F. *et al.* cannot be said to sufficiently substitute for the function of F.VIII/F.VIIIa, and its activity also seems to be insufficient.

**[0010]** Through dedicated research, the present inventors succeeded in producing bispecific antibodies that substitute for the effect of functional proteins, and thereby completed this invention.

(Patent Document 1) U.S. Patent Application No. 98/17364
(Patent Document 2) WO 01/19992
(Patent Document 3) U.S. Patent No. 4, 474,893
(Patent Document 4) EP 404,097
(Patent Document 5) WO 93/11161
(Patent Document 6) Japanese Patent Application No. 2002-112369
(Patent Document 7) Japanese Patent Application No. 2003-012648

```
(Patent Document 8) Japanese Patent Application Kokai Publication No. (JP-A) H5-304992
          (Patent Document 9) JP-A H2-145187
          (Patent Document 10) JP-A H5-213775
          (Patent Document 11) JP-A H10-165184
5
          (Patent Document 12) JP-A H11-71288
          (Patent Document 13) Japanese Patent Kohyo Publication No. (JP-A) 2002-518041
          (Patent Document 14) JP-A H11-506310
          (Patent Document 15) JP-A H5-199894
          (Patent Document 16) JP-A H10-511085
10
          (Patent Document 17) JP-A H5-184383
          (Non-Patent Document 1) Deng D et al., "Blood", 1998, Vol.92, No.6, p.1981-1988
          (Non-Patent Document 2) Nilsson IM et al., "J. Intern. Med.", 1992 Vol.235, p.25-32
          (Non-Patent Document 3) Löfqvist T et al., "J. Intern. Med.", 1997 Vol.241, p.395-400
          (Non-Patent Document 4) 24th Meeting of The Japanese Society on Thrombosis and Hematosis, Special Committee
15
          on Examining Hemophilia Standardization, Mini-symposium, 2001, http://www.jsth.org
          (Non-Patent Document 5) Bulletin #193 1994
          (Non-Patent Document 6) Mertens K et al., "Thromb. Haemost.", 1999, Vol.82, p.209-217
          (Non-Patent Document 7) Lapan KA et al., "Thromb. Haemost.", 1998, Vol.80, p.418-422
          (Non-Patent Document 8) Segal DM et al., "Journal of Immunological Methods", 2001, Vol.248, p. 1-6
20
          (Non-Patent Document 9) Bos R and Nieuwenhuitzen W, "Hybridoma", 1992, Vol. 11, No. 1, p.41-51
          (Non-Patent Document 10) Brennan M et al., "Science", 1985, Vol.229, No.1708, p.81-3
          (Non-Patent Document 11) Karpovsky B et al., "J. Exp. Med.", 1984, Vol. 160, No.6, p.1686-701
          (Non-Patent Document 12) Suresh MR et al., "Methods Enzymol.", 1986, Vol.121, p. 210-28
          (Non-Patent Document 13) Massimo YS et al., "J. Immunol. Methods", 1997, Vol.201, p.57-66 (Non-Patent Document
25
          14) Brennan M et al., "Science", 1985, Vol.229, p. 81
          (Non-Patent Document 15) Shalaby MR et al., "J. Exp. Med.", 1992, Vol.175, p.217-25
          (Non-Patent Document 16) Holliner P et al., "Proc. Natl. Acad. Sci. USA", 1993, Vol.90, p. 6444-8
          (Non-Patent Document 17) Ridgway JB et al., "Protein Eng.", 1996, Vol.9, p. 617-21
          (Non-Patent Document 18) Hammerling U et al., "J. Exp. Med.", 1968, Vol.128, p.1461-73
30
          (Non-Patent Document 19) Kurokawa T et al., "Bio/Technology", 1989, Vol.7, p.1163
          (Non-Patent Document 20) Link BK et al., "Blood", 1993, Vol.81, p.3343
          (Non-Patent Document 21) Nitta T et al., "Lancet", 1990, Vol.335, p.368-71
          (Non-Patent Document 22) deLeij L et al., "Foundation Nationale de Transfusion Sanguine, Les Ulis France", 1990,
35
          (Non-Patent Document 23) Le Doussal JM et al., "J. Nucl. Med.", 1993, Vol.34, p. 1662-71
          (Non-Patent Document 24) Stickney DR et al., "Cancer Res.", 1991, Vol.51, p.6650-5
          (Non-Patent Document 25) Weiner LM et al., "Cancer Res.", 1993, Vol.53, p.94-100
          (Non-Patent Document 26) Kroesen BJ et al., "Br. J. Cancer", 1994, Vol.70, p.652-61
          (Non-Patent Document 27) Weiner GJ et al., "J. Immunol.", 1994, Vol. 152, p.23 85
40
          (Non-Patent Document 28) Suresh MR et al., "Proc. Natl. Acad. Sci. USA", 1986, Vol.83, p.7989-93
          (Non-Patent Document 29) Milstein C and Cuello AC et al., "Nature", 1983, Vol.305, p.537
          (Non-Patent Document 30) Xiang J et al., "Mol. Immunol.", 1990, Vol.27, p.809
          (Non-Patent Document 31) Bebbington CR et al., "Bio/Technology", 1992, Vol.10, p. 169
          (Non-Patent Document 32) Huse WD et al., "Science", 1989, Vol. 246, p.1275
45
          (Non-Patent Document 33) McCafferty J et al., "Nature", 1990, Vol.348, p.552
          (Non-Patent Document 34) Kang AS et al., "Proc. Natl. Acad. Sci. USA", 1991, Vol.88, p. 4363
```

#### Disclosure of the Invention

- [0011] An objective of the present invention is to provide bispecific antibodies that substitute for the effect of functional proteins. More specifically, the present invention aims to provide bispecific antibodies that functionally substitute for ligands of receptors comprising heteroreceptor molecules and bispecific antibodies that functionally substitute for the cofactors which enhance enzymatic reaction.
  - **[0012]** Through dedicated research, the present inventors succeeded in separating antibodies that functionally substitute for ligands of a type I interferon receptor which comprises two types of molecules: AR1-chain and AR2-chain. In other words, for the first time, the present inventors successfully separated bispecific antibodies that can functionally substitute for ligands of heteromolecule-comprising receptors.
  - [0013] Through dedicated research, the present inventors succeeded in discovering bispecific antibodies that specif-

ically bind to both F.IX/F.IXa and F.X, and substitute for the effect of cofactor F.VIIIa (i.e., a function to promote F.X activation by F.IXa). That is, the present inventors succeeded in producing bispecific antibodies that recognize both an enzyme and its substrate and functionally substitute for cofactors of the enzyme.

**[0014]** The above-mentioned ligand proteins of heteromolecular receptors and the above-mentioned enzyme cofactors are both functional proteins. Indeed, the present inventors have developed for the first time bispecific antibodies that functionally substitute for functional proteins.

**[0015]** The present invention relates to bispecific antibodies that substitute for functional proteins. More specifically, the present invention relates to bispecific antibodies that have an effect of substituting for the ligand function of heteromolecule-comprising receptors, and bispecific antibodies which functionally substitute for cofactors that enhance enzymatic reactions. More specifically, the present invention provides:

[1] A bispecific antibody that substitutes for the effect of a functional protein.

10

15

20

25

30

35

40

45

50

- [2] A bispecific antibody that has an activity of functionally substituting for a ligand of a heteromolecule-comprising receptor.
- [3] The antibody according to [2], wherein said heteromolecule-comprising receptor is a dimer.
- [4] The antibody according to [2], wherein said receptor is a cytokine receptor.
- [5] The antibody according to [4], wherein said cytokine receptor is an interferon receptor.
- [6] The antibody according to [5], wherein said interferon receptor is a type I interferon receptor.
- [7] The antibody according to [6], wherein said type I interferon receptor comprises an AR1 chain and an AR2 chain.
- [8] The antibody according to [7], wherein said antibody functionally substitutes for an interferon which is a ligand of a type I interferon receptor.
- [9] The antibody according to [8], wherein said antibody comprises the variable region of an anti-AR1 chain antibody and the variable region of an anti-AR2 chain antibody.
- [10] The antibody according to [9], wherein said antibody comprises an anti-AR1 chain antibody variable region comprising the amino acid sequence of (a) below and an anti-AR2 chain antibody variable region comprising the amino acid sequence of any of the following (b1) to (b10):
  - (a) the H chain variable region amino acid sequence described in SEQ ID NO: 1 and the L chain variable region amino acid sequence described in SEQ ID NO:2;
  - (b1) the H chain variable region amino acid sequence described in SEQ ID NO: 7 and the L chain variable region amino acid sequence described in SEQ ID NO: 8;
  - (b2) the H chain variable region amino acid sequence described in SEQ ID NO: 9 and the L chain variable region amino acid sequence described in SEQ ID NO: 10;
  - (b3) the H chain variable region amino acid sequence described in SEQ ID NO: 19 and the L chain variable region amino acid sequence described in SEQ ID NO: 20;
  - (b4) the H chain variable region amino acid sequence described in SEQ ID NO: 13 and the L chain variable region amino acid sequence described in SEQ ID NO: 14;
  - (b5) the H chain variable region amino acid sequence described in SEQ ID NO: 23 and the L chain variable region amino acid sequence described in SEQ ID NO: 24;
  - (b6) the H chain variable region amino acid sequence described in SEQ ID NO: 5 and the L chain variable region amino acid sequence described in SEQ ID NO: 6;
  - (b7) the H chain variable region amino acid sequence described in SEQ ID NO: 17 and the L chain variable region amino acid sequence described in SEQ ID NO: 18;
  - (b8) the H chain variable region amino acid sequence described in SEQ ID NO: 15 and the L chain variable region amino acid sequence described in SEQ ID NO: 16;
  - (b9) the H chain variable region amino acid sequence described in SEQ ID NO: 21 and the L chain variable region amino acid sequence described in SEQ ID NO: 22;
  - (b10) the H chain variable region amino acid sequence described in SEQ ID NO: 11 and the L chain variable region amino acid sequence described in SEQ ID NO: 12.
- [11] The antibody according to [9], wherein said antibody comprises an anti-AR1 chain antibody variable region comprising the amino acid sequence of (a) below or an anti-AR2 chain antibody variable region comprising the amino acid sequence of any of the following (b1) to (b3):
  - (a) the H chain variable region amino acid sequence described in SEQ ID NO: 3 and the L chain variable region amino acid sequence described in SEQ ID NO: 4;
  - (b1) the H chain variable region amino acid sequence described in SEQ ID NO: 25 and the L chain variable region amino acid sequence described in SEQ ID NO: 26;

- (b2) the H chain variable region amino acid sequence described in SEQ ID NO: 9 and the L chain variable region amino acid sequence described in SEQ ID NO: 10;
- (b3) the H chain variable region amino acid sequence described in SEQ ID NO: 21 and the L chain variable region amino acid sequence described in SEQ ID NO: 22.
- [12] A composition comprising the antibody according to any one of [2] to [11] and a pharmaceutically acceptable carrier.
- [13] The composition according to [12], wherein said composition is a pharmaceutical composition used for preventing and/or treating viral disease, malignant neoplasm, or immune disease.
- [14] The composition according to [13], wherein said viral disease is a disease that arises and/or progresses as a result of hepatitis C virus infection.
- [15] The composition according to [14], wherein the disease that arises and/or progresses as a result of hepatitis C virus infection is acute or chronic hepatitis C, cirrhosis, or liver cancer.
- [16] The composition according to [13], wherein said viral disease is a disease that arises and/or progresses as a result of hepatitis B virus infection.
- [17] The composition according to [16], wherein the disease that arises and/or progresses as a result of hepatitis B virus infection is acute or chronic hepatitis B, cirrhosis, or liver cancer.
- [18] The composition according to [13], wherein the malignant neoplasm is chronic myelocytic leukemia, malignant melanoma, multiple myeloma, renal cancer, gliosarcoma, medulloblastoma, astrocytoma, hairy cell leukemia, AIDS-related Kaposi's sarcoma, skin T lymphoma, or non-Hodgkin's lymphoma.
- [19] The composition according to [13], wherein the immune disease is multiple sclerosis.

5

10

15

20

25

30

35

40

45

- [20] A method for preventing and/or treating viral disease, malignant neoplasm, or immune disease, comprising the step of administering the antibody according to any one of [2] to [11], or the composition according to any one of [12] to [19].
- [21] Use of the antibody according to any one of [2] to [11] for producing the composition according to any one of [12] to [19].
- [22] A kit used in the method of preventing and/or treating diseases according to [20], wherein said kit comprises at least the antibody according to any one of [2] to [11], or the composition according to [12].
- [23] An antibody recognizing both an enzyme and a substrate thereof, wherein said antibody is a bispecific antibody which functionally substitutes for a cofactor that enhances the enzymatic reaction.
- [24] The antibody according to [23], wherein said enzyme is a proteolytic enzyme.
- [25] The antibody according to [24], wherein said proteolytic enzyme, substrate, and cofactor are blood coagulation/fibrinolysis associated factors.
- [26] The antibody according to [25], wherein the enzyme of a blood coagulation/fibrinolysis associated factor is blood coagulation factor IX and/or activated blood coagulation factor IX; the substrate is blood coagulation factor X; and the cofactor is blood coagulation factor VIII and/or activated blood coagulation factor VIII.
- [27] The antibody according to any one of [23] to [26], wherein said antibody comprises a complementarity determining region comprising the amino acid sequence of anti-blood coagulation factor IX/IXa antibody CDR3 of the following (a1) or (a2) or a complementarity determining region functionally equivalent thereto, and a complementarity determining region comprising the amino acid sequence of anti-blood coagulation factor X antibody CDR3 described in any one of the following (b1) to (b9) or a complementarity determining region functionally equivalent thereto:
  - (a1) H chain CDR3 amino acid sequence described in SEQ ID NO: 42;
  - (a2) H chain CDR3 amino acid sequence described in SEQ ID NO: 46;
  - (b1) H chain CDR3 amino acid sequence described in SEQ ID NO: 50;
  - (b2) H chain CDR3 amino acid sequence described in SEQ ID NO: 54;
  - (b3) H chain CDR3 amino acid sequence described in SEQ ID NO: 58;
  - (b4) H chain CDR3 amino acid sequence described in SEQ ID NO: 62;
  - (b5) H chain CDR3 amino acid sequence described in SEQ ID NO: 66;
  - (b6) H chain CDR3 amino acid sequence described in SEQ ID NO: 70;
  - (b7) H chain CDR3 amino acid sequence described in SEQ ID NO: 74;
  - (b8) H chain CDR3 amino acid sequence described in SEQ ID NO: 78;
  - (b9) H chain CDR3 amino acid sequence described in SEQ ID NO: 82.
- [28] The antibody according to any one of [23] to [26], wherein said antibody comprises a complementarity determining region comprising the amino acid sequences of anti-blood coagulation factor IX/IXa antibody CDR of the following (a1) or (a2) or a complementarity determining region functionally equivalent thereto, and a complementarity determining region comprising the amino acid sequence of anti-blood coagulation factor X antibody CDR described in

any one of the following (b1) to (b9) or a complementarity determining region functionally equivalent thereto:

5

10

15

20

25

35

45

50

```
(a1) H chain CDR 1,2, and 3 amino acid sequences described in SEQ ID NOs: 40,41, and 42, respectively; (a2) H chain CDR 1, 2, and 3 amino acid sequences described in SEQ ID NOs: 44, 45, and 46, respectively; (b1) H chain CDR 1, 2, and 3 amino acid sequences described in SEQ ID NOs: 48, 49, and 50, respectively; (b2) H chain CDR 1, 2, and 3 amino acid sequences described in SEQ ID NOs: 52, 53, and 54, respectively; (b3) H chain CDR 1, 2, and 3 amino acid sequences described in SEQ ID NOs: 56, 57, and 58, respectively; (b4) H chain CDR 1, 2, and 3 amino acid sequences described in SEQ ID NOs: 60, 61, and 62, respectively; (b5) H chain CDR 1, 2, and 3 amino acid sequences described in SEQ ID NOs: 64, 65, and 66, respectively; (b6) H chain CDR 1, 2, and 3 amino acid sequences described in SEQ ID NOs: 68, 69, and 70, respectively; (b7) H chain CDR 1, 2, and 3 amino acid sequences described in SEQ ID NOs: 72, 73, and 74, respectively; (b8) H chain CDR 1, 2, and 3 amino acid sequences described in SEQ ID NOs: 76, 77, and 78, respectively; (b9) H chain CDR 1, 2, and 3 amino acid sequences described in SEQ ID NOs: 80, 81, and 82; respectively.
```

- [29] A composition comprising the antibody according to any one of [23] to [28] and a pharmaceutically acceptable carrier.
- [30] The composition according to [29], wherein said composition is a pharmaceutical composition used for preventing and/or treating bleeding, disorder accompanied by bleeding, or disorder caused by bleeding.
- [31] The composition according to [30], wherein the bleeding, disorder accompanied by bleeding, or disorder caused by bleeding is a disorder that arises and/or progresses as a result of an activity decrease or deficiency of blood coagulation factor VIII and/or activated blood coagulation factor VIII.
  - [32] The composition according to [31], wherein the disorder that arises and/or progresses as a result of an activity decrease or deficiency of blood coagulation factor VIII and/or activated blood coagulation factor VIII is hemophilia A. [33] The composition according to [31], wherein the disorder that arises and/or progresses as a result of an activity decrease or deficiency of blood coagulation factor VIII and/or activated blood coagulation factor VIII is a disorder in which an inhibitor against blood coagulation factor VIII and/or activated blood coagulation factor VIII is generated. [34] The composition according to [31], wherein the disorder that arises and/or progresses as a result of an activity decrease or deficiency of blood coagulation factor VIII and/or activated blood coagulation factor VIII is acquired hemophilia.
- [35] The composition according to [31], wherein the disorder that arises and/or progresses as a result of an activity decrease of blood coagulation factor VIII and/or activated blood coagulation factor VIII is von Willerbrand's disease. [36] A method for preventing and/or treating bleeding, disorder accompanied by bleeding, or disorder caused by bleeding, wherein said method comprises the step of administering the antibody according to any one of [23] to [28], or the composition according to any one of [29] to [35].
  - [37] Use of the antibody according to any one of [23] to [28] for preparing the composition according to any one of [29] to [35].
    - [38] A kit used in the method of preventing and/or treating disorders according to [36], wherein said kit comprises at least the antibody according to any one of [23] to [28] or the composition according to [29].
- [0016] A bispecific antibody according to the present invention is a molecule comprising two types of antibodies or antibody fragments having specificities for different antigens. The bispecific antibody is not particularly limited, but preferably monoclonal.
  - **[0017]** The bispecific antibodies of the present invention are preferably recombinant antibodies generated using gene recombination techniques (see e.g. Borrebaeck CAK and Larrick JW, THERAPEUTIC MONOCLONAL ANTIBODIES, Published in the United Kingdom by MACMILLAN PUBLISHERS LTD, 1990). A recombinant antibody can be obtained by cloning an antibody-encoding DNA from antibody-producing cells, such as hybridomas or sensitized lymphocytes, incorporating the DNA into an appropriate vector, and introducing the vector into a host for antibody production.
  - **[0018]** Further, antibodies of the present invention may be antibody fragments or modified antibodies. Antibody fragments may include diabody (Db), linear antibody, single-strand antibody (hereinafter also referred to as scFv) molecules, etc. Herein, "Fv" fragment represents the smallest antibody fragment, comprising a complete antigen-recognizing site and binding site. An "Fv" fragment is a dimer ( $V_H$ - $V_L$  dimer) in which one heavy (H) chain variable region ( $V_H$ ) and one light (L) chain variable region ( $V_L$ ) are strongly connected by a non-covalent bond. Three complementarity determining region (CDRs) of each variable region interact to form an antigen-binding site on the surface of a  $V_H$ - $V_L$  dimer. Six CDRs confer an antigen-binding site on an antibody. However, even one variable region (or half of an Fv, which contains only three antigen specific CDRs) is capable of recognizing an antigen and binding thereto, although its affinity is lower than that of the entire binding site.
  - [0019] In addition, Fab fragment (also referred to as (F(ab)) further contains an L chain constant region and an H chain constant region (CH1). A Fab' fragment differs from a Fab fragment in that the former contains several additional residues

derived from the carboxyl terminal of an H chain CH1 region, which comprises one or more cysteines from the hinge region of an antibody. Fab'-SH refers to Fab' having a free thiol group in one or more cysteine residues of the constant region. F(ab') fragments are generated by cleaving the disulfide bond in the cysteines of the hinge portion of an F(ab')<sub>2</sub> pepsin digest. Other chemically bound antibody fragments are also known to those skilled in the art.

**[0020]** Diabody refers to a bivalent antibody fragment constructed by gene fusion (Holliger P *et al.*, Proc. Natl. Acad. Sci. USA 90: 6444-6448 (1993); EP 404,097; WO 93/11161; etc.). Diabody is a dimer comprising two peptide chains; in each polypeptide chain, an L chain variable region ( $V_L$ ) is connected to an H chain variable region ( $V_H$ ) on the same chain via a linker that is too short to allow paring between the two regions (for example, about 5 residues).  $V_L$  and  $V_H$  encoded on the same polypeptide chain form a dimer because they cannot form a single-stranded variable region fragment due to the short linker between them. Thus, a diabody ends up with two antigen binding sites.

**[0021]** A single-strand antibody or scFv fragment contains the  $V_H$  and  $V_L$  regions of an antibody, and these regions exist in a single polypeptide chain. In general, an Fv polypeptide further contains a polypeptide linker between  $V_H$  and  $V_L$  regions, such that scFv is able to form a structure that is necessary for antigen binding (see Pluckthun "The Pharmacology of Monoclonal Antibodies" Vol. 113 (Rosenburg and Moore ed (Springer Verlag, New York) pp. 269-315, 1994 for general remarks on scFv). The linkers of the present invention are not particularly limited, as long as they do not inhibit expression of the antibody variable regions connected to both ends of a linker.

[0022] An IgG type bispecific antibody can be secreted by a hybrid hybridoma (quadroma) formed by fusing two types of hybridomas that produce IgG antibodies (Milstein C *et al.*, Nature 1983, 305: 537-540). It can also be secreted by introducing into cells genes of the L chains and H chains that constitute the two IgGs of interest (a total of four types of genes) for co-expression. In this case, by appropriately substituting amino acid(s) in the CH3 region of an H chain, it is possible to preferentially secrete IgGs that have a heterologous combination of H chains (Ridgway, JB *et al.* Protein Engineering 1996, 9: 617-621, Merchant, AM *et al.* Nature Biotechnology 1998, 16: 677-681).

**[0023]** A bispecific antibody can also be prepared by chemically cross-linking Fab's. A bispecific  $F(ab')_2$  can be produced, for example, by maleimidating a Fab' prepared from one antibody with o-PDM (ortho-phenylenedi-maleimide) and reacting the product with a Fab' prepared from another antibody, so as to cross-link Fab's derived from different antibodies (Keler T *et al.* Cancer Research 1997, 57: 4008-4014). Further, a method for chemically connecting antibody fragments such as a Fab'-thionitrobenzoic acid (TNB) derivative and Fab'-thiol (SH) is also known (Brennan M *et al.* Science 1985, 229: 81-83).

[0024] Instead of cross linkage, a leucine zipper derived from Fos and Jun or the like can be used. Although Fos and Jun also form a homodimer, their preferential heterodimer formation is utilized. A Fab' added with a Fos leucine zipper and a second Fab' added with a Jun leucine zipper is expressed for preparation. By mixing and reacting monomeric Fab'-Fos and Fab'-Jun, which have been reduced under mild conditions, a bispecific  $F(ab')_2$  can be formed (Kostelny SA *et al.* J. of Immunology, 1992, 148: 1547-53). This method is not limited to Fab' and can also be applied to scFv, Fv, etc. [0025] A bispecific antibody can also be prepared in a form of diabody. A bispecific diabody is a heterodimer comprising two crossover scFv fragments. That is, a bispecific diabody can be prepared by constructing a heterodimer using  $V_H$  (A)- $V_L$ (B) and  $V_H$ (B)- $V_L$ (A), which have been formed by connecting  $V_H$  and  $V_L$  derived from two types of antibodies: A and B, with a relatively short linker of about 5 amino acid residues (Holliger P *et al.* Proc. of the National Academy of Sciences of the USA 1993, 90: 6444-6448).

30

35

40

45

[0026] In this case, construction of a bispecific diabody of interest can be promoted by performing appropriate amino acid substitutions (knobs-into-holes: Zhu Z *et al.* Protein Science. 1997, 6: 781-788) so as to link two types of scFv's with a flexible and relatively long linker of about 15 amino acid residues (a single-chain diabody: Kipriyanov SM *et al.* J. of Molecular Biology. 1999, 293: 41-56).

[0027] sc(Fv)<sub>2</sub> which can be prepared by linking two types of scFv's with a flexible and relatively long linker of about 15 amino acid residues can also become a bispecific antibody (Mallender WD *et al.* J. of Biological Chemistry, 1994, 269: 199-206).

**[0028]** A modified antibody may be, for example, an antibody that binds to various molecules such as polyethylene glycol (PEG). In the modified antibodies of the present invention, substances to be bound are not limited. Such modified antibodies can be obtained by chemically modifying the antibodies obtained. These methods have already been established in this field.

[0029] The antibodies of the present invention include human antibody, mouse antibody, rat antibody and such, without any limitation on their origins, and may be genetically modified antibodies such as chimera antibody and humanized antibody.

**[0030]** Methods for obtaining human antibodies are known, and a human antibody of interest can be obtained, for example, by immunizing a transgenic animal having all repertoires of human antibody genes with an antigen of interest (see WO 93/12227, WO 92/03918, WO 94/02602, WO 94/25585, WO 96/34096, WO 96/33735).

[0031] Genetically modified antibodies can be produced by known methods. Specifically, for example, a chimera antibody comprises variable regions from the H and L chains of an antibody from immunized animals, and constant regions from the H and L chains of a human antibody. A chimera antibody can be obtained by linking a DNA encoding

the variable region of an antibody derived from immunized animals with a DNA encoding the constant region of a human antibody, inserting the resulting DNA into an expression vector, and introducing the recombinant vector into a host for production.

**[0032]** A humanized antibody is a modified antibody also referred to as reshaped human antibody. A humanized antibody is constructed by grafting the complementarity determining region (CDR) of an antibody derived from immunized animals into the CDR of a human antibody. General genetic engineering technologies are also known.

[0033] Specifically, a DNA sequence designed to link the CDR of a mouse antibody to the framework region (FR) of a human antibody is synthesized by PCR, using several oligonucleotides that have been prepared to contain overlapping portions at their terminal regions. After linking the obtained DNA to a DNA encoding the constant region of a human antibody, the resulting DNA is incorporated into an expression vector and introduced into a host to produce a humanized antibody (see EP 239400 and WO 96/02576). As a human antibody FR to be linked via CDR, one that is capable of forming an antigen-binding site with a good complementarity determining region is selected. Amino acids of the framework region in an antibody variable region may be substituted as necessary, so that the complementarity determining region of a reshaped human antibody forms an appropriate antigen-binding site (Sato K *et al*, Cancer Research 1993, 53: 851-856). The framework region may be substituted with framework regions derived from various human antibodies (see WO 99/51743).

10

20

30

40

45

50

55

**[0034]** The present invention provides bispecific antibodies that functionally substitute for functional proteins, more preferably, bispecific antibodies that functionally substitute for functional proteins. A preferred embodiment of the antibodies of the present invention is an antibody that has an activity to functionally substitute for heteromolecule-comprising receptors.

[0035] In the present invention, heteromolecule-comprising receptors refer to receptors (multimer) composed of two or more different proteins (receptor molecules). Multimers are not limited by the number of proteins (receptor molecules) and include dimers, trimers, tetramers, etc., but are preferably dimers. For example, in the case of a dimer receptor, a heteroreceptor indicates that the two constitutional proteins (receptor molecule) are not identical.

**[0036]** Antibodies having an activity to functionally substitute for ligands refer to antibodies that have an agonistic action against certain receptors. In general, when a ligand (i.e., an agonist) binds to a receptor, the tertiary structure of the receptor protein changes and the receptor is activated (in the case of a membrane protein receptor, cell proliferation signals and such are usually emitted). When the receptor type is one that forms a dimer, antibodies that functionally substitute for the ligand can work similarly to a ligand by dimerizing the receptor at an appropriate distance and angle. In other words, anti-receptor antibodies can mimic ligand-induced dimerization of receptors, and become antibodies that functionally substitute for ligands.

[0037] In a preferred embodiment of the present invention, the receptor of the present invention is a cytokine heteroreceptor.

**[0038]** The term "cytokine" is normally used as a collective term to refer to bioactive proteins that regulate the proliferation and differentiation of various types of hemocytes. It is also used to refer to growth factors and growth inhibitory factors of cells including non-immune cells. Therefore, the term "cytokine" collectively refers to cell-released proteinaceous factors that mediate cell-cell interactions such as regulation of immunoreaction and inflammatory response, antiviral actions, antitumor actions, and regulation of cell proliferation and/or differentiation.

**[0039]** Specific examples of cytokines that act on heteroreceptors of the present invention include IL-2, 3, 4, 5, 6, 7, 9, 10, 11, 12, 13, and 15, colony-stimulating factors (GM-CSF, etc.), interferons (IFN- $\alpha$ , IFN- $\beta$ , IFN- $\gamma$ , etc.), CNTF, LIF, Oncostatin M, CT-1, and such, but are preferably interferons, especially type I interferons.

[0040] Interferons include IFN- $\alpha$ , IFN- $\beta$ , IFN- $\gamma$ , IFN- $\tau$ , etc. IFN- $\alpha$  and IFN- $\beta$  are highly homologous and thus, these two IFNs can react via a same receptor. Furthermore, IFN- $\alpha$ , IFN- $\beta$ , and IFN- $\tau$  are classified as type I interferon.

[0041] Examples of type I interferon receptors include receptors having an AR1 chain (GenBank ACCESSION No: J03171, literature: Uze G *et al.* Cell 1990, 60: 225-34) and an AR2 chain (GenBank ACCESSION No: U29584, literature: Domanski P *et al.* J of Biological Chemistry 1995, 270: 21606-11, LutfaUa G *et al.* EMBO J 1995, 14: 5100-8).

[0042] The method for obtaining bispecific antibodies that functionally substitute for ligands of the present invention are not particularly limited, and may be obtained by any method. For example, to obtain a bispecific antibody that functionally substitutes for a ligand of a heteroreceptor comprising two types of receptor molecules (A chain and B chain), anti-A chain antibody and anti-B chain antibody are first obtained. Subsequently, a bispecific antibody comprising the H chain and L chain of the anti-A chain antibody, and the H chain and L chain of anti-B chain antibody is produced. Preferably, multiple types of anti-A chain antibodies and anti-B chain antibodies are obtained to produce as many combinations of bispecific antibodies as possible. Bispecific antibodies are produced, and then those that have an activity to functionally substitute for ligands are selected. Bispecific antibodies may be produced by known methods such as fusion of antibody-producing hybridomas, or introduction of antibody expressing vectors into cells.

**[0043]** Antibodies against receptors may be obtained by methods known to a person skilled in the art. For example, antibodies may be prepared by immunizing immune animals with antigens. Antigens that are used for animal immunization include complete antigens having immunogenicity, and incomplete antigens lacking immunogenicity (including haptens).

In the present invention, a receptor whose ligand is functionally substituted by an antibody of the present invention presumed to act as the ligand is used as an antigen (immunogen) mentioned above. The above-mentioned receptor of the present invention is not particularly limited, but is preferably a heterodimer. For example, mice, hamsters, or rhesus monkeys may be used as an immune animal. These animals may be immunized with antigens by a person skilled in the art, using well known methods. In the present invention, variable regions of the L chain and H chain are preferably recovered from immunized animals, or cells of the animals. This process may be carried out by methods generally known to a person skilled in the art. Animals immunized with an antigen express antibodies against the antigen, especially in their spleen cells. For example, mRNAs may be prepared from spleen cells of the immunized animals, and the L chain and H chain variable regions may be recovered by RT-PCR using primers that correspond to the variable region of the animal.

10

20

30

35

40

45

50

55

[0044] Specifically, the A chain and B chain are each used to immunize an animal. Receptors used as the immunogen may be a whole protein constituting a receptor, or a partial peptide of the protein. Further, the immunogen used for animal immunization may be made into a soluble immunogen by binding an antigenic molecule, or fragments thereof, with other molecules. When transmembrane molecules, such as receptors, are used as an antigen, it is preferable to use their fragments (for example, extracellular region of a receptor). Cells expressing a transmembrane molecule on their cell surface may also be used as an antigen. Such cells may be naturally occurring cells (tumor cell lines etc.) or cells constituted by genetic recombination techniques to express transmembrane molecules. mRNAs are extracted from spleen cells of an immunized animal, and cDNAs of the L chain and H chain variable regions are recovered by RT-PCR using primers corresponding to regions in the vicinity of the variable regions. Primers corresponding to CDR, primers corresponding to framework regions which are less diversified than CDR, or primers corresponding to signal sequences and CH1 or L chain constant region ( $C_1$ ) may also be used. Lymphocytes may be immunized in vitro and used to construct scFv- or Fab-presenting libraries. Clones of antigen-bound antibodies are concentrated by panning and cloned, and antibody expression vectors are produced using their variable regions. Anti-A chain antibody expression vector and anti-B chain antibody expression vector are introduced into a same cell, and by expressing the antibodies, a bispecific antibody is obtained. In this case, screening may be performed using similar mRNA libraries derived from human peripheral blood mononuclear cells, spleen, tonsil and such, or those of unimmunized animals.

[0045] Antibodies that have an activity to functionally substitute for ligands may be selected, for example, by the following methods.

- (1) Add an antibody to a culture of cells that proliferate in a ligand-dependent manner, check whether or not the cells proliferate as in the case of ligand addition, and use it as an indicator. If the cells proliferate, the subject multispecific antibody is judged to have an effect of functionally substituting for the ligand.
- (2) Add an antibody to the culture of a cell line that reflects the original activity of a ligand (but not necessarily proliferation), check whether or not the cells react to the added antibody the same way as to the ligand and use it as an indicator. If the cells react the same way as how they react to the ligand, the antibody is judged to have an effect of functionally substituting for the ligand.

[0046] The above cells normally express on their cell surface heteroreceptors against which antibodies can act as agonists, and the receptors bind to ligands to emit signals. Cells used in the above method are preferably cells that can proliferate dependently on receptor ligands (ligand-dependent proliferating cells). Normally, the above receptors are preferably those that emit cell proliferation signals by binding to a ligand. However, if the above receptor is one that does not emit cell proliferation signals, the receptor can be fused with a type of receptor that emits cell proliferation signals to form a so-called chimeric receptor, for use in the above methods. The chimeric receptor emits cell proliferation signals by binding with a ligand. Receptors that are suitable for the construction of chimeric receptors by fusing with a receptor are not particularly limited as long as they are a type of receptor that emits cell proliferation signals. They are normally membrane proteins, and preferably, receptors comprising a receptor fragment with a ligand-binding function (extracellular region), and a receptor fragment with a signal transduction function (intracellular region). Receptors used for the intracellular region are specifically GH receptor, G-CSF receptor, MPL, EPO receptor, c-Kit, Flt-3 IL-2 receptor, IL-3 receptor, IL-5 receptor, GM-CSF receptor and such. Specifically, suitable examples of the above ligand-dependent proliferating cells of the present invention include, ligand-dependent proliferating cell Ba/F3, which expresses chimeric receptors in which the extracellular region is a ligand receptor fragment and the intracellular region is a G-CSF receptor fragment. Examples of cells that can be used in the above methods include, for example, NFS60, FDC-P1, FDC-P2, CTLL-2, DA-1, and KT-3.

**[0047]** The antibodies thus obtained may be purified to homogeneity. Separation and purification of antibodies may be performed by separation and purification methods used for general proteins. Without being limited thereto, antibodies can be separated and purified by, for example, arbitrarily selecting and combining chromatography columns such as affinity chromatography, filters, ultrafiltration, salt precipitation, dialysis, SDS polyacrylamide gel electrophoresis, and isoelectric focusing (Antibodies: A Laboratory Manual. Ed Harlow and David Lane, Cold Spring Harbor Laboratory, 1988).

Columns used for affinity chromatography include protein A column, protein G column and such.

[0048] When the antibody of the present invention is, for example, an antibody that has an effect of functionally substituting for a ligand of a type I interferon receptor comprising an AR1 chain and an AR2 chain, the antibody preferably has a structure comprising the variable region of an anti-AR1 chain antibody and the variable region of an anti-AR2 chain antibody. An antibody that functionally substitutes for interferon was produced by the following method. IL-3 dependent mouse proB cell line Ba/F3, which expresses a chimeric receptor comprising the intracellular region of G-CSF receptor and the extracellular region of either of the receptor molecules (AR1 chain and AR2 chain) of the type I interferon receptor, was established. BALB/c was intraperitoneally immunized with either of the cells.

[0049] PolyA(+)RNA was extracted from the spleen of an immunized mouse with an elevated antibody titer, scFv was synthesized by RT-PCR, and an scFv presenting phage library was constructed. After mixing a phage library derived from the spleen of an AR1 chain-expressing Ba/F3 immunized mouse and biotinylated soluble AR1 chain, bound phages were concentrated by a panning method, which captures the phages by streptavidin magnetic beads. Phages presenting the anti-AR1 chain antibody were selected by ELISA using soluble AR1 chain. Similarly, anti-AR2 chain antibody phages were selected using soluble AR2 chain and library phages derived from the spleen of an AR2 chain-expressing Ba/F3 immunized mouse. Antibodies comprising a different amino acid sequence for the H chain CDR3, which is thought to be most involved in antibody specificity, were selected.

[0050] An scFv-CH1-Fc expression vector was produced by inserting scFv between a signal sequence for animal cells and CH1-hinge-CH2-CH3. Anti-AR1 chain antibodies and anti-AR2 chain antibodies were introduced into cells in various combinations for the expression of bispecific antibodies.

[0051] BaF3-ARG was established by introducing into Ba/F3, expression vectors of chimeric molecules comprising the extracellular region of AR1 chain or AR2 chain and the intracellular region of G-CSF receptor. These cells proliferated IFN- $\alpha$  dependently. Bispecific antibodies comprising an antibody combination that could support BaF3-ARG proliferation were selected.

**[0052]** Daudi cells are a human B-cell line that is highly sensitive to cell growth inhibition activity by IFN- $\alpha$ . The earlier selected bispecific antibodies were added to Daudi cells and confirmed to inhibit proliferation like IFN- $\alpha$ . The antibodies are not particularly limited and include, for example, antibodies comprising either of the following anti-AR1 chain antibody variable regions, or one of the following anti-AR2 chain antibody variable regions.

- Variable regions of anti-AR1 chain antibody: AR1-41, AR1-24

15

30

35

40

45

50

55

- Variable regions of anti-AR2 chain antibody: AR2-37, AR2-11, AR2-13, AR2-45, AR2-22, AR2-43, AR2-40, AR2-14, AR2-44, AR2-33, and AR2-31

**[0053]** Amino acid sequences of the  $V_H$  and  $V_L$  for each of the above-mentioned variable regions are shown in SEQ ID NOs: 1 to 26 (correlation between the variable regions  $V_H$  and  $V_L$  and the SEQ ID NOs: is shown in Table 1 below).

Table 1

Variable region	SEQ II	NO:
	V <sub>H</sub>	V <sub>L</sub>
AR1-41	1	2
AR1-24	3	4
AR2-37	5	6
AR2-11	7	8
AR2-13	9	10
AR2-45	11	12
AR2-22	13	14
AR2-43	15	16
AR2-40	17	18
AR2-14	19	20
AR2-44	21	22
AR2-33	23	24
AR2-31	25	26

[0054] When the anti-AR1 chain antibody is AR1-24, its partner anti-AR2 chain antibody is preferably AR2-13, AR2-31, or AR2-44, and when the anti-AR1 chain antibody is AR1-41, its partner anti-AR2 chain antibody is preferably AR2-11, AR2-13, AR2-14, AR2-22, AR2-33, AR2-37, AR2-40, AR2-43, AR2-44, or AR2-45. AR2-13 and AR2-44 can become a partner for both AR1-41 and AR1-24 antibodies. The present invention also includes antibodies that form pairs as shown above.

[0055] A preferred embodiment of a bispecific antibody that functionally substitutes for a functional protein of the present invention is a bispecific antibody that functionally substitutes for a cofactor that recognizes both an enzyme and its substrate.

[0056] Cofactors of the present invention are not particularly limited, as long as they are capable of acting on an enzyme to enhance the enzymatic reaction. A cofactor of the present invention is, for example, a cofactor of a proteolytic enzyme. Specific examples of a cofactor of a proteolytic enzyme are cofactors for blood coagulation and fibrinolysis associated factors (F.VIII/F.VIIIa, PZ, TM, TM/PS system), cofactors for complement reactions (C4b, MCP, CR1, H factor), and such.

[0057] The following combinations can be listed as specific examples of enzyme and enzyme substrate, as well as enzyme cofactors.

(a) Cofactor for blood coagulation and fibrinolysis associated factor (Example 1)

## [0058]

20

30

35

40

15

Enzyme: F.IXa Substrate: F.X

Cofactor: F.VIII/F.VIIIa

[0059] Cofactor F.VIIIa binds to both F.IXa and F.X and enhances F.X activation by F.IXa. Among bispecific antibodies that recognize both the above-described enzyme F.IXa and substrate F.X, some have an enhancing effect on F.X activation. Some of these antibodies are thought to have an effect of substituting for the function of cofactor F.VIII/F.VIIIa.

(b) Cofactor for blood coagulation and fibrinolysis associated factor (Example 2)

[0060]

Enzyme: ZPI Substrate: F.X/F.Xa Cofactor: PZ

[0061] Cofactor PZ binds to ZPI of the serpin family and F.Xa to enhance the F.Xa-inhibiting activity of ZPI. Specifically, some bispecific antibodies that recognize both ZPI and F.X/F.Xa are thought to have an effect of substituting for the PZ function.

(c) Cofactor for blood coagulation and fibrinolysis associated factor (Example 3)

#### [0062]

45 Enzyme: thrombinSubstrate: TAFICofactor: TM

**[0063]** Cofactor TM enhances TAFI activation by thrombin. Specifically, some bispecific antibodies that recognize both thrombin and TAFI are thought to have an effect of substituting for the TM function.

(d) Cofactors for blood coagulation and fibrinolysis associated factor (Example 4)

## [0064]

55

50

Enzyme: thrombin Substrate: PC Cofactors: TM/PS

[0065] The TM/PS system enhances PC activation by thrombin. Specifically, some bispecific antibodies that recognize both thrombin and PC are thought to functionally substitute for the TM/PS system.

(e) Cofactor for complement reactions (Example 1)

[0066]

5

30

40

45

50

55

Enzyme: C1s Substrate: C2 Cofactor: C4b

[0067] C4b has C1s' promoting effect on C2 decomposition. That is, among the bispecific antibodies that recognize both C1s and C3, some are thought to functionally substitute for C4b.

(f) Cofactors for complement reactions (Example 2)

## [0068]

Enzyme: Complement Regulatory Factor I

20 Substrate: C3b

Cofactors: Complement Regulatory Factor H,

Membrane Cofactor Protein (MCP), and

Complement Receptor 1 (CR1)

[0069] Complement Regulatory Factors H, MCP, and CR1 have the promoting effect of Complement Regulatory Factor 1 on C3b degradation. Specifically, among bispecific antibodies that recognize both Complement Regulatory Factor 1 and C3b, some are thought to functionally substitute for Complement Regulatory Factors H, MCP, and CR1.

**[0070]** Among the above-described cofactors, F.VIII/F.VIIIa is particularly preferable. Although F.VIII/F.VIIIa undergoes limited proteolysis by proteolytic enzymes such as thrombin, as long as it has F.VIII/F.VIIIa activity, its form does not matter. Further, F.VIII/F.VIIIa variants and F.VIII/F.VIIIa that have been artificially modified by gene recombination techniques are also included in F.VIII/F.VIIIa, as long as they retain F.VIII/F.VIIIa cofactor activity.

[0071] Methods for obtaining bispecific antibodies which functionally substitute for cofactors of the present invention are not particularly limited, and may be obtained by any methods. For example, when obtaining a bispecific antibody that functionally substitutes for enzyme A and substrate B, enzyme A and substrate B are each immunized to an animal to obtain anti-enzyme A antibody and anti-substrate B antibody. Subsequently, a bispecific antibody comprising the anti-enzyme A antibody H and L chains and the anti-substrate B antibody H and L chains is produced. Herein, it is desirable to obtain several types of each of the anti-enzyme A antibody and the anti-substrate B antibody, such that these antibodies can be preferably used to produce as many combinations of bispecific antibodies as possible. After bispecific antibodies are produced, antibodies with an activity that substitutes for cofactor function are selected.

[0072] Antibodies against an enzyme or a substrate can be obtained by methods known to those skilled in the art. For example, antibodies can be prepared by immunizing animals with antigens. Antigens for immunizing animals are, for example, complete antigens having immunogenicity and incomplete antigens (including hapten) without immunogenicity. In the present invention, an enzyme whose cofactor can be functionally substituted by an antibody of the present invention which acts as the cofactor, or a substrate of the enzyme, is used as the above-described antigen (immunogen). As animals to be immunized, for example, mouse, hamster, or rhesus monkey can be used. Immunization of these animals with antigens can be performed by methods known to those skilled in the art. In the present invention, antibody L chain and H chain variable regions are preferably collected from immunized animals or cells thereof. This procedure can be performed by one skilled in the art by using generally known methods. Antigen-immunized animals express antibodies against the antigen, especially in the spleen cells. Therefore, for example, mRNA can be prepared from spleen cells of an immunized animal, and variable regions of the L chain and H chain can be recovered by RT-PCR using primers to the animal's variable regions.

**[0073]** Specifically, animals are immunized with an enzyme or a substrate. The enzyme and substrate used as immunogens may be whole proteins or partial peptides thereof. Further, depending on the circumstances, a candidate antigen bound to another molecule to form a soluble antigen, or fragments of which, may be used as an immunogen for immunizing animals.

[0074] mRNA is extracted from the spleen cells of immunized animals, and cDNAs of the L chain and H chain variable regions are recovered by RT-PCR, using primers to the vicinity of the variable regions. Primers to CDR, primers to framework regions which are less diversified than CDR, or primers to signal sequences and CH1 or L chain constant

region ( $C_L$ ) may also be used. Further, lymphocytes can also be immunized *in vitro*, and used to construct scFv or Fab presenting libraries. Antigen-binding antibody clones are concentrated and cloned by panning, and their variable regions are used to produce antibody expression vectors. By introducing an anti-enzyme antibody expression vector and an anti-substrate antibody expression vector into a same cell and expressing the antibodies, a bispecific antibody can be obtained. In this case, screening can also be performed using similar libraries constructed from mRNAs derived from the peripheral blood monocytes, spleen, tonsil and such of human and non-immunized animals as materials.

[0075] Antibodies that have a cofactor function-substituting activity can be selected, for example, by the methods described below.

10

15

20

30

35

40

45

50

55

- (1) In a reaction system comprising the enzyme and the substrate, the selection is performed using elevation of enzyme activity (substrate degradation ability) as an index, wherein the elevation of enzyme activity is a result of antibody addition.
- (2) In a system for measuring or simulating the biological functions which the enzyme, substrate, and cofactor are involved in (for example, a system for measuring plasma coagulation), the selection is performed using activity of functional recovery as an index, wherein the activity of functional recovery is a result of antibody addition in the absence of the cofactor.

[0076] The antibody thus obtained can be purified to homogeneity. Separation and purification of the antibody may be performed by separation and purification methods used for general proteins. For example, antibodies can be separated and purified by appropriately selecting and combining chromatography columns such as affinity chromatography, filter, ultrafiltration, salting out, dialysis, SDS polyacrylamide gel electrophoresis, isoelectric electrophoresis and so on (Antibodies: A Laboratory Manual. Ed Harlow and David Lane, Cold Spring Harbor Laboratory, 1988), but the methods are not limited thereto. A column used in affinity chromatography is, for example, protein A column, protein G column and such. [0077] For example, when F.VIII/F.VIIIa is the substitute cofactor, that is, when the enzyme and substrate combination is plasma coagulation and fibrinolysis associated factors F.IXa and F.X, the bispecific antibody of the present invention preferably has a structure comprising the variable region of an anti-F.IXa antibody and the variable region of an anti-F.X antibody.

[0078] Bispecific antibodies of the present invention which functionally substitute for F.VIII/F.VIIIa were generated by the following method. Mice were subcutaneously immunized with commercial F.IXa or F.X. Spleen cells were isolated from spleens of the immunized mice with an elevated antibody titer, and fused with mouse myeloma cells to form hybridomas. Hybridomas that bind to antigen F.IXa or F.X were selected, and the L chain and H chain variable regions were recovered by RT-PCR, using primers to the variable regions. The L chain variable region was incorporated into a C<sub>L</sub>-containing L chain expression vector, and the H chain variable region was inserted into an H chain expression vector containing an H chain constant region.

[0079] The anti-F.IXa antibody (H chain, L chain) expression vectors and anti-F.X antibody (H chain, L chain) expression vectors were introduced into same cells for antibody expression and bispecific antibodies were obtained.

**[0080]** Bispecific antibodies thus obtained were assessed for their effects to functionally substitute for F.VIII/F.VIIIa (cofactors for F.X activation by F.IXa) in an assay system comprising F.XIa (F.IX activating enzyme), F.IX (F.X activating enzyme), F.X, a synthetic substrate (S-2222) for F.Xa, and phospholipid. Given this result, bispecific antibodies having the activity to substitute for F.VIII/F.VIIIa were selected.

**[0081]** The bispecific antibodies selected above were measured for their ability to restore coagulation in a coagulation assay system (APTT) that uses human F.VIII-deficient plasma. The results confirmed that bispecific antibodies which have the ability to restore coagulation in human F.VIII-deficient plasma were obtained.

[0082] The H chain CDR3s of the present invention's antibodies are not particularly limited, but specifically have a complementarity determining region comprising either the amino acid sequence of the XB12 H chain CDR3 sequence (SEQ ID NO: 42) or the XT04 H chain CDR3 sequence (SEQ ID NO: 46) described below in the examples, or those functionally equivalent thereto, and the complementarity determining region comprising an amino acid sequence described in any one of the H chain CDR3 sequences (SEQ ID NOs: 50, 54, 58, 62, 66, 70, 74, 78, and 82) in SB04, SB05, SB06, SB07, SB21, SB30, SB34, SB38, and SB42, respectively, or those functionally equivalent thereto.

[0083] Further, a specific example of the above-described antibodies is preferably combined from an antibody having a complementarity determining region comprising either an H chain CDR sequence of XB12 (SEQ ID NOs: 40-42) or an H chain CDR sequence of XT04 (SEQ ID NOs: 44-46), or a complementarity determining region functionally equivalent thereto, and an antibody having a complementarity determining region comprising any one of the H chain CDR sequences (SEQ ID NOs: 48-50, 52-54, 56-58, 60-62, 64-66, 68-70, 72-74, 76-78, or 80-82) in SB04, SB05, SB06, SB07, SB21, SB30, SB34, SB38, and SB42, respectively, or a complementarity determining region functionally equivalent thereto.

**[0084]** The amino acid sequences of the H chain variable regions of XB 12, XT04, SB04, SB05, SB06, SB07, SB21, SB30, SB34, SB38, and SB42 disclosed in the present invention are shown as SEQ ID NOs: 39, 43, 47, 51, 55, 59, 63, 67, 71, 75, and 79.

[0085] When preparing a full-length antibody using the variable regions disclosed in the present invention, the constant regions are not particularly limited, and those known to one skilled in the art, for example, constant regions described in "Sequences of proteins of immunological interest, (1991), U.S. Department of Health and Human Services. Public Health Service National Institutes of Health" and "An efficient route to human bispecific IgG, (1998). Nature Biotechnology vol. 16, 677-681", and such can be used.

**[0086]** In one embodiment of the antibodies of the present invention, the antibody of the present invention is expected to, through its ligand function-substituting effect, become an effective drug against diseases caused by a decrease in the activity (function) of the receptor on which the antibody acts.

**[0087]** When the ligand for which the antibody of the present invention functionally substitutes is IFN- $\alpha/\beta$ , the above diseases include, for example, viral diseases, malignant neoplasms, and immune diseases.

[0088] Viral diseases include, for example, diseases that arise and/or progress via hepatitis C virus, and more specifically, acute hepatitis C, chronic hepatitis C, cirrhosis, liver cancer and such.

[0089] Chronic hepatitis C is a chronic inflammatory disease caused by host immune response against hepatitis C virus-infected cells. As the symptoms progress, liver function gradually decreases and through cirrhosis, leads to liver cancer at the end. In order to eliminate hepatitis C virus from chronic hepatitis C patients, interferon- $\alpha/\beta$  therapy is carried out. However, due to their short half life in blood, daily administration is required and thus places a considerably heavy burden on the patient. Therefore, drugs which have the interferon- $\alpha/\beta$  effect and an outstanding sustainability are in demand.

[0090] Other examples of viral diseases include diseases that arise and/or progress via hepatitis B virus, and more specifically, acute hepatitis B, chronic hepatitis B, cirrhosis, liver cancer and such.

**[0091]** Examples of malignant neoplasms include chronic myelocytic leukemia, malignant melanoma, multiple myeloma, renal cancer, gliosarcoma, medulloblastoma, astrocytoma, hairy cell leukemia, AIDS related Kaposi's sarcoma, skin T lymphoma, and non Hodgkin's lymphoma.

[0092] An example of an immune disease is multiple sclerosis.

30

35

40

45

50

55

[0093] In other embodiments, the antibodies of the present invention have an effect to functionally substitute for cofactors, and are thus expected to become effective drugs for diseases caused by decrease in the activity (function) of these cofactors. In cases where the cofactor functionally substituted by an antibody of the present invention is a blood coagulation and fibrinolysis-associated factor, the above-described diseases are, for example, bleeding, diseases accompanied by bleeding, diseases caused by bleeding, and such. In particular, functional reduction and deficiency in F.VIII/F.VIIIa, F.IX/F.IXa, and F.XI/F.XIa have been known to cause abnormal hemorrhage referred to as hemophilia.

[0094] Of the hemophilias, abnormal hemorrhage due to congenital hypofunction of F.VIII/F.VIIIa or deficiency in F.VIII/F.VIIIa is referred to as hemophilia A. When hemophilia A patient bleeds, replacement therapy with a F.VIII formulation is performed. In addition, preventive administration of a F.VIII formulation may be performed (see Non-Patent Documents 2 and 3) on the day of vigorous exercise or on field trip, when frequent intra-articular bleeding occurs, or when the patient is classified as severe hemophilia. Since this preventive administration of F.VIII formulation remarkably reduces hemorrhage episodes of patients with hemophilia A, it has recently become widely popular. Reduction of bleeding episodes not only reduces lethal and nonlethal bleeding risks and the accompanying agony, but also prevents hemophilic arthropathy caused by frequent intra-articular hemorrhage. As a result, it greatly contributes to the improvement of hemophilia A patients' QOL.

[0095] The half life of a F.VIII formulation in blood stream is as short as about 12 to 16 hours. Therefore, for continuous prevention, it is necessary to administer an F.VIII formulation about three times a week. This is equivalent to maintaining approximately 1 % F.VIII activity or more (see Non-Patent Documents 4 and 5). Also, in replacement therapies for bleeding event, it is necessary to periodically administer booster F.VIII formulations for a certain period of time, except when the bleeding is mild, in order to prevent rebleeding and establish complete hemostasis.

**[0096]** Further, F.VIII formulations are intravenously administered. There are technical difficulties in performing intravenous administration, and it becomes even more difficult particularly when performing administration on young patients whose veins are thin.

**[0097]** In the above-described preventive administration of F.VIII formulation and emergency administration thereof in cases of bleeding event, home treatment and self injection are used in most cases. The need for frequent administration and the technical difficulties involved not only inflict pain on patients, but also become a reason that hinders home treatment and self-injection from becoming popular.

[0098] Accordingly, there have been strong demands for, as compared to current blood coagulation Factor VIII formulations, drugs that have longer administration intervals and drugs that can be easily administered.

**[0099]** Further, anti-F.VIII antibodies which are referred to as inhibitors may be generated in hemophilia A patients, particularly in severe hemophilia A patients. If an inhibitor is generated, effects of F.VIII formulation become hindered by the inhibitor. As a result, hemostasis control becomes very difficult for patients.

[0100] When such hemophilia A inhibitor patient bleeds, neutralization therapy using a mass dose of F.VIII formulation, or bypass therapy using a complex concentrate or F.VIIa formulation is usually performed. However, in neutralization

therapy, administration of a mass dose of F.VIII formulation may adversely enhance the inhibitor (anti-F.VIII antibody) titer. Additionally, in bypass therapy, the relatively short half-lives (about 2 to 8 hours) of complex concentrates and the F.VIIa formulation are becoming problematic. Furthermore, since their action mechanisms are independent of the F.VIII/F.VIIIa function, that is, a function to catalyze the activation of F.X by F.IXa, hemostatic mechanism may not function well and become nonresponsive. Therefore, in many cases of hemophilia A inhibitor patients, sufficient hemostatic effects are not obtained when compared to hemophilia A non-inhibitor patients,.

[0101] Therefore, there have been strong demands for drugs that are unaffected by the presence of inhibitors and which can functionally substitute for F.VIII/F.VIIIa.

10

20

30

35

40

45

50

[0102] In addition to hemophilia and acquired hemophilia caused by anti-F.VIII autoantibody, von Willebrand's disease, which is caused by functional abnormality or deficiency of vWF, has been known as an abnormal bleeding disorder associated with F.VIII/F.VIIIa. vWF is necessary not only for the normal adhesion of platelets to subendothelial tissues at sites of vessel wall damage, but also for the formation of complexes with F.VIII to maintain a normal plasma F.VIII level. In patients with von Willebrand's disease, these functions decline and functional abnormality of hemostasis occurs. [0103] In the above-described respects, methods that utilize antibodies may be considered for creation of drugs that (i) have long administration intervals, (ii) are easily administered and (iii) are unaffected by the presence of inhibitors, and (iv) can functionally substitute for F.VIII/F.VIIIa in a F.VIII/F.VIIIa-independent manner. Generally, the half-lives of antibodies in blood stream are relatively long - from several days to several weeks. Further, antibodies are known to migrate into the blood stream after subcutaneous administration. That is, antibody drugs meet the above-described requirements of (i) and (ii).

[0104] Other embodiments of the present invention's functional proteins include proteins that control multiple different physiological functions by binding to two types of proteins having different physiological functions. Suitable examples include C4b binding protein (C4bp) which binds to fourth component of complement (C4b) and protein S (PS). C4bp not only dissociates C2b from the C4b-C2b complex, but also acts to eliminate the aPC cofactor activity of PS. Therefore, C4bp shows regulatory effects towards the complement system and blood coagulation system. Bispecific antibodies against C4b and PS are thought to have an effect of substituting for the C4bp function. Further, C4bp acts as a cofactor in C4b decomposition by the I Factor. Therefore, bispecific antibodies against the I Factor and C4b are also considered to have an effect of substituting for the C4bp function.

[0105] The present invention provides pharmaceutical compositions comprising an antibody of the present invention as an active ingredient. For example, when an antibody of the present invention is an antibody that has an activity of functionally substituting for interferons against cytokine receptors, the antibody is thought to have cytokine-mimetic effects. Therefore, the antibody is expected to become a pharmaceutical (pharmaceutical composition) or drug with an antiviral effect, antitumor effect, and cell growth and/or differentiation regulating effect. On the other hand, an antibody that functionally substitutes for IL-2 is expected to become a pharmaceutical (pharmaceutical composition) or drug with adjuvanticity and/or an anti-tumor effect by differentiation and/or activation of T cells or NK cells; an antibody that functionally substitutes for IL-3 is expected to become a pharmaceutical (pharmaceutical composition) or drug with an effect of promoting hemocyte recovery by proliferation of hemopoietic precursor cells; an antibody that functionally substitutes for IL-4 is expected to become a pharmaceutical (pharmaceutical composition) or drug with an anti-allergic effect by Th2 induction (humoral immunity); an antibody that functionally substitutes for IL-5 is expected to become a pharmaceutical (pharmaceutical composition) or drug with adjuvanticity and/or an anti-tumor effect by B cell induction and/or eosinophil proliferation and/or differentiation; an antibody that functionally substitutes for IL-6 is expected to become a pharmaceutical (pharmaceutical composition) or drug with an effect of stimulating platelet production; an antibody that functionally substitutes for IL-7 is expected to become a pharmaceutical (pharmaceutical composition) or drug with adjuvanticity and/or an anti-tumor effect by proliferation of T cells and/or B cells; an antibody that functionally substitutes for IL-9 is expected to become a pharmaceutical (pharmaceutical composition) or drug with an effect of promoting hemocyte recovery by proliferation and/or hematopoiesis of mast cells; an antibody that functionally substitutes for IL-10 is expected to become a pharmaceutical (pharmaceutical composition) or drug with an immunosuppressive effect; an antibody that functionally substitutes for IL-11 is expected to become a pharmaceutical (pharmaceutical composition) or drug with an effect of stimulating platelet production; an antibody that functionally substitutes for IL-12 is expected to become a pharmaceutical (pharmaceutical composition) or drug with adjuvanticity and/or an anti-tumor effect by Th1 induction (cellular immunity); an antibody that functionally substitutes for IL-15 is expected to become a pharmaceutical (pharmaceutical composition) or drug with adjuvanticity and/or an anti-tumor effect by the activation of NK cells; an antibody that functionally substitutes for GM-CSF is expected to become a pharmaceutical (pharmaceutical composition) or drug with an effect of promoting leukocyte recovery after chemotherapy or bone marrow transplantation; an antibody that functionally substitutes for CNTF is expected to become a pharmaceutical (pharmaceutical composition) or drug with an anti-obesity effect; an antibody that functionally substitutes for LIF is expected to become a pharmaceutical (pharmaceutical composition) or drug with an effect of stimulating platelet production and/or an effect of decreasing blood cholesterol; an antibody that functionally substitutes for Oncostatin M is expected to become a pharmaceutical (pharmaceutical composition) or drug with a hematopoiesis accelerating effect; and an antibody that functionally sub-

stitutes for CT-1 is expected to become a pharmaceutical (pharmaceutical composition) or drug with a cardiac muscle protective effect.

**[0106]** Further, when the antibody of the present invention is one of the antibodies that recognize both F.IX or F.IXa and F.X, and can functionally substitute for F.VIIIa, the antibody is expected to become a pharmaceutical (pharmaceutical composition) or drug for preventing or treating bleeding, disorders accompanied by bleeding, or disorders caused by bleeding.

**[0107]** At the same time, it is expected that an antibody that binds to ZPI and F.X and functionally substitutes for PZ becomes a pharmaceutical (pharmaceutical composition) or drug with anti-thrombotic action; an antibody that binds to thrombin and TAFI and functionally substitutes for TM becomes a pharmaceutical (pharmaceutical composition) or drug with hemostasis-promoting action; and a pharmaceutical (pharmaceutical composition) or drug that binds to thrombin and PC and has an effect of functionally substituting for PS/TM system.

**[0108]** In addition, since complement C4 deficiency causes systemic lupus erythematosus (SLE), an antibody that functionally substitutes for C4b is expected to become a pharmaceutical (pharmaceutical composition) or drug with an effect that suppresses SLE occurrence. Since H factor deficiency causes suppurative infection and autoimmune glomerulonephritis, an antibody that functionally substitutes for H factor is expected to become a pharmaceutical (pharmaceutical composition) or drug with an effect of suppressing the onset of these diseases.

[0109] Since C4bp deficiency causes Behcet's disease, an antibody that substitutes for the C4bp function is expected to become a pharmaceutical (pharmaceutical composition) or drug with an effect of suppressing the onset of Behcet's disease

20

30

35

40

45

50

55

[0110] For formulation of pharmaceuticals, pharmaceutical compositions comprising an antibody of the present invention used for treatment or prevention as an active ingredient may be mixed with an appropriate pharmaceutically acceptable carrier, medium and such that are inert thereto, if needed. For example, sterile water or physiological saline, stabilizer, excipient, antioxidant (ascorbic acid etc.), buffer (phosphoric acid, citric acid, other organic acids, etc.), antiseptic, surfactant (PEG, Tween, etc.), chelating agent (EDTA, etc.), binding agent and such can be cited. Pharmaceutical compositions may also contain other low molecular weight polypeptides, proteins such as serum albumin, gelatin, and immunoglobulin, amino acids such as glycine, glutamine, asparagine, arginine, and lysine, sugars such as polysaccharide and monasaccharide and carbohydrates, and sugar alcohols such as mannitol and sorbitol. When preparing aqueous solutions for injection, for example, solubilizing agents include physiological saline, isotonic solutions containing glucose and other adjunctive agents such as D-sorbitol, D-mannose, D-mannitol, and sodium chloride, and may be used in combination with appropriate solubilizing agents such as alcohol (ethanol etc.), polyalcohol (propylene glycol, PEG etc.), and non-ionic surfactant (polysorbate 80, HCO-50 etc.).

**[0111]** Further, if necessary, antibodies of the present invention may be encapsulated into microcapsules (microcapsules made of hydroxymethyl cellulose, gelatin, poly(methyl methacrylate), etc.), or included in a colloidal drug delivery system (liposome, albumin microsphere, microemulsion, nanoparticle, and nanocapsule, etc.) (see "Remington's Pharmaceutical Science 16th edition", Oslo Ed. (1980) etc.). Methods for formulating sustained-release drugs are also known, and can be applied to antibodies of the present invention (Langer *et al., J.*Biomed.Mater.Res. 15: 267-277 (1981); Langer, Chemtech. 12: 98-105 (1982); U.S. Patent No: 3,773,919; European Patent Application No (EP): 58,481; Sidman *et al., Biopolymers* 22: 547-556 (1983); EP133,988).

[0112] Although the dosage of the pharmaceutical compositions of the present invention is appropriately determined considering the type of formulation, method of administration, age and body weight of patients, symptoms of patients, type and progress of disease, etc, and ultimately by doctors, generally, doses of 0.1-2000 mg/day can be divided into one to several oral administrations for adults. The dosage is preferably 1 to 1000 mg/day, more preferably 5 to 500 mg/day, and most preferably 100 to 300 mg/day. Although the dosage varies according to the body weight and age of patients, administration methods and such, one skilled in the art can suitably select an appropriate dosage. Preferably, the dosing period is also appropriately determined according to, for example, the healing process of patients.

[0113] Further, it is also possible to perform gene therapy by inserting a gene encoding an antibody of the present invention into gene therapy vectors. As an administration method apart from direct administration of naked plasmids, the genes may be administered by packaging into liposome and such, or insertion into various virus vectors such as retrovirus vectors, adenovirus vectors, vaccinia virus vectors, pox virus vectors, adeno-associated virus vectors, and HVJ vectors (see Adolph "Virus Genome Method" CRC Press, Florid (1996)), or by coating onto carrier beads such as colloidal gold particle (WO93/17706 etc.). However, the gene may be administered by any methods, as long as the antibody can be expressed *in vivo* to exert its action. Preferably, a sufficient dose is administered through an appropriate parenteral route, such as intravenous, intraperitoneal, subcutaneous, intracutaneous, intra-adipose tissue, intramammary, and intramuscular injection and infusion, inhalation, gas-inducible particle bombardment method (with an electron gun and such), or mucosal route using nasal drop. Genes encoding an antibody of the present invention may be administered by introducing the gene into blood cells, cells derived from bone marrow and such, using *ex vivo* liposome transfection, particle bombardment method (U.S. Patent No. 4,945,050) or virus infection, and re-introducing these cells into animals.

**[0114]** The present invention also provides methods for preventing and/or treating bleeding, disorders accompanied by bleeding, or disorders caused by bleeding, comprising the steps of administering an antibody or composition of this invention. Antibodies or compositions can be administered, for example, by the aforementioned methods.

[0115] The present invention also relates to use of the antibodies of this invention for manufacturing (pharmaceutical) compositions of this invention.

**[0116]** Further, the present invention provides kits comprising at least an antibody or composition of this invention to be used in the above-described methods. Glass syringe, injection needle, pharmaceutically acceptable medium, alcohol cotton, bandage, instruction manual that describes the usage, or such may also be optionally packaged into the kits.

## Brief Description of the Drawings

## [0117]

15

20

25

30

35

40

45

50

55

- Fig. 1 is a drawing showing the insertion site of pcDNA4-g4H.
- Fig. 2 is a drawing showing the insertion site of pcDNA4-g4L and pIND-g4L.
- Fig. 3 is a drawing showing the insertion site of pIND-g4H.

Fig. 4 shows results of measuring the F.VIIIa-mimetic activity of an anti-F.IXa/anti-F.X bispecific antibody generated from anti-F.IXa antibody XB12 and anti-F.X antibody SB04, SB21, SB42, SB38, SB30, SB07, SB05, SB06, or SB34. The concentration of the antibody solutions was 10  $\mu$ g/mL (final concentration 1  $\mu$ g/mL). As a result, nine types of bispecific antibodies showed an increase of F.VIIIa-mimetic activity in the order of activity strength: XB12/SB04, XB12/SB21, XB12/SB42, XB12/SB38, XB12/SB30, XB12/SB07, XB12/SB05, XB12/SB06, and XB12/SB34.

Fig. 5 shows results of measuring the F.VIIIa-mimetic activity of the XT04 antibody or an anti-F.IXa/ F.X bispecific antibody generated from anti-F.IXa antibody XT04 and anti-F.X antibody SB04, SB21, SB42, SB38, SB30, SB07, SB05, SB06, or SB34. The concentration of the antibody solutions was 10  $\mu$ g/mL (final concentration 1  $\mu$ g/mL). As a result, XT04/SB04, XT04/SB21, XT04/SB42, XT04/SB38, XT04/SB30, XT04/SB07, XT04/SB05, XT04/SB06, and XT04/SB34 showed elevated F.VIIIa-mimetic activity.

Fig. 6 shows results of measuring the F.VIIIa-mimetic activity of various concentrations of XB12/SB04, which showed the highest activity in Fig. 4. As a result, XB12/SB04 showed a concentration-dependent increase of F.VIIIa-mimetic activity.

Fig. 7 shows results of measuring the plasma coagulation time (APTT) in the presence of XB12/SB04, XB12/SB21, XB12/SB42, XB12/SB38, XB12/SB30, XB12/SB07, XB12/SB05, XB12/SB06, or XB12/SB34. The antibody solution concentration was 20  $\mu$ g/mL, except for XB12/SB06 which was 3.4  $\mu$ g/mL: As a result, XB12/SB04, XB12/SB01, XB12/SB05, XB12/SB05, XB12/SB06, and XB12/SB34 showed a coagulation time shortening effect compared with in the absence of the antibodies.

Fig. 8 shows results of measuring the plasma coagulation time (APTT) in the presence of XT04/SB04, XT04/SB21, XT04/SB42, XT04/SB38, XT04/SB30, XT04/SB07, XT04/SB05, XT04/SB06, or XT04/SB34. The antibody solution concentration was 20  $\mu$ g/mL, except for XT04/SB06 which was 10  $\mu$ g/mL. As a result, XT04/SB04, XT04/SB21, XT04/SB42, XT04/SB38, XT04/SB30, XT04/SB07, XT04/SB05, and XT04/SB06 showed a coagulation time shortening effect compared with in the absence of the antibodies. XT04/SB34 did not show a coagulation time-shortening effect.

Fig. 9 shows results of measuring the coagulation time with various concentrations of XB12/SB04, which showed the highest coagulation time (APTT)-shortening effect in Figs. 7 and 8. As a result, XB12/SB04 showed a concentration-dependent effect of shortening the coagulation time.

Figs. 10 to 13 show the ISRE activation ability of antibodies against pISRE-Luc introduced K562 cells.  $\square$  shows IFN- $\alpha$ 2a and • shows the combination of anti-AR1 chain and anti-AR2 chain bispecific antibodies in each figure. The antibodies are shown to activate ISRE in a dose-dependent manner with a per-molecule specific activity comparable to that of IFN.

## Best Mode for Carrying Out the Invention

[0118] Herein below, the present invention will be specifically described with reference to Examples, but it is not to be construed as being limited thereto.

## [Example 1] Antigen and immunization

**[0119]** Expression vectors for a soluble receptor, in which the C terminal of the extracellular region of either human AR1 chain or AR2 chain was tagged with FLAG (AR1FLAG, AR2FLAG) or His6 (AR1His, AR2His), were introduced into CHO cells separately and purified from culture supernatants using affinity columns. The expression vector for a chimeric

molecule comprising the extracellular region of human AR1 chain and the intracellular region of G-CSF receptor was introduced into mouse proB cell line Ba/F3 to establish a high expression cell line. A high expression cell line was similarly established for a chimeric molecule comprising the extracellular region of human AR2 chain and the intracellular region of G-CSF receptor. The cells were individually used to intraperitoneally immunize BALB/c. AR1 His or AR2His was intravenously injected three days before excising the spleen.

[Example 2] Separation of antibodies form an scFv presenting library

(a) Panning of phage library

10

20

30

35

40

45

50

55

[0120] PolyA(+)RNA was extracted from the spleen of an immunized mouse, and scFv was synthesized by RT-PCR to construct a phagemid library expressing scFv as a fusion protein with gene3 of f1 phage (J. Immun. Methods, 201, (1997), 35-55). The E. coli library (2 x 109 cfu) was inoculated into 50 mL of 2x YTAG (2x TY containing 100 μg/mL ampicillin and 2% glucose), and cultured at 37°C till OD 600 reached 0.4 to 0.5. 4 x 10<sup>11</sup> of helper phage VCSM13 was added to the culture, which was left to stand at 37°C for 15 minutes for infection. The infected cells were cultured at 26°C for 10 hours, following addition of 450 mL of 2x YTAG and 25 μL of 1 mol/L IPTG. The culture supernatant was collected by centrifugation, mixed with 100 mL of PEG-NaCl (10% polyethylene glycol 8000, 2.5 mol/L NaCl), and left to stand at 4 °C for 60 minutes. Phage was precipitated by centrifugation at 10,800x g for 30 minutes, and the precipitate was suspended in 40 mL of water, mixed with 8 mL of PEG-NaCl, and left to stand at 4°C for 20 minutes. Phage was precipitated by centrifugation at 10,800x g for 30 minutes, and suspended in 5 mL of PBS. AR1FLAG and AR2FLAG prepared in Example 1 were labeled with biotin using No-Weigh Premeasured NHS-PEO₄-Biotin Microtubes (Pierce). 100 pmol of biotin labeled AR1FLAG or AR2FLAG was added to the phage library and contacted with the antigen for 60 minutes. 600 μL of Streptavidin MagneSphere (Promega) washed with 5% M-PBS (PBS containing 5% skim milk) added for binding for 15 minutes. Beads were washed with 1 mL PBST (PBS containing 0.1% Tween-20) and PBS three times each. The beads were suspended in 0.8 mL of 0.1 mol/L glycine/HCl (pH 2.2) for 5 minutes to elute the phage. The phage solution thus collected was neutralized by adding 2 mol/L Tris (45 μL), added to 10 mL of XL1-Blue in logarithmic growth phase (OD 600 = 0.4 to 0.5), and left to stand for 30 minutes at 37°C for infection. The mixture was spread on a 2x YTAG plate and cultured at 30°C. Colonies were collected, inoculated into 2x YTAG, and cultured at 37°C until OD 600 = 0.4 to 0.5. IPTG (1 mol/L; 5 µL) and helper phage VCSM13 (1011 pfu) were added to the culture solution (10 mL), and the mixture was left to stand at 37°C for 30 minutes. The cells were collected by centrifugation, resuspended in 2x YTAG (100 mL) containing kanamycin (25 µg/mL), and cultured at 30°C for 10 hours. The culture supernatant was collected by centrifugation, mixed with of PEG-NaCl (20 mL), and left to stand at 4°C for 20 minutes. Phage was precipitated by centrifugation at 10,800x g for 30 minutes, and suspended in PBS (2 mL), and provided for the subsequent panning. Beads were washed five times each for PBST and PBS at the second panning. Clones producing AR chain binding phages were selected by ELISA, from *E.coli* that could infect the eluted phages.

(b) Phage ELISA

[0121] The above-described single colony was inoculated into 2x YTAG (150  $\mu$ L) and cultured at 30 °C overnight. After 5  $\mu$ L of this culture was inoculated into 2x YTAG (500  $\mu$ L) and cultured at 37 °C for 2 hours, helper phage (2.5 x 10 pfu) and 2x YTAG (100  $\mu$ L) containing 1 mol/L IPTG (0.3  $\mu$ L) was added, and the culture was then left to stand at 37 °C for 30 minutes. After subsequent overnight culture at 30 °C, the centrifuged supernatant was subjected to ELISA. StreptaWell 96 microtiter plate (Roche) was coated over night with PBS (100  $\mu$ L) containing 1.0  $\mu$ g/mL biotin-labeled AR1FLAG or AR2FLAG. After washing with PBST to remove the antigen, the reaction was blocked with 200  $\mu$ L of 2% (w/v) M-PBS over night. After removal of 2% (w/v) M-PBS, the culture supernatant was added therein and left to stand for 40 minutes for antibody binding. After washing, the bound phage was detected with an HRP-bound anti-M13 antibody (Amersham Pharmacia Biotech) diluted with 2% (w/v) M-PBS, and BM blue POD substrate (Roche). The reaction was stopped by adding sulfuric acid, and the A450 value was measured.

(c) Sequence determination and clone selection

[0122] The scFv region was amplified by PCR using primers PBG3-F1 (5'-CAGCTATGAAATACCTATTGCC -3'/ SEQ ID NO: 27) and PBG3-R1 (5'-CTTTTCATAATCAA.AATCACCGG -3'/ SEQ ID NO: 28) from the phage solution of an ELISA positive clone, and its nucleotide sequence was determined. A PCR reaction solution (20  $\mu$ L) containing 1  $\mu$ L phage solution, 2  $\mu$ L 10 x KOD Dash buffer solution, 10  $\mu$ mol/L primer (0.5  $\mu$ L each), and 0.3  $\mu$ L KOD Dash polymerase (TOYOBO, 2.5 U/ $\mu$ L) was amplified on a Perkin Elmer 9700 via 30 cycles of 96°C, 10 seconds, 55°C, 10 seconds, and 72°C, 30 seconds. After PCR, 3 $\mu$ L of ExoSAP-IT (Amersham) was added to 5  $\mu$ L of the reaction solution, and incubated at 37°C for 20 minutes, then at 80°C for 15 minutes. This sample was reacted with primer PBG3F2 (5'- ATTGCCTACG-

GCAGCCGCT -3'/SEQ ID NO:29) or PBG3-R2 (5'-AAATCACCGGAACCAGAGCC -3'/SEQ ID NO:30) using a BigDye Terminator Cycle Sequencing kit (Applied Biosystems), and electrophoresed on an Applied Biosystems PRISM 3700 DNA Sequencer. For each of the anti-AR1 chain and anti-AR2 chain, 45 clones with CDR3 amino acid sequences different from those predicted from the nucleotide sequences were selected.

[Example 3] Expression of bispecific antibodies

[0123] For expression as scFv-CH1-Fc, an expression vector pCAGGss-g4CH hetero IgG4, where scFv can be inserted between a human signal sequence (driven by promoter CAGG) and the intron -CH1-Fc (human IgG4 cDNA) via an Sfil site, was constructed. For expression as a heteromolecule, amino acid substitutes that are substituted at the CH3 site of IgG4 were produced based on the knobs-into-holes of IgG1 (Ridgway JB *et al.* Protein Engineering 1996, 9: 617-621). Type A is a substitute with Y349C and T366W substitutions, and type B is a substitute with E356C, T366S, L368A, and Y407V substitutions. The substitution of -ppcpScp-to -ppcpPcp- was introduced into the hinge region of both types. Type A was constructed with a human IL-3 signal sequence (pCAGG-IL3ss-g4CHPa) and type B with a human IL-6 signal sequence (pCAGG-IL6ss-g4CHPb). PCR products of the scFv region of the clones selected based on the nucleotide sequences were Sfil treated, then the anti-AR1 chain clone was subcloned into pCAGG-IL3ss-g4CHPa and the anti-AR2 chain clone was subcloned into pCAGG-IL3ss-g4CHPb. Expression vectors for a total of 2025 combinations (anti-AR1 chain and anti-AR2 chain clones 45 x 45) were used to transfect HEK 293 cells using lipofectamine 2000, and three days later, culture supernatants were collected.

[Example 4] Separation of ligand function-substituting bispecific antibodies

(a) Ba/F3 growth assay

5

20

30

35

- [0124] BaF3-ARG was established by introducing expression vectors for chimeric molecules comprising the extracellular region of AR1 chain or AR2 chain and the intracellular region of G-CSF receptor into Ba/F3 cells, which proliferate in a mouse IL-3-dependent manner. BaF3-ARG proliferated IFNα-dependently. After three washes, 0.1 mL medium containing the sample and 1 x 10<sup>3</sup> cells per well was seeded to a 96-well plate. After four days of culture, 10 μL of Cell Count Reagent SF (Nacalai Tesque) was added and incubated at 37°C for two hours, and then A450 was measured.
  - (b) Daudi cell proliferation inhibition assay
  - [0125] Daudi cells are a human B cell line with high sensitivity towards IFN.  $6.25 \times 10^3$  cells per well were seeded to a 96-well plate in 0.1 mL medium containing the sample. After four days of culture, 10  $\mu$ L of Cell Count Reagent SF (Nacalai Tesque) was added and incubated at 37°C for two hours, and then A450 was measured.
  - (c) Sequences of ligand function-substituting bispecific antibodies
  - [0126] Amino acid sequences of the variable regions of the antibodies selected by the above screening method are described as SEQ ID NOs: 1 to 26. Correlation between the name of each antibody and the SEQ ID NO is shown in the above Table 1.
    - (d) Reporter gene assay using ISRE
- [0127] 40 μg of pISRE-Luc was added to 3 mL of OPTI-MEM I and 100 μL DMRIE-C (Invitrogen), stirred, and left to stand at room temperature for 20 minutes. This was added to 8 x 10<sup>6</sup> human K562 cells prepared in 2 mL OPTI-MEM I, and after four hours of culturing at 37°C, 10 mL of 15%FCS-RPMI1640 was added and the cells were cultured overnight. The next day, K562 collected by centrifugation was resuspended in 10.5 mL of 10% FCS-RPMI1640 and seeded to a 96-well flat bottom plate at 70 μL/well.
- [0128] Bispecific scFv-CH in the culture supernatants of HEK293 cells introduced with the antibody gene was adjusted to a concentration of 12.5 ng/mL with reference to IgG and a series of 5-fold dilutions were made. Alternatively, culture supernatants of COS7 cells expressing bispecific IgG were diluted 2-fold and a series of 5-fold dilutions were made. These were added to cells introduced with a reporter plasmid at 30 μL/well. For the positive control wells, a series of 5-fold dilutions of IFN-α 2a were dispensed at 30 μL/well. After culturing at 37°C for 24 hours, 50 μL/mL of a Bright-Glo Luciferase Assay System (Promega) was added and left to stand at room temperature for 10 minutes, and luciferase activity was determined with Analyst HT (LJL) (Fig. 10, Fig. 11, Fig. 12, and Fig. 13).

[Example 5] Preparation of non-neutralizing antibody against Factor IXa (F.IXa)

5-1. Immunization and preparation of hybridomas

[0129] Eight BALB/c mice (male, 6 weeks old when immunization was initiated (Charles River, Japan)) and five MRL/ 1pr mice (male, 6 weeks old when immunization was initiated (Charles River, Japan)) were immunized with Factor IXaß (Enzyme Research Laboratories, Inc.) as described below. As an initial immunization, Factor IXaβ (40 μg/head) emulsified with FCA (Freund's complete adjuvant H37 Ra (Difco laboratories)) was subcutaneously administered. Two weeks later, Factor IXaβ (40 μg/head) emulsified with FIA (Freund's incomplete adjuvant (Difco laboratories)) was subcutaneously administered. Afterward, three to seven booster immunizations were performed at one week intervals. After the titer of a plasma antibody against Factor IXaβ was confirmed to be elevated by ELISA (Enzyme linked immunosorbent assay) described in 5-2, Factor IXa $\beta$  (40  $\mu$ g/head) diluted in PBS(-) (phosphate buffered saline free of calcium ion and magnesium ion) was intravenously administered as a final immunization. Three days after the final immunization, mice spleen cells were fused with mouse myeloma cells P3X63Ag8U.1 (referred to as P3U1, ATCC CRL-1597) by a standard method using PEG1500 (Roche Diagnostics). Fused cells suspended in RPMI1640 medium (Invitrogen) containing 10% FBS (Invitrogen) (hereinafter referred to as 10%FBS/RPMI1640) were seeded in a 96-well culture plate, and 1, 2, 3, and 5 days after the fusion, the medium was replaced with a HAT selection medium (10% FBS/RPMI1640 / 2% HAT 50x concentrate (Dainippon Pharmaceutical Co. Ltd) / 5% BM-Condimed H1 (Roche Diagnostics) to selectively culture hybridomas. Using the supernatants collected on the 8th or 9th day after fusion, Factor IXa-binding activity was measured by ELISA described in 5-2 to select hybridomas having Factor IXa-binding activity. Subsequently, the activity of neutralizing Factor IXa enzymatic activity was measured by the method described in 5-3 to select hybridomas that do not have Factor IXa-neutralizing activity. Hybridomas were cloned twice by performing limiting dilutions in which one cell is seeded in each well of a 96-well culture plate. Single colony cells confirmed by microscopic observation were subjected to ELISA and neutralization activity assay as described in 5-2 and 5-3 was performed for clone selection. Ascites containing the cloned antibody was prepared by the method described in 5-4, and the antibody was purified from the ascites. The purified antibody was unable to extend APTT (activated partial thromboplastin time) and this was confirmed by the method described in 5-5.

#### 5-2. Factor IXa ELISA

20

30

35

40

45

50

55

**[0130]** Factor IXaβ was diluted to 1 μg/mL with a coating buffer (100 mM sodium bicarbonate, pH 9.6, 0.02% sodium azide) and distributed in Nunc-Immuno plate (Nunc-Immuno<sup>TM</sup> 96 MicroWell<sup>TM</sup> plates MaxiSorp<sup>TM</sup> (Nalge Nunc International)) at 100 μL/well. Then, the plate was incubated at 4 °C overnight. After washing the plate with PBS(-) containing Tween<sup>(R)</sup> 20 thrice, it was blocked with a diluent buffer (50 mM Tris-HCl, pH 8.1, 1% bovine serum albumin, 1 mM MgCl<sub>2</sub>, 0.15 M NaCl, 0.05% Tween<sup>(R)</sup> 20, 0.02% sodium azide) at room temperature for 2 hours. After removal of the buffer, a diluent buffer-diluted mouse antiserum or hybridoma culture supernatant was added at 100 μL/well, and incubated at room temperature for 1 hour. After washing the plate thrice, alkaline phosphatase-labeled goat anti-mouse IgG (H+L) (Zymed Laboratories) which had been diluted to 1/2000 with the diluent buffer was added at 100 μL/well, and incubated at room temperature for 1 hour. After washing the plate six times, a colorimetric substrate Blue-Phos<sup>TM</sup> Phosphate Substrate (Kirkegaard & Perry Laboratories) was added at 100 μL/well, and incubated at room temperature for 20 minutes. After adding the Blue-Phos<sup>TM</sup> Stop Solution (Kirkegaard & Perry Laboratories) (100 μL/well), absorbance at 595 nm was measured with a Model 3550 Microplate Reader (Bio-Rad Laboratories).

## 5-3. Measurement of Factor IXa neutralizing activity

[0131] Phospholipid (Sigma-Aldrich) was dissolved in distilled water for injection, and ultrasonicated to prepare a phospholipid solution (400  $\mu$ g/mL). Tris buffered saline containing 0.1% bovine serum albumin (hereinafter abbreviated as TBSB) (40  $\mu$ L), 30 ng/mL Factor IXa $\beta$  (Enzyme Research Laboratories) (10  $\mu$ L), 400  $\mu$ g/mL phospholipid solution (5  $\mu$ L), TBSB containing 100 mM CaCl $_2$  and 20 mM MgCl $_2$  (5  $\mu$ L), and hybridoma culture supernatant (10  $\mu$ L) were mixed in a 96-well plate, and incubated at room temperature for 1 hour. To this mixed solution, 50  $\mu$ g/mL Factor X (Enzyme Research Laboratories) (20  $\mu$ L) and 3 U/mL Factor VIII (American diagnostica) (10  $\mu$ L) were added and reacted at room temperature for 30 minutes. The reaction was stopped by adding 0.5 M EDTA (10  $\mu$ L). After addition of an S-2222 solution (50  $\mu$ L; Chromogenix) and incubation at room temperature for 30 minutes, the absorbance was measured at measurement wavelength 405 nm and reference wavelength 655 nm on a Model 3550 Microplate Reader (Bio-Rad Laboratories, Inc.).

### 5-4. Ascites preparation and antibody purification

**[0132]** Ascites of the established hybridomas was produced according to standard procedures. That is, the hybridoma was cultured *in vitro* (2 x 10<sup>6</sup>) and transplanted into the peritoneal cavity of a BALB/c mouse (male, 5 to 7 weeks old at the time experiment was started, Japan Charles River) or BALB/c nude mouse (female, 5 to 6 weeks old at the time experiment was started, Japan Charles River and Japan CLEA), which was intraperitoneally administered twice with pristane (2,6,10,14-tetramethylpentadecane, WAKO Pure Chemical Industries) in advance. One to four weeks after the transplantation, ascites was collected from the mouse with an inflated abdomen.

[0133] The antibody was purified from the ascites using a Protein G Sepharose™ 4 Fast Flow column (Amersham Biosciences). The ascites was diluted 2-fold with a binding buffer (20 mM sodium acetate, pH 5.0) and applied to the column, which had been washed with 10 column volumes of the binding buffer. The antibody was eluted with 5 column volumes of an elution buffer (0.1 M glycine-HCl, pH 2.5), and neutralized with a neutralizing buffer (1 M Tris-HCl, pH 9.0). The resulting solution was concentrated using a Centriprep™ 10 (Millipore), and the solvent was replaced with TBS (50 mM Tris-buffered saline). The antibody concentration was calculated from the absorbance at 280 nm with A (1%, 1 cm) = 13.5. Absorbance was measured with DU-650 (Beckman Coulter).

## 5-5. Measurement of APTT (Activated Partial Thromboplastin Time)

[0134] APTT was measured with a CR-A (Amelung)-connected KC10A (Amelung). A mixture of the TBSB-diluted antibody solution (50  $\mu$ L), standard human plasma (Dade Behring) (50  $\mu$ L), and APTT reagent (Dade Behring) (50  $\mu$ L) was warmed at 37 °C for 3 minutes. To this mixture, 20 mM CaCl<sub>2</sub> (Dade Behring) (50  $\mu$ L) was added to start a coagulation reaction, and the coagulation time was measured.

[Example 6] Preparation of non-Factor X (F.X)-neutralizing antibody

## 6-1. Immunization and hybridoma preparation

[0135] Eight BALB/c mice (male, 6 weeks old when immunization was initiated, Japan Charles River) and five MRL/ 1pr mice (male, 6 weeks old when immunization was initiated, Japan Charles River) were immunized with Factor X (Enzyme Research Laboratories) as described below. As an initial immunization, Factor X (40 μg/head) emulsified with FCA was subcutaneously administered. Two weeks later, Factor X (20 or 40 μg/head) emulsified with FIA was subcutaneously administered. Subsequently, three to six booster immunizations were given at one week intervals. After the titer of a plasma antibody against Factor X was confirmed to be elevated by ELISA as described in 6-2, Factor X (20 or 40 µg/head) diluted in PBS (-) was administered intravenously as a final immunization. Three days after the final immunization, mouse spleen cells were fused with mouse myeloma P3U1 cells, according to a standard method using PEG1500. Fused cells suspended in 10% FBS/RPMI1640 medium were seeded in a 96-well culture plate, and hybridomas were selectively cultured by replacing the medium with a HAT selection medium 1, 2, 3 and 5 days after the fusion. Binding activity toward Factor X was measured by ELISA described in 6-2, using the culture supernatant collected on the 8th day after fusion. Hybridomas having Factor X-binding activity were selected, and their activities to neutralize Factor Xa enzymatic activity were measured by the method described in 6-3. Hybridomas that do not have a neutralizing activity toward Factor Xa were cloned by performing limiting dilution twice. Ascites containing the cloned antibody was prepared by the method described in 5-4, and the antibody was purified from the ascites. The purified antibody was unable to extend APTT and this was confirmed by the method described in 5-5.

#### 6-2. Factor X ELISA

20

25

30

35

40

45

50

55

[0136] Factor X was diluted to 1  $\mu$ g/mL with a coating buffer, and dispersed into Nunc-Immuno plate at 100  $\mu$ L/well. Then the plate was incubated at 4°C overnight. After washing the plate with PBS (-) containing Tweer(R) 20 thrice, it was blocked with a diluent buffer at room temperature for 2 hours. After removal of the buffer, a diluent buffer-diluted mouse antiserum or hybridoma culture supernatant was added to the plate, and incubated at room temperature for 1 hour. After washing the plate thrice, alkaline phosphatase-labeled goat anti-mouse IgG (H+L) which had been diluted to 1/2000 with the diluent buffer was added, and incubated at room temperature for 1 hour. After washing the plate six times, a colorimetric substrate Blue-Phos<sup>TM</sup> Phosphate Substrate (Kirkegaard & Perry Laboratories)was added at 100  $\mu$ L/well, and incubated at room temperature for 20 minutes. After adding Blue-Phos<sup>TM</sup> Stop Solution (Kirkegaard & Perry Laboratories) (100  $\mu$ L/well), absorbance ate 595 nm was measured with a Model 3550 Microplate Reader (Bio-Rad Laboratories).

6-3. Measurement of Factor Xa-neutralizing activity

15

20

30

40

45

50

[0137] Hybridoma culture supernatant diluted to 1/5 with TBSB ( $10\,\mu$ L) was mixed with 40  $\mu$ L of TBCP (TBSB containing 2.78 mM CaCl<sub>2</sub> and 22.2  $\mu$ M phospholipids (phosphatidyl choline:phosphatidyl serine = 75:25, Sigma-Aldrich) containing 250 pg/mL Factor Xa (Enzyme Research Laboratories), and incubated at room temperature for 1 hour. To this mixed solution, TBCP ( $50\,\mu$ L) containing prothrombin (Enzyme Research Laboratories) ( $20\,\mu$ g/mL) and 100 ng/mL activated coagulation factor V (Factor Va (Haematologic Technologies)) were added, and reacted at room temperature for 10 minutes. The reaction was stopped by adding 0.5 M EDTA ( $10\,\mu$ L). To this reaction solution, 1 mM S-2238 solution (Chromogenix) ( $50\,\mu$ L) was added, and after incubation at room temperature for 30 minutes, absorbance at 405 nm was measured with a Model 3550 Microplate Reader (Bio-Rad Laboratories).

[Example 7] Construction of chimera bispecific antibody expression vector

7-1. Preparation of antibody variable region-encoding DNA fragments from hybridomas

[0138] From the hybridomas that produce anti-F.IXa antibody or anti-F.X antibody, total RNA was extracted using the QIAGEN<sup>(R)</sup> RNeasy<sup>(R)</sup> Mini Kit (QIAGEN) according to the method described in the instruction manual. The total RNA was dissolved in sterile water (40  $\mu$ L). Single-stranded cDNA was synthesized by RT-PCR using the SuperScript cDNA synthesis system (Invitrogen) with the purified RNA (1 to 2  $\mu$ g) as template, according to the method described in the instruction manual.

7-2. PCR amplification of antibody H chain variable region and sequence analysis

[0139] As primers for amplifying the mouse antibody H chain variable region (VH) cDNA, an HB primer mixture and HF primer mixture described in the report by Krebber et al. (J. Immunol. Methods 1997; 201: 35-55) were prepared. Using 0.5  $\mu$ L each of the 100  $\mu$ M HB primer mixture and 100  $\mu$ M HF primer mixture, a reaction solution (25  $\mu$ L) (cDNA solution prepared in 7-1 (2.5 μL), KOD plus buffer (TOYOBO), 0.2 mM dNTPs, 1.5 mM MgCl<sub>2</sub>, 0.75 units DNA polymerase KOD plus (TOYOBO)) was prepared. Using a thermal cycler GeneAmp PCR system 9700 (Parkin Elmer), PCR was performed according to amplification efficiency of the cDNA fragments, either under conditions A (3 min heating at 98°C followed by 32 cycles of reaction (98°C, 20 sec, 58°C, 20 sec, and 72°C, 30 sec in one cycle)) or conditions B (3 min heating at 94°C followed by 5 cycles of reaction (94°C, 20 sec, 46°C, 20 sec, and 68°C, 30 sec in one cycle) and 30 cycles of reaction (94°C, 20 sec, 58°C, 20 sec, and 72°C, 30 sec in one cycle)). After PCR, the reaction solution was subjected to 1% agarose gel electrophoresis. Amplified fragments of the desired size (about 400 bp) were purified using a QIAquick Gel Extraction Kit (QIAGEN) according to the methods described in the attached instruction manual, and eluted with sterile water (30 µL). Nucleotide sequences of the DNA fragments were determined using a BigDye Terminator Cycle Sequencing Kit (Applied Biosystems) on a DNA sequencer ABI PRISM 3100 Genetic Analyzer (Applied Biosystems), according to the method described in the attached instruction manual. Sequence groups determined by this method were comparatively analyzed using an analytical software, GENETYX-SV/RC Version 6.1 (Genetyx), and DNAs with different sequences were selected.

7-3. Preparation of antibody variable region DNA fragments for cloning

[0140] The following procedure was performed to add restriction enzyme Sfi I cleavage sites for cloning to both termini of the antibody variable region amplification fragments.

[0141] To amplify the VH fragments added with an Sfi I cleavage site (Sfi I-VH), a primer (primer VH-5' end) in which the primer HB (Gly4Ser)2-linker sequence was replaced with a sequence containing Sfi I cleavage site (SEQ ID NO: 31) was prepared. Using 0.5  $\mu$ L each of the 10  $\mu$ M sequence-specific primer VH-5' end and 10  $\mu$ M primer scfor (J. Immunol. Methods 1997; 201: 35-55), a reaction solution (20  $\mu$ L) (purified solution of VH cDNA amplification fragment prepared in 7-2 (1  $\mu$ L), KOD plus buffer (TOYOBO), 0.2 mM dNTPs, 1.5 mM MgCl<sub>2</sub>, 0.5 units DNA polymerase KOD plus (TOYOBO)) was prepared. Using a thermal cycler GeneAmp PCR system 9700 (Parkin Elmer), PCR was performed according to amplification efficiency of the cDNA fragments, either under conditions A (3 min heating at 98 °C followed by 32 cycles of reaction (98 °C, 20 sec, 58 °C, 20 sec, and 72 °C, 30 sec in one cycle)) or conditions B (3 min heating at 94 °C followed by 5 cycles of reaction (94 °C, 20 sec, 46 °C, 20 sec, and 68 °C, 30 sec in one cycle) and 30 cycles of reaction (94 °C, 20 sec, 58 °C, 20 sec, and 72 °C, 30 sec in one cycle)). After PCR, the reaction solution was subjected to 1% agarose gel electrophoresis. Amplified fragments of the desired size (about 400 bp) were purified using a QlAquick Gel Extraction Kit (QlAGEN) by the method described in the attached instruction manual, and eluted with sterile water (30  $\mu$ L).

[0142] To amplify the mouse antibody L chain variable region (VL) cDNA fragments, 0.5 μL each of the 100 μM LB

primer mixture and 100 µM LF primer mixture described in the report by Krebber et al. (J. Immunol. Methods 1997; 201: 35-55) was first used, and a reaction solution (25  $\mu$ L) (cDNA solution prepared in 7-1 (2.5  $\mu$ L), KOD plus buffer (TOYOBO), 0.2 mM dNTPs, 1.5 mM MgCl<sub>2</sub>, 0.75 units DNA polymerase KOD plus (TOYOBO)) was prepared. Using a thermal cycler GeneAmp PCR system 9700 (Parkin Elmer), PCR was performed according to amplification efficiency of the fragments, under conditions of 3 minutes heating at 94 °C followed by 5 cycles of reaction (94 °C, 20 sec, 46 °C, 20 sec, and 68 °C, 30 sec in one cycle) and 30 cycles of reaction (94°C, 20 sec, 58°C, 20 sec, and 72°C, 30 sec in one cycle). After PCR, the reaction solution was subjected to 1% agarose gel electrophoresis. Amplified fragments of the desired size (about 400 bp) were purified using the QIAquick Gel Extraction Kit (QIAGEN) by the method described in the attached instruction manual, and eluted with sterile water (30 μL). The fragments are in a state in which the primer LF-derived (Gly4Ser)3linker sequence is added to their C termini. In order to add an Sfi I cleavage site to the C termini of the fragments, a primer (primer VL-3' end) in which the primer LF (Gly4Ser)3-linker sequence was replaced with a sequence having Sfi I cleavage site (SEQ ID NO: 32) was prepared. To amplify the VL fragments added with an Sfi I cleavage site (Sfi I-VL),  $0.5~\mu L$  each of the 10  $\mu M$  VL-3' end primer mixture and 10  $\mu M$  scback primer was used, and a reaction mixture (20  $\mu L$ ) (purified solution of VL cDNA amplification fragment (1 μL), KOD plus buffer (TOYOBO), 0.2 mM dNTPs, 1.5 mM MgCl<sub>2</sub>, 0.5 units DNA polymerase KOD plus (TOYOBO)) was prepared. PCR was performed using a thermal cycler GeneAmp PCR system 9700 (Parkin Elmer) under conditions of 3-minutes heating at 94 °C followed by 5 cycles of reaction (94 °C, 20 sec, 46°C, 20 sec, and 68°C, 30 sec in one cycle) and 30 cycles of reaction (94°C, 20 sec, 58°C, 20 sec, and 72°C, 30 sec in one cycle). After PCR, the reaction solution was subjected to 1% agarose gel electrophoresis. Amplified fragments of the desired size (about 400 bp) were purified using the QIAquick Gel Extraction Kit (QIAGEN) by the method described in the attached instruction manual, and eluted with sterile water (30 µL).

[0143] The purified Sfi I-VH and Sfi I-VL fragments were digested with Sfi I (Takara Bio) at 50 °C overnight in a reaction solution prepared according to the method described in the attached instruction manual. Subsequently, the reaction solution was purified using a QIAquick PCR Purification Kit (QIAGEN) by the method described in the attached instruction manual, and eluted with Buffer EB (30 µL) included in the kit.

7-4. Human IgG4-Mouse chimera bispecific IgG antibody expression plasmid

25

30

35

40

45

50

55

[0144] When producing the bispecific IgG antibody of interest, the knobs-into-holes technique of IgG1 (Ridgway et al., Protein Eng. 1996; 9: 617-621) was referred to when preparing IgG4 with an amino acid-substituted CH3 portion to form heteromolecules for each H chain. Type a (IgG4 $\gamma$ a) is substituted with Y349C and T366W, and type b (IgG4 $\gamma$ b) is substituted with E356C, T366S, L368A, and Y407V. Further, a substitution (-ppcpScp-->-ppcpPcp-) was also introduced at the hinge regions of both types. Almost all the H chains become heteromolecules by this technique; however, this does not necessarily apply to L chains, and the formation of unnecessary antibody molecules may affect subsequent activity measurements. Therefore, to separately express the arms of each antibody molecule (called HL molecule), which have different specificities, and efficiently form the type of bispecific IgG antibody of interest within cells, those that are inducible by different drugs were used as the expression vectors for each HL molecule.

[0145] As an expression vector for an arm of the antibody molecule (called right arm HL molecule for convenience), pcDNA4-q4H or pcDNA4-q4L (Fig. 1 or Fig. 2) was prepared, in which the respective H chain or L chain region, that is, an appropriate mouse antibody variable region (VH or VL) and a human IgG4γa constant region (SEQ ID NO: 33) or κ constant region (SEQ ID NO: 34), were incorporated into the tetracycline-inducible type vector pcDNA4 (Invitrogen) downstream of the signal sequence (IL3ss) for animal cells (Proc. Natl. Acad. Sci. USA. 1984; 81: 1075). First, Eco RV and Not I (Takara Bio) were used to digest pcDNA4 at the restriction enzyme cleavage sites that are present in its multicloning site. The right arm H chain- or L chain-expression unit (about 1.6 kb or about 1.0 kb respectively) of a chimera bispecific antibody having appropriate antibody variable regions was digested with Xho I (Takara Bio). Then, it was purified with the QIAquick PCR Purification Kit (QIAGEN) by the method described in the attached instruction manual, and reacted with DNA polymerase KOD (TOYOBO) at 72°C for 10 minutes in a reaction solution composition described in the attached instruction manual to blunt the ends. The blunt-end fragments were purified with the QIAquick PCR Purification Kit (QIAGEN) by the method described in the attached instruction manual, and digested with Not I (Takara Bio). The Not I/blunt end fragments (about 1.6 kb or 1.0 kb respectively) and the Eco RV/Not I-digested pcDNA4 were subjected to a ligation reaction using Ligation High (TOYOBO), according to the method described in the attached instruction manual. An E, coli DH5 $\alpha$  strain (Competent high DH5 $\alpha$  (TOYOBO)) was transformed with the above-described reaction solution. From the ampicillin-resistant clones thus obtained, respective plasmid DNAs were isolated using the QIAprep Spin Miniprep Kit (QIAGEN).

[0146] As an expression vector for the antibody molecule's other arm (called left arm HL molecule for convenience), pIND-g4H or pIND-g4L (Fig. 2 or Fig. 3) was prepared according to the above-described method, in which the H chain or L chain respective region, that is, an appropriate mouse antibody variable region (VH or VL) and a human  $IgG4\gamma b$  constant region (SEQ ID NO: 35) or  $\kappa$  constant region (SEQ ID NO: 34), were incorporated into the ecdysone analogue inducible type vector pIND (Invitrogen) downstream of the signal sequence (IL3ss) for animal cells (EMBO. J. 1987; 6:

2939), and the respective plasmid DNAs were isolated.

10

20

30

35

40

50

55

7-5. Construction of bispecific antibody expression vector

[0147] The tetracycline-inducible type expression plasmid prepared in 7-4 (pcDNA4-g4H or pcDNA4-g4L) was digested with Sfi I, and was subjected to 1% agarose gel electrophoresis. Fragments (about 5 kb) lacking the intrinsic antibody variable region part (VH or VL (see Fig. 1 or Fig. 2)) were purified using the QIAquick Gel Extraction Kit (QIAGEN) by the method described in the attached instruction manual, and eluted with sterile water (30  $\mu$ L). The fragments, and the corresponding Sfi I-VH or Sfi-VL fragment derived from the Sfi I-digested anti-F.IXa antibody prepared in 7-3, were subjected to a ligation reaction using the Quick Ligation Kit (New England Biolabs) according to the method described in the attached instruction manual. An *E. coli* DH5 $\alpha$  strain (Competent high DH5 $\alpha$  (TOYOBO)) was transformed with the above-described reaction solution. Further, fragments obtained by removing the antibody variable region part by a similar technique as described above (VH or VL (see Fig. 2 or Fig. 33)) from the Sfi I-digested ecdysone analogue-inducible type expression plasmid (pIND-g4H or pIND-4GL) prepared in 7-4 and the corresponding Sfi I-digested anti-F.X antibody-derived Sfi I-VH or Sfi I-VL fragment prepared in 7-3 were incorporated by a similar method.

[0148] In each of the ampicillin-resistant transformants thus obtained, insertion of the fragment of interest was confirmed by colony PCR method using primers that sandwich the inserted fragment. First, for the anti-F.IXa antibody chimeric H chain or L chain expression vector, a 21-mer CMVF primer (SEQ ID NO: 36) which anneals to the CMV forward priming site upstream of the insertion site, and an 18-mer BGHR primer (SEQ ID NO: 37) which anneals to the BGH reverse priming site downstream of the insertion site were synthesized (Sigma Genosys). For the anti-F.X antibody chimeric H chain or L chain expression vector, a 24-mer EcdF primer (SEQ ID NO: 38), which anneals to the upstream of the insertion site and an 18-mer BGHR primer (SEQ ID NO: 37) which anneals to the BGH reverse priming site downstream of the insertion site were synthesized (Sigma Genosys). For colony PCR, a reaction solution (20 μL) (0.2 μL primer (10  $\mu$ M), KOD dash buffer (TOYOBO), 0.2 mM dNTPs, and 0.75 units DNA polymerase KOD dash) (TOYOBO)) was prepared. To this reaction solution, cells of the transformant strain were added in appropriate amounts and PCR was performed. PCR was performed using a thermal cycler GeneAmp PCR system 9700 (Parkin Elmer) under conditions of 1 minute heating at 96°C followed by 30 cycles of reaction (96°C, 10 sec, 55°C, 10 sec, and 72°C, 30 sec in one cycle). After PCR, the reaction solution was subjected to 1% agarose gel electrophoresis, and clones from which amplification fragments of the desired size were obtained were selected. The PCR product was treated with an ExoSAP-IT (Amersham Biosciences) to inactivate excess primers and dNTPs according to the attached instruction manual. Nucleotide sequences of the DNA fragments were determined using a BigDye Terminator Cycle Sequencing Kit (Applied Biosystems) on a DNA sequencer ABI PRISM 3100 Genetic Analyzer (Applied Biosystems), according to the method described in the attached instruction manual. Sequence groups determined by the present method were analyzed with an analytical software, GENETYX-SV/RC Version 6.1 (Genetyx). For VH, clones of interest having no insertion, deletion, or mutation were selected. For VL, different from the P3U1-derived pseudo VL gene used in hybridomas, clones of interest having no insertion, deletion, or mutation were selected.

[0149] From the clones of interest, the respective plasmid DNAs were isolated by using a QIAprep Spin Miniprep Kit (QIAGEN), and then dissolved in sterile water (100 µL). Anti-F.IXa antibody chimeric H chain expression vector, anti-F.IXa antibody chimeric L chain expression vector, anti-F.X antibody chimeric L chain expression vector were named pcDNA4-g4IXaHn, pcDNA4-g4IXaLn, pIND-g4XHn, and pIND-g4XLn, respectively. Each plasmid solution was stored at 4 °C till use.

[Example 8] Expression of chimera bispecific antibodies in animal cells

### 45 8-1. Preparation of DNA solutions

**[0150]** Expression of the antibody's right arm HL molecule expression vectors (pcDNA4-g4lXaHn and pcDNA4-g4lXaLn) is induced by tetracycline. In the absence of tetracycline, Tet repressor-encoding plasmid pcDNA6/TR (Invitrogen) is required to completely suppress their expressions. Further, expression of the left arm antibody HL molecule expression vectors (plND-g4XHn and plND-g4XLn) was induced by an insect hormone ecdysone analogue (ponasterone A). This requires plasmid pVgRXR (Invitrogen) which encodes the ecdysone receptor and retinoid X receptor that react with ponasterone A and induce expression. Therefore, for the transfection of animal cells, a mixture of six types of plasmid DNAs in total was prepared. For 1 mL of cell culture, pcDNA4-g4lXaHn, pcDNA4-g4lXaLn, plND-g4XHn and plND-g4XLn (218.8 ng each), as well as pcDNA6/TR and pVgRXR (1312.5 ng each) were used.

## 8-2 Transfection of animal cells

[0151] A HEK293H strain (Invitrogen) derived from human fetal renal cancer cells was suspended in DMEM medium

(Invitrogen) containing 10% FCS (MOREGATE), plated onto each well of a 12-well plate for cell adhesion at a cell density of 5 x  $10^5$  cells/mL, and cultured in a  $CO_2$  incubator (37°C, 5%  $CO_2$ ), The plasmid DNA mixture prepared in 8-1 was added to a mixed solution of transfection reagent Lipofectamine 2000 (7  $\mu$ L; Invitrogen) and Opti-MEM I medium (250  $\mu$ L; Invitrogen) and left to stand at room temperature for 20 minutes. This mixed solution was added to cells in each well, and the cells were incubated in a  $CO_2$  incubator (37°C, 5%  $CO_2$ ) for four to five hours.

8-3 Induction of bispecific IgG antibody expression

10

20

30

35

40

45

50

55

[0152] After the medium was removed by suction from the above transfected cell cultures, 1 mL CHO-S-SFM-II (Invitrogen) medium containing 1  $\mu$ g/mL tetracycline (WAKO Pure Chemical Industries) was added, and primary expression of the antibody's right arm HL molecule was induced by culturing the cells in a CO<sub>2</sub> incubator (37 °C, 5% CO<sub>2</sub>) for one day. Subsequently, the medium was removed by suction, and the cells were washed once with 1 mL of CHO-S-SFM-II medium, and cultured in a CO<sub>2</sub> incubator (37 °C, 5% CO<sub>2</sub> for 2 or 3 days following the addition of 1 mL of CHO-S-SFM-II medium containing 5  $\mu$ M ponasterone A (Invitrogen), and secondary expression of the antibody's left arm HL molecule was induced for secretion of the bispecific IgG antibody into the medium. The collected culture supernatant was centrifuged (approximately 2000g, 5min, room temperature) to remove the cells, and concentrated as needed by Microcon<sup>(R)</sup> YM-50 (Millipore). The samples were stored at 4 °C till use.

[Example 9] Quantification of human IgG concentration

[0153] Goat affinity purified antibody to human IgG Fc (Cappel) was prepared at 1  $\mu$ g/mL with a coating buffer, and solid-phased onto a Nunc-Immuno plate. After blocking with a diluent buffer (D.B.), samples of culture supernatants appropriately diluted with D.B. were added. As a standard for calculating the antibody concentration, human IgG4 (humanized anti-TF antibody, see WO 99/51743) diluted with D.B. in a 2-fold dilution series with 11 levels from 1000 ng/mL was similarly added. After three washes, alkaline phosphatase goat anti-human IgG (Biosource International) was added for reaction. After five washes, the plate was color developed using the Sigma  $104^{(R)}$  phosphatase substrate (Sigma-Aldrich) as a substrate, and the absorbance at 405 nm was measured on an absorbance reader Model 3550 (Bio-Rad Laboratories) with a reference wavelength of 655 nm. Using the Microplate Manager III (Bio-Rad Laboratories) software, human IgG concentration in the culture supernatant was calculated from the standard curve.

[Example 10] F.VIIIa (activated coagulation factor VIII)-mimetic activity assay

[0154] The F.VIIIa-mimetic activity of a bispecific antibody was assessed by the following enzymatic assay. The following reactions were all performed at room temperature. A mixed solution of 40  $\mu$ L Factor IX (3.75  $\mu$ g/mL; Enzyme Research Laboratories) and 10  $\mu$ L of the antibody solution was incubated in a 96-well plate for one hour. Then, 10  $\mu$ L Factor XIa (10 ng/mL; Enzyme Research Laboratories), 20  $\mu$ L Factor X (50  $\mu$ g/mL; Enzyme Research Laboratories), 5  $\mu$ L phospholipid (400  $\mu$ g/mL; see Example 5-3), and 15  $\mu$ L TBSB containing 5mM CaCl<sub>2</sub> and 1mM MgCl<sub>2</sub> (hereinafter abbreviated as TBSB-S) were added to initiate the enzymatic reaction. After one hour, the reaction was stopped by adding 10  $\mu$ L of 0.5M EDTA.

[0155] After adding a colorimetric substrate solution (50 μL) to each well, absorbance at 405 nm (reference wave length 655 nm) was measured at 0 and 30 minutes with a Model 3550 Microplate Reader (Bio Rad Laboratories). The F.VIIIa-mimetic activity was presented as a value obtained by subtracting the value of absorbance change in 30 minutes without antibody addition from that with the antibody addition (see Fig. 4 and Fig. 5).

[0156] TBSB was used as a solvent for phospholipids, while TBSB-S was used as a solvent for Factor XIa, Factor IX, and Factor X. The colorimetric substrate solution was a 1:1 mixture of "Tesutochimu" colorimetric substrate S-2222 (Chromogenix) dissolved according to the attached instruction manual and a polybrene solution (0.6 mg/L hexadimethrine bromide (Sigma)).

[0157] Further, the concentration dependency of XB12/SB04's F.VIIIa-mimetic activity, which was the highest among all, was measured (Fig. 6).

[Example 11] Plasma coagulation assay

**[0158]** To elucidate whether a bispecific antibody corrects the coagulation ability of hemophilia A blood, effects of the bispecific antibody on activated partial thromboplastin time (APTT) were examined using F.VIII-deficient plasma. A mixed solution comprising an antibody solution at various concentrations (50  $\mu$ L), F.VIII-deficient plasma (50  $\mu$ L; Biomerieux) and APTT reagent (50  $\mu$ L; Dade Behring) was warmed at 37 °C for 3 minutes. Coagulation reaction was initiated by adding 20 mM CaCl<sub>2</sub> (50  $\mu$ L; Dade Behring) to the above-described mixture. The time required for coagulation was measured with CR-A (Amelung)-connected KC10A (Amelung) (Figs. 7 and 8).

[0159] Further, XB12/SB04, which showed the highest coagulation time-shortening activity, was measured for its concentration dependency (Fig. 9).

## [Example 12] Antibody purification

[0160] The culture supernatant (10 mL) obtained by the method described in Example 8 was concentrated to 1 mL with Centricon<sup>(R)</sup> YM-50 (Millipore). To this concentrate, 10% BSA (10  $\mu$ L), 1% Tween<sup>(R)</sup> 20 (10  $\mu$ L), and rProtein A Sepharose<sup>TM</sup> Fast Flow (Amersham Biosciences) (100  $\mu$ L) were added, and the solution was mixed by overturning at 4°C overnight. The solution was transferred to an Ultrafree<sup>(R)</sup>-MC 0.22  $\mu$ m filter cup (Millipore), and after washing with TBS containing 0.01% Tween<sup>(R)</sup> 20 (500  $\mu$ L) thrice, the rProtein A Sepharose<sup>TM</sup> resin was suspended in 100  $\mu$ L of 0.01% Tween<sup>(R)</sup> 20 (pH 2.0) containing 10 mM HCl, and left to stand for 3 minutes. Then, the antibody was eluted, and the eluate was immediately neutralized with the addition of 5  $\mu$ L 1M Tris-HCl, pH 8.0. Using the Microplate Manager III (Bio-Rad Laboratories) software, the human IgG concentration was calculated from the standard curve. The antibody concentration was quantified according to Example 9.

## Industrial Applicability

5

10

15

20

25

30

35

40

45

50

55

[0161] The present invention provides bispecific antibodies that have the effect of functionally substituting for ligands of heteromolecule-comprising receptors.

**[0162]** The present invention also provides bispecific antibodies that recognize both an enzyme and its substrate, and which functionally substitute for a cofactor that enhances the enzymatic activity.

**[0163]** The bispecific antibodies according to the present invention are thought to have high stability in blood and low antigenicity. Thus, it is greatly expected that they will become pharmaceuticals.

# SEQUENCE LISTING

5	<110>	CHUG	AI S	EIYA	KU K	ABUS	нікі	KAI	SHA						
10	<120>	BISP	ECIF	IC A	NTIB	ODY :	SUBS	TITU'	TING	FOR	FUN	CTIO	NAL :	PROT	EINS
15	<130>	C1-A	0313	P2											
	<140>	PCT/	JP20	03/0	1312	3									
20	<141>														
25	<160>	82													
	<170>	Pate	nt In	ver	sion	3 1									
30	(110)	1400		V 01	oron	0. 1									
35	<210>	1													
	<211>	120													
	<212>	PRT													
40	<213>	Homo	sapi	iens											
_	<400>	1													
45	Gln Va		Leu	Lvs	Gln	Ser	G1 v	Ala	G1u	Leu	Val	Arg	Pro	G1 v	Ala
	1	2 0111	Bou	5	0111		01,	*****	10	204		111.6		15	
50				-					- *						
	Ser Va	l Arg	Leu	Ser	Cys	Lys	Ala	Ser	Gly	Tyr	Thr	Phe	Thr	Phe	Tyr
55			20					25					30		

35 40 45  Gly Arg Ile Asp Pro Tyr Asp Ser Glu Thr Arg Tyr Asn Gln Ly 50 55 60  Lys Asp Lys Ala Ile Leu Thr Val Asp Lys Tyr Ser Ser Thr Af 65 70 75  Met Gln Leu Ser Ser Leu Thr Ser Glu Asp Ser Ala Val Tyr Ty	5	Trp	Ile	Asn	Trp	Ile	Lys	Gln	Arg	Pro	Glu	G1n	Gly	Leu	Glu	Trp	Ile
Lys Asp Lys Ala Ile Leu Thr Val Asp Lys Tyr Ser Ser Thr Al				35					40					45			
Lys Asp Lys Ala Ile Leu Thr Val Asp Lys Tyr Ser Ser Thr Ala 65 70 75  Met Gln Leu Ser Ser Leu Thr Ser Glu Asp Ser Ala Val Tyr Ty 85 85 90 90 95  Ala Lys Gly Val Tyr Asp Gly His Trp Phe Phe Asp Val Trp Glu 100 105 110  Gly Thr Ser Val Thr Val Ser Ser 120  (210) 2  (210) 2  (213) Homo sapiens	10	Gly	Arg	Ile	Asp	Pro	Tyr	Asp	Ser	Glu	Thr	Arg	Tyr	Asn	G1n	Lys	Phe
Lys Asp Lys Ala Ile Leu Thr Val Asp Lys Tyr Ser Ser Thr Alagoria (55) 70 75 75 75 75 75 75 75 75 75 75 75 75 75			50					55					60				
Met Gln Leu Ser Ser Leu Thr Ser Glu Asp Ser Ala Val Tyr Ty 85 90 91 91 92 90 91 91 91 91 91 91 91 91 91 91 91 91 91	15																
Met Gln Leu Ser Ser Leu Thr Ser Glu Asp Ser Ala Val Tyr Ty 85 90 98  Ala Lys Gly Val Tyr Asp Gly His Trp Phe Phe Asp Val Trp Gi 100 105 110  Gly Thr Ser Val Thr Val Ser Ser 115 120  (210> 2  (211> 108 (213> Homo sapiens  (400> 2		Lys	Asp	Lys	Ala	Ile	Leu	Thr	Val	Asp	Lys	Tyr	Ser	Ser	Thr	Ala	Tyr
25 85 90 98  30 Ala Lys Gly Val Tyr Asp Gly His Trp Phe Phe Asp Val Trp G 100 105 110  35 Gly Thr Ser Val Thr Val Ser Ser 115 120  40  <210> 2  <211> 108 <212> PRT <213> Homo sapiens  50  <400> 2	20	65					70					75					80
Ala Lys Gly Val Tyr Asp Gly His Trp Phe Phe Asp Val Trp G  100 105 110  35  Gly Thr Ser Val Thr Val Ser Ser  115 120  40  <210> 2  45  <211> 108  <212> PRT  <213> Homo sapiens  50  <400> 2		Met	Gln	Leu	Ser	Ser	Leu	Thr	Ser	Glu	Asp	Ser	Ala	Val	Tyr	Tyr	Cys
100 105 110  35  Gly Thr Ser Val Thr Val Ser Ser  115 120  40  <210> 2  45 <211> 108  <212> PRT  <213> Homo sapiens  50  <400> 2	25					85					90					95	
100 105 110  35  Gly Thr Ser Val Thr Val Ser Ser  115 120  40  <210> 2  45 <211> 108  <212> PRT  <213> Homo sapiens  50  <400> 2		4.7	T	01	W - 1	Т	۸	C1	u: -	Т	Dha	Dha	A an	Vol	Twn	G1 <sub>w</sub>	<b>11</b> a
Gly Thr Ser Val Thr Val Ser Ser  115 120  40  <210> 2  45 <211> 108  <212> PRT  <213> Homo sapiens  50  <400> 2	30	Ala	Lys	GIÀ		lyr	Asp	GIY	піѕ		rne	rne	кѕр	vai		Gly	піа
Gly Thr Ser Val Thr Val Ser Ser  115 120  40  <210> 2  45 <211> 108  <212> PRT  <213> Homo sapiens  50  <400> 2					100	•				105					110		
<pre>40</pre>	35	Gly	Thr	Ser	Val	Thr	Val	Ser	Ser								
<pre> <pre> &lt;210&gt; 2  &lt;211&gt; 108  &lt;212&gt; PRT  &lt;213&gt; Homo sapiens  </pre>  &lt;400&gt; 2</pre>				115					120								
<pre>45</pre>	40																
<pre>&lt;212&gt; PRT</pre>		<210	)>	2													
<213> Homo sapiens  <400> 2	45	<211	<b>L&gt;</b>	108													
<400> 2		<212	2>	PRT													
	50	<213	3>	Homo	sap	iens											
Asp Ile Val Met Thr Gln Ser His Lys Phe Met Ser Thr Ser Va		<400	)>	2					•								
	55	Asp	Ile	Val	Met	Thr	Gln	Ser	His	Lys	Phe	Met	Ser	Thr	Ser	Val	G1y

	1				5					10					15	
5	Asp	Arg	Val	Ser	Ile	Thr	Cys	Lys	Ala	Ser	Gln	Asp	Val	Ser	Thr	Ala
				20					25					30		
10															٠	
	Val	Ala	Trp	Tyr	Gln	G1n	Lys	Pro	Gly	Gln	Ser	Pro	Lys	Leu	Leu	Ile
15			35					40					<b>4</b> 5			
20	Tyr	Ser	Ala	Ser	Tyr	Arg	Tyr	Thr	Gly	Val	Pro	Ala	Arg	Phe	Ser	Gly
20		50					55					60				
25	Ser	Gly	Ser	Gly	Thr	Asp	Phe	Thr	Phe	Thr	Ile	Ser	Ser	Val	Gln	Thr
	65					70					75					80
30																
	Glu	Asp	Leu	Ala	Val	Tyr	Tyr	Cys	Gln		His	Tyr	Arg	Thr		Pro
35					85					90					95	
	Thr	Phe	Gly	Gly	Gly	Thr	Lys	Leu	Glu	Leu	Lys	Arg				
40				100					105							
45	<210	)> 3	3													
	<211	.> 1	19													
	<212	2> I	PRT													
50	<213	3> I	lomo	sapi	ens											
55	<400	)> 3	3													

	Gln	Val	Gln	Leu	G1n	Gln	Ser	Gly	Pro	Glu	Leu	Glu	Lys	Pro	Gly	Ala
5	1				5					10					15	
10	Ser	Val	Lys	Ile 20	Ser	Cys	Lys	Ala	Ser 25	Gly	Tyr	Ser	Phe	Ser 30	Asp	Tyr
15	Asn	Met	Asn 35.	Trp	Val	Lys	Gln'	Ser 40	Asn	Gly	Lys	Ser	Leu 45	Glu	Trp	Ile
20	Gly	Asn 50	Ile	Asp	Pro	Tyr	Asn 55	Gly	Asp	Thr	Asn	Tyr 60	Asn	G1n	Lys	Phe
25																
		Gly	Lys	Ala	Thr		Thr	Leu	Asp	Lys		Ser	Ser	Thr	Ala	
30	65					70					75					80
35	Met	G1n	Leu	Lys	Ser 85	Leu	Thr	Ser	G1u	Asp 90	Ser	Ala	Val	Tyr	Phe 95	Cys
40	Ala	Arg	Ser	Arg 100	Gly	Trp	Leu	Leu	Pro 105	Phe	Ala	Tyr	Trp	Gly 110	Gln	Gly
45	Thr	Leu	Val	Thr	Val	Ser	Ala									
50			110													
	<210	)> 4	1													
EE																
55	<211	) 1	108													

	<212	2> 1	PRT													
5	<213	3> 1	Homo	sapi	iens											
	<400	)> 4	4													
10	Asp	Ile	Leu	Met	Thr	Gln	Ser	Gln	Lys	Phe	Met	Ser	Thr	Ser-	Val	G1y
	1				5					10					15	
15													, -			
	Asp	Arg	Val	Ser	Val	Thr	Cys	Lys		Ser	G1n	Asn	Val		Ile	Asn
20				20					25					30		
			_		0.1	0.1	<b>.</b>	Б.	0.1	01	G	D	T	4.7	T	т1.
25	Val	Ala	Trp	Tyr	GIn	Gln	Lys		Gly	GIn	Ser	Pro		Ala	Leu	116
20			35					40					45			
	Tvr	Ser	Ala	Ser	Tvr	Arg	Tvr	Ser	Glv	Val	Pro	Asp	Arg	Phe	Thr	G1y
30	- 3 -	50			•	J	5 <b>5</b>		-			60				
35	Ser	Gly	Ser	Gly	Thr	Asp	Phe	Thr	Leu	Thr	Ile	Ser	Asn	Val	Gln	Ser
	65					70					75					80
40													•			
	Glu	Asp	Leu	Ala	Glu	Tyr	Phe	Cys	Gln	Gln	Tyr	Asn	Ser	Tyr	Pro	Leu
45					85					90					95	
50	Thr	Phe	Gly	G1y	Gly	Thr	Lys	Leu		Ile	Lys	Arg				
				100					105							
55	/C1	2.	_		٠			,								
55	<210	J>	5													

	<211	.>	117													
_	<212	<b>!&gt;</b> ]	PRT													
5	<213	\$> ]	Homo	sap	iens											
10	<400	)> !	5											-		
	Gln	Val	Gln	Leu	Gln	G1n	Ser	Gly	Pro	Glu	Leu	Val	Arg	Pro	Gly	Val
15	1				5					10					15	
,,																
	Ser	Val	Lys	Ile	Ser	Cys	Lys	Gly	Ser	Gly	Tyr	Thr	Phe	Thr	Asp	Tyr
20			•	20		-	•		25					30		
25	Δla	٦١a	His	Trn	Va1	Arø	Gln	Ser	His	Ala	G1 n	Ser	Leu	Glu	Trp	Ile
	AIG	116	35	пр	741	ni 5	JIII	40	1115		01	501	45	014		
			33					10					10			
30	0.1	17 1	τ1.	C1	TL	Т	C	C1	<b>1</b> an	Ana	Aan	Тугъ	\ an	Gln.	Lvo	Pho
	Gly		Ile	GIY	ınr	lyr		GIY	ASII	Arg	ASII		ASII	GIII	Lys	rne
35		50					55					60				
								_		_						_
	Lys	Gly	Lys	Ala	Thr	Met	Thr	Val	Asp	Lys	Ser	Ser	Ser	Thr	Ala	Tyr
40	65					70					75					80
45	Met	Glu	Leu	Ala	Arg	Leu	Thr	Ser	Glu	Asp	Ser	Ala	Ile	Tyr	Tyr	Cys
					85					90					95	
50																
50	Ala	Arg	Ser	Ala	Gly	Tyr	Ser	Leu	Asp	Phe	Trp	Gly	Gln	Gly	Thr	Ser
				100					105					110		

	Val Thr Va	.1 Ser Se	er				
5	11	5					
	<210> 6						
10	<211> 112	;					
	<212> PRT	•					
15	<213> Hom	o sapien	ıs				
	<400> 6						
20	Asp Val Va	1 Met Th	nr Gln Thr	Pro Leu Th	r Leu Ser	Val Thr Ile Gl	у
	1	5		10		15	
25							
	Gln Pro Al	a Ser Il	le Ser Cys	Lys Ser Se	r Gln Ser	Leu Leu Asp Se	r
30		20		25		30	
	Asp Gly Ly	s Thr Ty	r Leu Asn	Trp Leu Le	u Gln Arg	Pro Gly Gln Se	r
35	35	5		40		<b>4</b> 5	
40	Pro Ive Ar	o Len II	le Tvr Leu	Val Ser Lv	rs Leu Asp	Ser Gly Val Pr	0.
	50	3	55	•	60	·	
45							
	Asp Arg Ph	ne Thr G	ly Ser Gly	Ser Gly Th	nr Asp Phe	Thr Leu Lys Il	.e
50	65		70		75	80	)
	Ser Arg Va	al Glu Al	la Glu Asp	Leu Gly Va	al Tyr Tyr	Cys Trp Gln Gl	Ĺу
55		8!	5	90	)	95	

5	Lys	His	Phe	Pro 100	Trp	Thr	Phe	Gly	Gly 105	Gly	Thr	Lys	Leu	Glu 110	Ile	Lys
10	<210 <211		7 119													
15	<212	2> :	PRT Homo	sapi	iens											
20	<400	o> '	7													
25	Gln 1	Val	Gln	Leu	Gln 5	Gln	Ser	Gly	Gly	Glu 10	Leu	Val	Arg	Pro	Gly 15	Thr
30	Ser	Val	Lys	Val 20	Ser	Cys	Lys	Ala	Ser 25	Gly	Tyr	Ala	Phe	Thr	Asn	Tyr
35	Leu	Ile	Glu	Trp	Ile	Arg	Gln		Pro	Gly	G1n	Gly		G1u	Trp	Ile
40			35					40					45			
45	Gly	Val 50	Ile	Asn	Pro	Gly	Ser 55	Gly	Asn	Ser	Lys	Ser 60	Ser	Lys	Asn	Leu
50	Lys 65	Gly	Lys	Ala	Thr	Leu 70	Thr	Ala	Asp	Lys	Ser 75	Ser	Asn	Thr	Ala	Tyr 80
55	Met	Gln	Leu	Ser	Ser	Leu	Thr	Ser	Asp	Asp	Ser	Ala	Val	Tyr	Phe	Cys

		85	90	95
5	Ala Arg Ser Gly	Val Tyr Gly Ser	Ser Pro Asp Tyr Ti	rp Gly Gln Gly
10	100		105	110
15	Thr Thr Leu Thr	Val Ser Ser		
	Z210\			
20	<210> 8 <211> 113			
25	<212> PRT <213> Homo sapi	ens		
30	<400> 8	m al m p		1 71 01
35	Asp val val met	5	Leu Thr Leu Ser Va	15
40	Gln Pro Ala Ser 20	Ile Ser Cys Lys	Ser Ser Gln Ser Le	eu Leu Asp Ser 30
45	Asp Gly Lys Thr	Tyr Leu Asn Trp	Leu Leu Gln Arg Pr 45	
50	Pro Lys Arg Leu	Ile Tyr Leu Val	Ser Lys Leu Asp Se	er Gly Val Pro

	Asp Ar	g Phe	Thr	Gly	Ser	Gly	Ser	Gly	Thr	Asp	Phe	Thr	Leu	Lys	Ile
5	65				70					75					80
10	Ser Ar	g Val	Glu	Ala 85	Glu	Asp	Leu	G1y	Val 90	Tyr	Tyr	Cys	Trp	Gln 95	Gly
15	Thr Hi	s Phe	Pro	Gln	Thr	Phe	Gly	Gly 105	Gly	Thr	Lys	Leu	Glu 110	Ile	Lys
20	Arg														
25															
35	<210><211><211><212><213>	9 118 PRT Homo	sap	iens											
40	<400> Gln Va	9 1 Gln	Leu	Gln 5	Gln	Ser	Gly	Gly	Glu 10	Leu	Val	Arg	Pro	Gly 15	Thr
45	Ser Va	l Lys		Ser	Cys	Lys	Ala	Ser 25	Gly	Tyr	Ala	Phe	Thr	Asn	Tyr
50	Leu Il	e G111	20 Trn	Val	[.vs	Gln	Arg		G1v	Gln	Glv	Leu		Trp	Ile
55	Dog 11	35	111	,41	בינם	0111	40	110	01)	J.11	,	45		- <b>- P</b>	

5	Gly		Ile	Asn	Pro	Gly		Gly	Gly	Thr	Lys	Cys	Asn	Lys	Lys	Phe
		50					55					60				
10	Lvo	G1 <sub>37</sub>	Two	Va 1	Thr	Lou	Thr	Λla	Acn	Lvo	Sor	Sor	Sor	ፐኬኮ	۸1۵	Тиг
		ату	Lys	Val	1111	Leu	1111	на	АЅР	Lys		ser	Sel	1111	нта	
	65					70					75					80
15																
	Met	His	Leu	Ser	Ser	Leu	Thr	Ser	Asp	Asp	Ser	Ala	Val	Tyr	Phe	Cys
20					85					90					95	
20																
	Ala	Arg	Ser	Gly	Trp	Val	Ser	Ala	Met	Asp	Tyr	Trp	Gly	Gln	G1y	Thr
25				100					105					110		
00	Sar	Val	Thr	Val	Sor	Sar										
30	561	741		141	Del	561										
			115													
35																
	<210	)> ]	.0													
	<211	> 1	13													
40	<212	> F	PRT													
	<213	> F	lomo	sapi	ens											
45																
	<400	> 1	.0													
	Asp	Ile	Val	Met	Thr	Gln	Thr	Pro	Leu	Thr	Leu	Ser	Val	Thr	Ile	Gly
50	1				5					10					15	
	_				-											
55	C1	D-	<b>4</b> 1	C	т 1	C	<b>C</b>	<b>T</b>	C	C	C1	c	7	т.	<b>A</b> .	<b>C</b>
	Gln	Pro	Ala	Ser	116	Ser	Cys	Lys	Ser	Ser	Gln	Ser	Leu	Leu	Asp	Ser

				20					25					30		
5																
	Asp	Gly	Lys	Thr	Tyr	Leu	Asn	Trp	Leu	Leu	Gln	Arg	Pro	Gly	Gln	Ser
			35					40					45			
10																
	Pro	Lys	Arg	Leu	Ile	Tyr	Leu	Val	Ser	Lys	Leu	Asp	Ser	Gly	Val	Pro
15		50					55					60				
	Asp	Arg	Phe	Thr	G1y	Ser	G1y	Ser	Gly	Thr	Asp	Phe	Thr	Leu	Lys	Ile
20	65					70					75					80
25	Ser	Arg	Val	Glu	Ala	Glu	Asp	Leu	Gly	Val	Tyr	Tyr	Cys	Trp	Gln	Gly
					85					90					95	
30																
	Thr	His	Phe	Pro	Gln	Thr	Phe	Gly	Gly	Gly	Thr	Lys	Leu	Glu	Leu	Lys
				100					105					110		
35																
	Arg															
40	6															
	<210		1 1													
45																
	<211		118													
50	<212															
	<213	3>	Ното	sap	iens											
55	<400	)>	11													

	Gln	Val	Gln	Leu	Gln	Gln	Ser	Gly	Val	Glu	Leu	Val	Arg	Pro	Gly	Thr
5	1				5					10					15	
10	Ser	Val	Lys	Val 20	Ser	Cys	Lys	Ala	Ser 25	Gly	Tyr	Ala	Phe	Thr 30	Asn	Tyr
15	Leu	Ile	Glu 35	Trp	Val	Lys	Gln	Arg 40	Pro	Gly	Gln	Gly	Leu 45	Asp	Trp	Ile
20	G1y	Met 50	Ile	Asn	Pro	Gly	Ser 55	Gly	Gly	Thr	Lys	Cys 60	Asn	Lys	Lys	Phe
25																
	Lys	Gly	Lys	Val	Thr	Leu	Thr	Ala	Asp	Lys	Ser	Ser	Ser	Thr	Ala	Tyr
						70					75					80
30	65					10					13				•	
35		His	Leu	Ser	Ser 85		Thr	Ser	Asp	Asp 90		Ala	Val	Tyr	Phe 95	
	Met		Leu Ser		85	Leu				90	Ser				95	Cys
35	Met Ala	Arg	Ser Thr	Gly 100	85 Trp	Leu Val			Met	90	Ser			Gln	95	Cys
<i>35 40</i>	Met Ala Ser	Arg Val	Ser Thr 115	Gly 100	85 Trp	Leu Val			Met	90	Ser			Gln	95	Cys
<i>35 40</i>	Met Ala	Arg Val	Ser Thr	Gly 100	85 Trp	Leu Val			Met	90	Ser			Gln	95	Cys

	<212	2> ]	PRT													
5	<213	3> 1	Homo	sapi	iens											
	<400	)> :	12													
10	Asp	Val	Leu	Met	Thr	Gln	Thr	Pro	Leu	Thr	Leu	Ser	Val	Thr	Ile	G1y
	1				5					10					15	
15																
	Gln	Pro	Ala	Ser	Ile	Ser	Cys	Lys	Ser	Ser	Gln	Ser	Leu	Leu	Asp	Ser
20				20					25					30		
		01	<b>T</b>	mi .	т	T	A	Т	T	I	C1	۸	D	C1	C1-	C
25	Asp	GIÀ	Lys 35	Inr	lyr	Leu	ASN	1rp 40	Leu	Leu	GIII	Arg	45	GIY	GIII	Set
			50					10					10			
30	Pro	Lys	Arg	Leu	Ile	Tyr	Leu	Val	Ser	Lys	Leu	Asp	Ser	Gly	Val	Pro
		50					55					60				
05																
35	Asp	Arg	Phe	Thr	Gly	Ser	Gly	Ser	Gly	Thr	Asp	Phe	Thr	Leu	Lys	Ile
	65					70					75					80
40																
	Ser	Arg	Val	Glu		Glu	Asp	Leu	Gly		Tyr	Tyr	Cys	Trp		Gly
45					85					90					95	
	Thr	Hie	Phe	Pro	Gln	Thr	Phe	Glv	Glv	G1 v	Thr	Lvs	Leu	Glu	Leu	Lvs
50	1111	1110	1 110	100	<b>0</b> 211		11.9	01)	105	,		,-		110		-,-
55	Arg															

5	<210	>	13													
	<211	>	117									-				
10	<212	>	PRT													
	<213	> .	Ното	sapi	iens											
15																
	<400	>	13													
20	Gln	Val	Gln	Leu	G1n	Gln	Ser	Gly	Pro	Glu	Leu	Val	Arg	Pro	Gly	Val
20	1				5					10					15	
25	Ser	Val	Lys	Ile	Ser	Cys	Lys	Gly	Ser	Gly	Tyr	Arg	Phe	Thr	Asp	Tyr
				20					25					30		
30																
	Ala	Ile	His	Trp	Val	Lys	Gln	Ser	His	Ala	Lys	Ser	Leu	Glu	Trp	Ile
35			35					40					45			
	Gly	Val	Ile	Ser	Thr	Tyr	Tyr	Gly	Asn	Thr	Arg	Tyr	Asn	Gln	Lys	Phe
40		<b>50</b>					55					60				
45	Lys	Gly	Lys	Ala	Thr	Met	Thr	Val	Asp	Lys	Ser	Ser	Ser	Thr	Ala	Tyr
	65					70					75					80
50																
	Met	Glu	Leu	Ala	Ser	Leu	Thr	Ser	Glu	Asp	Ser	Val	Ile	Tyr	Tyr	Cys
					85					90					95	
55																

	Ala	Arg	Ser	Gly	G1y	Ser	Leu	Met	Asp	Tyr	Trp	Gly	G1n	Gly	Thr	Ser
5				100					105					110		
10	Val	Thr	Val	, Ser	Ser											
15	<210 <211		14 113												٠	
20	<212 <213		PRT Homo	sapi	ens											
25	<400		l4 Val	Met	Thr	Gln	Thr	Pro	Len	Thr	Leu	Ser	Val	Thr	Ile	Glv
30	1	110	,,,,	1100	5	5211				10					15	,
35	Gln	Pro	Ala	Ser 20	Ile	Ser	Cys	Lys	Ser 25	Ser	G1n	Ser	Leu	Leu 30	Asp	Ser
40	Asp	Gly	Lys 35	Thr	Tyr	Leu	Asn	Trp	Leu	Leu	Gln	Arg	Pro 45	Gly	Gln	Ser
45	Pro	Lys 50	Arg	Leu	Ile	Tyr	Leu 55	Val	Ser	Lys	Leu	Asp	Ser	Gly	Val	Pro
55	Asp 65	Arg	Phe	Thr	G1y	Ser 70	Gly	Ser	Gly	Thr	Asp 75	Phe	Thr	Leu	Lys	Ile 80

5	Ser Arg	Val	Glu	Ala 85	Glu	Asp	Leu	Gly	Val 90	Tyr	Tyr	Cys	Trp	Gln 95	Gly
10	Thr His	Phe	Pro	Tyr	Thr	Phe	Gly	Gly	Gly	Thr	Lys	Leu	Glu	Ile	Lys
			100					105					110		
15	Arg														
	m g														
20															
	<210>	15													
25	<211>	117													
	<212>	PRT													
30	⟨213⟩	Homo	sapi	iens											
	< <b>400</b> >	15													
35	Gln Val	Gln	Leu	Gln	Gln	Ser	Gly	Pro	G1u	Leu	Val	Arg	Pro	Gly	Val
	1			5					10					15	
40		_		~			0.1	~	9.7	_	m1	<b>5</b> 1	<b>7</b> 1		_
	Ser Val	Lys	11e 20	Ser	Cys	Lys	Gly	Ser 25	Gly	Tyr	Thr	Phe	30	Asp	Tyr
45			20					20							
	Ala Met	His	Trp	Val	Lys	Gln	Ser	His	Ala	Lys	Ser	Leu	Glu	Trp	Ile
50		35					40					45			
	01		9	m'i	<b></b>	<b></b>	<b>a</b>		m1		<b></b>		0.1	<b>.</b>	D1
55	Gly Val	lle	Ser	Inr	lyr	lyr	Ser	Asn	Thr	Arg	lyr	Asn	Gln	Lys	rne

	50	)				55					60				
5	Lys G]	ly Lys	Ala	Thr	Met	Thr	Val	Asp	Lys	Ser	Ser	Ser	Thr	Ala	Tyr
10	65				70					75					80
15	Met Gl	lu Leu	Ala	Arg 85	Leu	Thr	Ser	Glu	Asp	Ser	Ala	Ile	Tyr	Tyr 95	Cys
	Val Ar	rg Ser	Gly	Gly	Ser	Asn	Met	Asp	Tyr	Trp	Gly	Gln	Gly	Thr	Ser
20			100					105					110		
25	Val Th	nr Val 115	Ser	Ser											
30 .	<210>	16													
35	<211> <212>	113 PRT													
40	<213>	Homo	sapi	iens											
45	<400> Asp II	16 le Gln	Met	Thr	Gln	Thr	Pro	Leu	Thr	Leu	Ser	Val	Thr	Ile 15	Gly
50	Gln Pı	co Ala		Ile	Ser	Cys	Lys		Ser	Gln	Ser	Leu		Asp	Ser
			20					25					30		

	Asp	Gly	Lys	Thr	Tyr	Leu	Asn	Trp	Leu	Leu	Gln	Arg	Pro	Gly	Gln	Ser
			35					40					45			
5																
	Dwo	Lva	Ara	Lou	T1.	Тугъ	Lou	Va1	Sor	Lvc	Ī 611	Acn	Sar	G1v	Val	Pro
	rro		Arg	Leu	116	1 9 1		Val	261	ГАР	Leu		261	Uly	vai	110
10		50					55					60				
15	Asp	Arg	Phe	Thr	Gly	Ser	Gly	Ser	Gly	Thr	Asp	Phe	Thr	Leu	Lys	Ile
	65					70					75					80
20	Ser	Arg	Val	Glu	Ala	Glu	Asp	Leu	Gly	Val	Tyr	Tyr	Cys	Trp	Gln	Gly
		J			85		-			90					95	
05					00					50						
25												_	_			_
	Thr	His	Phe	Pro	Trp	Thr	Phe	Gly	Gly	Gly	Thr	Lys	Leu	Glu	Ile	Lys
30				100					105					110		
	Arg															
35																
40	<210		17													
	<211		117													
45	<212	2> 1	PRT													
	<213	3> 1	Homo	sapi	ens											
50	<400	)> :	17													
	Gln	Val	Gln	Leu	G1n	Gln	Ser	Gly	Pro	Glu	Leu	Val	Arg	Pro	Gly	Val
55	1				5					10					15	
	-				-											

5	Ser	Val	Lys	Ile	Ser	Cys	Lys	Gly	Ser	Ser	Tyr	Lys	Phe	Thr	Asp	Tyr
				20					25					30		
10	Ala	Met	His	Trp	Val	Lys	G1n	Ser	His	Ala	Lys	Ser	Leu	Glu	Trp	Ile
	•		35					40					45			
15																
	Gly	Val	Ile	Ser	Thr	Tyr	Tyr	Gly	Asn	Val	Lys	Tyr	Asn	Gln	Lys	Phe
20		50					55					60				
	Lys	Gly	Lys	Ala	Thr	Met	Thr	Val	Asp	Lys	Ser	Ser	Ser	Thr	Ala	Tyr
25	65					70					75					80
30	Met	Glu	Leu	Ala	Arg	Leu	Thr	Ser	Glu	Asp	Ser	Ala	Val	Tyr		Cys
					85					90					95	
35							_	_			_					_
	Ala	Arg	Ser		Gly	Ser	Tyr	Leu		Tyr	Trp	Gly	Gln		Thr	Ser
				100					105					110		
40		mi.	** 1		0											
	Val	Thr	Val	Ser	Ser										•	
45			115													
	<210	1	18													
50	<21		113													
	<21:		PRT													
55	<213		Homo	C C TY	iona											
	/41,	)/	иощо	sap.	16112											

_	<400	)> :	18													
5	Asp	Ile	Val	Met	Thr	Gln	Thr	Pro	Leu	Thr	Leu	Ser	Val	Thr	Ile	G1y
	1				5					10					15	
10																
	G1n	Pro	Ala	Ser	Ile	Ser	Cys	Lys	Ser	Ser	Gln	Ser	Leu	Leu	Asp	Ser
15			-	20					25					30		
00	Asp	Gly	Lys	Thr	Tyr	Leu	Asn	Trp	Leu	Leu	Gln	Arg	Pro	Gly	Gln	Ser
20			35					40					45			
25 .	Pro	Lys	Arg	Leu	Ile	Tyr	Leu	Val	Ser	Lys	Leu	Asp	Ser	Gly	Val	Pro
		50					55					60				
30																
	Asp	Arg	Phe	Thr	Gly	Ser	G1y	Ser	Gly	Thr	Asp	Phe	Thr	Leu	Lys	Ile
35	65					70					<b>7</b> 5					80
	Ser	Arg	Val	Glu	Ala	Glu	Asp	Leu	Gly	Val	Tyr	Tyr	Cys	Trp	Gln	Gly
40					85					90					95	
													_			_
45	Thr	His	Phe		Tyr	Thr	Phe	Gly		Gly	Thr	Lys	Leu		Ile	Lys
				100					105					110		
50																
	Arg															

	<210> 19	
_	<211> 119	
5	<212> PRT	
	<213> Homo sapiens	
10		
	<400> 19	
15	Gln Val Gln Leu Gln Gln Ser Gly Ala Glu Leu Val Arg Pro Gly Th	r
	1 5 10 15	
20		
	Ser Val Lys Val Ser Cys Lys Ala Ser Gly Tyr Ala Phe Thr Asn Ty	r
05	20 25 30	
25		
	Leu Ile Glu Trp Val Lys Gln Arg Pro Gly Gln Gly Pro Glu Trp Il	е
30	35 40 45	
	Gly Val Ile Asn Pro Gly Ser Gly Asn Ile Arg Tyr Asn Gly Lys Ph	e
35	50 55 60	•
40	Lys Gly Lys Ala Thr Leu Thr Ala Asp Lys Ser Ser Ser Thr Ala Ty	r
	65 70 75 80	
45		
	Met Gln Leu Ser Ser Leu Thr Ser Asp Asp Ser Ala Val Tyr Phe Cy	s
	85 90 95	
50		
	Ala Arg Asp Ala Tyr Tyr Val Gly Ala Met Asp Tyr Trp Gly Gln Gl	у
55	100 105 110	

5	Thr Se	er Val 115		Val	Ser	Ser									
10	<210>	20							-						
15	<211> <212>	PRT		•											
20	<213> <400>	Homo	sap.	iens											
25	Asp Va		Met	Thr 5	Gln	Thr	Pro	Leu	Thr	Leu	Ser	Val	Thr	Ile 15	G1y
30	Gln Pr	o Ala	Ser	Ile	Ser	Cys	Lys	Ser	Ser	G1n	Ser	Leu	Leu	Asp	Ser
			20					25					30		
35	Asp Gl	y Lys 35	Thr	Tyr	Leu	Asn	Trp	Leu	Leu	Gln	Arg	Pro 45	G1y	Gln	Ser
40	Dro Lu		T	Tla	T	Lou		°	T	I ou	A		C1	Vo 1	D-s
45	Pro Ly		Leu	iie	lyr	55	vai	ser	Lys	Leu	60	ser	СТА	Val	rro
50	Asp Ar	g Phe	Thr	-	Ser 70	Gly	Ser	Gly	Thr	Asp 75	Phe	Thr	Leu	Lys	Ile
55	Ser Ar	g Val	Glu	Ala	Glu	Asp	Leu	Gly	Val	Tyr	Tyr	Cys	Trp	Gln	G1y

Thr His Phe Pro Gln Thr Phe Gly Gly Gly Thr Lys Leu Glu Leu Lys Arg ⟨210⟩ <211> <212> PRT ⟨213⟩ Homo sapiens <400> 21 Gln Val Gln Leu Gln Gln Ser Glu Ala Glu Leu Val Arg Pro Glu Thr Ser Val Lys Val Ser Cys Lys Ala Ser Gly Tyr Ser Phe Arg Asn Tyr Leu Ile Glu Trp Val Lys Gln Arg Pro Gly Gln Gly Leu Glu Trp Ile 

Gly Val Ile Asn Pro Gly Ser Gly Asn Thr Lys Tyr Asn Glu Lys Phe

	Lys Gly Lys	s Ala Thr	Leu Thr	Ala Asp Lys	Ser Ser Ser	Thr Ala Tyr
5	65		70		75	80
10	Met Gln Le	ı Ser Ser 85	Leu Thr	Ser Asp Asp 90	Ser Ala Val	Tyr Phe Cys
15	Ala Arg Asp	Gly Tyr	Tyr Leu	Gly Thr Met	Asp Tyr Trp	Gly Gln Gly
20	Thr Ser Val		Ser Ser			
25	115	•				
<i>30</i>	<210> 22 <211> 113 <212> PRT <213> Homo	sapiens				
40	<400> 22 Asp Ile Val	Leu Thr	Gln Thr	Pro Leu Thr	Leu Ser Val	Thr Ile Gly
45			Ser Cys	Lys Ser Ser 25	Gln Ser Leu	
55	Asp Gly Lys	Thr Tyr	Leu Asn	Trp Leu Leu	Gln Arg Pro 45	Gly Gln Ser

5	Pro	Lys	Arg	Leu	Ile	Tyr	Leu	Val	Ser	Lys	Leu	Asp	Ser	Gly	Val	Pro
		50					55					60				
10	Asp	Arg	Phe	Thr	Gly	Ser	Gly	Ser	Gly	Thr	Asp	Phe	Thr	Leu	Lys	Ile
	65					70					75					80
15						•										
	Ser	Arg	Val	G1u	Ala	Glu	Asp	Leu	Gly	Val	Tyr	Tyr	Cys	Trp	Gln	Gly
20					85					90					95	
	Thr	His	Phe	Pro	Tyr	Thr	Phe	Gly	Gly	Gly	Thr	Lys	Leu	Glu	Ile	Lys
25				100					105					110		
30	Arg															
35																
33	<210	)> :	23													
	<211	l>	119													
40	<212	2> :	PRT													
	<213	3>	Homo	sap	iens											
45																
	<400	)>	23													
	Gln	Val	Gln	Leu	Gln	Gln	Ser	Gly	Ala	Glu	Leu	Val	Arg	Pro	Gly	Thr
50	1				5					10					15	
55	Ser	Val	Lys	Val	Ser	Cys	Lys	Ala	Ser	Gly	Tyr	Ala	Phe	Ile	Asn	Asn

				20					25					30		
5	Leu	Ile	Glu	Trp	Val	Gln	Gln	Arg	Pro	Gly	Gln	Gly	Leu	Glu	Trp	Ile
			35					40					45			
10																
	Gly	Val	Ile	Asn	Pro	Gly	Ser	Gly	Asn	Val	Lys	Tyr	Asn	G1u	Lys	Phe
15		50					55					60				
	Lys	Gly	Lys	Ala	Thr	Leu	Thr	Ala	Asp	Lys	Ser	Ser	Ser	Thr	Ala	Tyr
20	65					70					75					80
25	Met	Gln	Leu	Ser	Ser	Leu	Thr	Ser	Asp	Asp	Ser	Ala	Val	Tyr	Phe	Cys
					85					90					95	
30	_				_											
	Ala	Arg	Asp	Gly	Tyr	Tyr	Leu	Gly		Met	Asp	His	Trp		Gln	Gly
35				100					105					110		
	Thr	Sor	V=1	Thr	Val	Sar	Sor									
40	1111	001	115		741	DUI	Der									
			110													
45	<210	> 2	24													
	<211	> 1	.13													
	<212	> F	PRT													
50	<213	> E	Iomo	sapi	ens											
55	<400	> 2	24													

	Asp	Val	Val	Met	Thr	Gln	Thr	Pro	Leu	Thr	Leu	Ser	Val	Thr	Ile	Gly
5	1				5					10					15	
10	Gln	Pro	Ala	Ser 20	Ile	Ser	Cys	Lys	Ser 25	Ser	Gln	Ser	Leu	Leu 30	Asp	Ser
15	Asp	Gly	Lys 35	Thr	Tyr	Leu	Asn	Trp	Leu	Leu	Gln	Arg	Pro 45	Gly	Gln	Ser
20	Pro	Lys 50	Arg	Leu	Ile	Tyr	Leu 55	Val	Ser	Lys	Leu	Asp	Ser	Gly	Val	Pro
25																
	Asp	Arg	Phe	Thr	G1y	Ser	Gly	Ser	Gly	Thr	Asp	Phe	Thr	Leu	Lys	Ile
30	65					70					75					80
35	Ser	Arg	Val	Glu	Ala 85	G1u	Asp	Leu	Gly	Ile 90	Tyr	Tyr	Cys	Trp	Gln 95	Gly
40	Thr	His	Phe	Pro 100	Trp	Thr	Phe	Gly	Gly 105	Gly	Thr	Lys	Leu	Glu 110	Leu	Lys
45	Arg															
50																
	<210		25													
55	<21	1>	117													

	<212	2> 1	PRT													
5	<213	3> 1	Homo	sapi	iens											
	<400	)> :	25													
10	Glu	Val	Gln	Leu	G1n	Gln	Ser	Gly	Pro	Glu	Leu	Val	Arg	Pro	Gly	Val
	1				5					10					15	
15					-											
	Ser	Val	Lys	Ile	Ser	Cys	Lys	Gly	Ser	Ser	Tyr	Lys	Phe	Thr	Asp	Tyr
20				20					25					30		
	Ala	Met	His	Trp	Val	Lys	Gln	Ser	His	Ala	Lys	Ser	Leu	Glu	Trp	Ile
25			35					40					45			
30	Gly	Val	Ile	Ser	Thr	Tyr	Tyr	Gly	Asn	Val	Lys	Tyr	Asn	Gln	Lys	Phe
		50					55					60				
35															_	
	Lys	Gly	Lys	Ala	Thr		Thr	Val	Asp	Lys		Ser	Ser	Thr	Ala	
	65					70					75					80
40			_				<b></b>		0.1		C	4.7	17 1	Т	Т	C
	Met	Glu	Leu	Ala		Leu	Thr	Ser	Glu		Ser	Ala	vaı	1.yr		Cys
45					85					90					95	
	Ala	Ara	Ser	Tur	G1 v	Ser	Tvr	Leu	Asp	Tvr	Trp	Glv	Gln	G1v	Thr	Ser
50	niα	111.6	DCI	100	01)	501	- , -	204	105	-,-		,		110		
				100												
55	Val	Thr	Val	Ser	Ser											

5	<210	>	26													
	<211	>	112													
10	<212	> :	PRT													
	<213	> :	Homo	sapi	iens											
15																
	<400	> :	26													
	Asp	Ile	Val	Met	Thr	Gln	Thr	Pro	Leu	Thr	Leu	Ser	Val	Thr	Ile	Gly
20	1				5					10					15	
25	Gln	Pro	Ala	Ser	Ile	Ser	Cys	Lys	Ser	Ser	Gln	Ser	Leu	Leu	Asp	Ser
	•			20					25					30		
30																
	Asp	Gly	Lys	Thr	Tyr	Leu	Asn	Trp	Leu	Leu	Gln	Arg	Pro	Gly	G1n	Ser
25			35					40					45			
35																
	Pro	Lys	Arg	Leu	Ile	Tyr	Leu	Val	Ser	Lys	Leu	Asp	Ser	Gly	Val	Pro
40		50					55					60				
45	Asp .	Arg	Phe	Thr	G1y	Ser	Gly	Ser	Gly	Thr	Asp	Phe	Thr	Leu	Lys	Ile
	65					70					75					80

Ser Arg Val Glu Ala Glu Asp Leu Gly Val Tyr Tyr Cys Trp Gln Gly

	Thr Hi	s Phe Pro Trp Thr Phe G	Gly Gly Gly Thr Ly	s Leu Glu Ile Lys	
5		100	105	110	
	<210>	27		_	
10	<211>	22			
	<212>	DNA			
15	<213>	Artificial			
	<220>				
20	<223>	an artificially synthe	esized primer sequ	ence	
25	<400>	27			
	cagcta	tgaa atacctattg cc			22
30					
	<210>	28			
05	<211>	23			
35	<212>	DNA			
	<213>	Artificial			
40					
	<220>				
45	<223>	an artificially synthe	esized primer sequ	ence	
	<400>	28			
50	cttttc	ataa tcaaaatcac cgg			23
55	<210>	29			

	<211>	19	
F	<212>	DNA	
5	<213>	Artificial	
10	<220>		
	<223>	an artificially synthesized primer sequence	
15			
	<400>	29	
	attgcc	tacg gcagccgct	19
20			
	<210>	30	
25	<211>	20	
	<212>	DNA	
30	<213>	Artificial	
	<220>		
35	<223>	an artificially synthesized primer sequence	
40	<400>	30	
	aaatca	ccgg aaccagagcc	20
45			
	<210>	31	
	⟨211⟩	24	
50	<212>	DNA	
	<213>	Artificial	

	<220>		
5	<223>	an artificially synthesized primer sequence	
	<400>	31	
10	ttacto	egcgg cccagccggc catg	24
15	<210>	32	
	<211>	28	
00	<212>	DNA	
20	<213>	Artificial	
25	<220>		
	<223>	an artificially synthesized primer sequence	
30			
	<400>	32	
35	ggaatt	egge eccegaggee cacteacg	28
	<210>	33	
40	<211>	1215	
	<212>	DNA	
45	<213>	Homo sapiens	
	<400>	33	
50	ggcctc	gggg gccagctttc tggggcaggc caggcctgac cttggctttg gggcagggag	60
<i>55</i>	ggggct	aagg tgaggcaggt ggcgccagcc aggtgcacac ccaatgccca tgagcccaga	120

5	cactggacgc	tgaacctcgc	ggacagttaa	gaacccaggg	gcctctgcgc	cctgggccca	180
10	gctctgtccc	acaccgcggt	cacatggcac	cacctctctt	gcagcttcca	ccaagggccc	240
	atccgtcttc	ccctggcgc	cctgctccag	gagcacctcc	gagagcacag	ccgccctggg	300
15	ctgcctggtc	aaggactact	tccccgaacc	ggtgacggtg	tcgtggaact	caggcgccct	360
20	gaccagcggc	gtgcacacct	tcccggctgt	cctacagtcc	tcaggactct	acteceteag	420
25	cagcgtggtg	accgtgccct	ccagcagctt	gggcacgaag	acctacacct	gcaacgtaga	480
30	tcacaagccc	agcaacacca	aggtggacaa	gagagttgag	tccaaatatg	gtcccccatg	540
35	cccaccatgc	ccagcacctg	agttcctggg	gggaccatca	gtcttcctgt	teccecaaa	600
	acccaaggac	actctcatga	tctcccggac	ccctgaggtc	acgtgcgtgg	tggtggacgt	660
40	gagccaggaa	gaccccgagg	tccagttcaa	ctggtacgtg	gatggcgtgg	aggtgcataa	720
45	tgccaagaca	aagccgcggg	aggagcagtt	caacagcacg	taccgtgtgg	tcagcgtcct	780
50	caccgtcctg	caccaggact	ggctgaacgg	caaggagtac	aagtgcaagg	tetecaacaa	840
55	aggcctcccg	tcctccatcg	agaaaaccat	ctccaaagcc	aaagggcagc	cccgagagcc	900

5	acaggtgt	gc accetgeece	catcccagga	ggagatgacc	aagaaccagg	tcagcctgtg	960
10	gtgcctgg	tc aaaggcttct	accccagcga	catcgccgtg	gagtgggaga	gcaatgggca	1020
_	gccggaga	ac aactacaaga	ccacgcctcc	cgtgctggac	tccgacggct	ccttcttcct	1080
15	ctacagca	gg ctaaccgtgg	acaagagcag	gtggcaggag	gggaatgtct	tctcatgctc	1140
20	cgtgatgc	at gaggctctgc	acaaccacta	cacacagaag	agcetetece	tgtctctggg	1200
25	taaatgag	cg gccgc					1215
30	<210> 3	4					
	<211> 6	84					
0.5	<212> D	NA					
35	<213> H	omo sapiens					
40	<400> 3	4					
	ggcctcgg	gg gccgaattcc	taaactctga	gggggtcgga	tgacgtggcc	attctttgcc	60
45	taaagcat	tg agtttactgc	aaggtcagaa	aagcatgcaa	agccctcaga	atggctgcaa	120
50	agagetee	aa caaaacaatt	tagaacttta	ttaaggaata	gggggaagct	aggaagaaac	180
<i>55</i>	tcaaaaca	tc aagattttaa	atacgcttct	tggtctcctt	gctataatta	tctgggataa	240

5	gcatgctgtt ttctgtctgt ccctaacatg ccctgtgatt atccgcaaac aacacacca	300
10	agggcagaac tttgttactt aaacaccatc ctgtttgctt ctttcctcag gaactgtggc	360
15	tgcaccatct gtcttcatct tcccgccatc tgatgagcag ttgaaatctg gaactgcctc	420
,,	tgttgtgtgc ctgctgaata acttctatcc cagagaggcc aaagtacagt ggaaggtgga	480
20	taacgccctc caatcgggta actcccagga gagtgtcaca gagcaggaca gcaaggacag	540
<i>25</i>	cacctacago otcagoagoa cootgaogot gagoaaagoa gaotaogaga aacacaaagt	600
30	ctacgcctgc gaagtcaccc atcagggcct gagctcgccc gtcacaaaga gcttcaacag	660
35	gggagagtgt tagagggcgg ccgc	684
	<210> 35	
40	<211> 1215	
	<212> DNA	
45	<213> Homo sapiens	
	<400> 35	
50	ggcctcgggg gcctcccagg ctctgggcag gcacaggcta ggtgccccta acccaggccc	60
55	tgcacacaaa ggggcaggtg ctgggctcag acctgccaag agccatatcc gggaggaccc	120

5	tgcccctgac	ctaagcccac	cccaaaggcc	aaactctcca	ctccctcagc	tcggacacct	180
10	tctctcctcc	cagattccag	taactcccaa	tettetetet	gcagcttcca	ccaagggccc	240
15	atccgtcttc	ccctggcgc	cctgctccag	gagcacctcc	gagagcacag	ccgccctggg	300
	ctgcctggtc	aaggactact	tccccgaacc	ggtgacggtg	tcgtggaact	caggcgccct	360
20	gaccagcggc	gtgcacacct	tcccggctgt	cctacagtcc	tcaggactct	actccctcag	420
25	cagcgtggtg	accgtgccct	ccagcagctt	gggcacgaag	acctacacct	gcaacgtaga	480
30	tcacaagccc	agcaacacca	aggtggacaa	gagagttgag	tccaaatatg	gtccccatg	540
35	cccaccatgc	ccagcacctg	agttcctggg	gggaccatca	gtcttcctgt	tcccccaaa	600
40	acccaaggac	actctcatga	tctcccggac	ccctgaggtc	acgtgcgtgg	tggtggacgt	660
	gagccaggaa	gaccccgagg	tccagttcaa	ctggtacgtg	gatggcgtgg	aggtgcataa	720
45	tgccaagaca	aagccgcggg	aggagcagtt	caacagcacg	taccgtgtgg	tcagcgtcct	780
50	caccgtcctg	caccaggact	ggctgaacgg	caaggagtac	aagtgcaagg	tctccaacaa	840
55	aggcctcccg	tcctccatcg	agaaaaccat	ctccaaagcc	aaagggcagc	cccgagagcc	900

5	acaggt	gtac	accetgeece	catcccagtg	cgagatgacc	aagaaccagg	tcagcctgtc	960
10	ctgcgcg	ggtc	aaaggcttct	atcccagcga	catcgccgtg	gagtgggaga	gcaatgggca	1020
45	gccgga	gaac	aactacaaga	ccacgcctcc	cgtgctggac	tccgacggct	ccttcttcct	1080
15	cgtgag	cagg	ctaaccgtgg	acaagagcag	gtggcaggag	gggaatgtct	tctcatgctc	1140
20	cgtgat	gcat	gaggctctgc	acaaccacta	cacacagaag	agcetetece	tgtctctggg	1200
25	taaatga	agcg	gccgc					1215
30	<210> <211>	36 21						
35	<212> <213>	DNA Arti	ificial					
40	<220> <223>	an a	artificiall	y synthesiz	ed primer s	equence <sub>.</sub>		
45	<400>	36						
50	cgcaaa	tggg	cggtaggcgt	g				21
	<210>	37						
55	<211>	18						

	<212>	DNA	
5	<213>	Artificial	
	<220>		
10	<223>	an artificially synthesized primer sequence	
15	<400>	37	
	tagaag	gcac agtcgagg	18
20	<210>	38	
	<211>	24	
25	<212>	DNA	
	<213>	Artificial	
30			
	<220>		
35	<223>	an artificially synthesized primer sequence	
	<400>	38	
40	ctctga	atac tttcaacaag ttac	24
	<210>	39	
45	<211>	116	
	<212>	PRT	
50	<213>	Mus musculus	
55	<400>	39	

	Met	Glu	Val	Gln	Leu	Gln	Gln	Ser	Gly	Pro	Gly	Leu	Val	Lys	Pro	Thr
5	1				5					10					15	
10	Gln	Ser	Leu	Ser 20	Leu	Thr	Cys	Ser	Val 25	Thr	Gly	Tyr	Ser	Ile 30	Thr	Ser
15	Gly	Tyr	Tyr 35	Trp	Thr	Trp	Ile	Arg 40	Gln	Phe	Pro	Gly	Asn 45	Asn	Leu	Glu
20	Trp	Ile 50	Gly	Tyr	Ile	Ser	Phe 55	Asp	Gly	Thr	Asn	Asp	Tyr	Asn	Pro	Ser
25																
	Leu	Lys	Asn	Arg	Ile	Ser	Ile	Thr	Arg	Asp	Thr	Ser	Glu	Asn	G1n	Phe
30	65					70					75					80
35		Leu	Lys	Leu	Asn 85		Val	Thr	Thr	Glu 90		Thr	Ala	Thr	Tyr 95	
	Phe				85	Ser					Asp				95	Tyr
35	Phe Cys	Ala	Arg Ser	Gly 100	85	Ser			Tyr	90	Asp			Thr	95	Tyr
<i>35</i> 40	Phe Cys	Ala	Arg	Gly 100	85	Ser			Tyr	90	Asp			Thr	95	Tyr
35 40 45	Phe Cys	Ala Val	Arg Ser	Gly 100	85	Ser			Tyr	90	Asp			Thr	95	Tyr

	<212>	PRT											
5	<213>	Mus musc	ulus										
	<400>	40	•										
10	Ser Gl	y Tyr Tyr	Trp	Thr									
	1		5										
15													
	<210>	41											
00	<211>	16											
20	<212>	PRT											
	<213>	Mus musci	ılus										
25													
	<400>	41											
30	Tyr Ile	e Ser Phe	Asp	Gly	Thr A	Asn As	зр Туг	Asn	Pro	Ser	Leu	Lys	Asn
	1		5				10					15	
35	<210>	42											
	<211>	6											
40	<212>	PRT ·											
	<213>	Mus musc	ılus										
45				-									
	<400>	42											
	Gly Pro	o Pro Cys	Thr	Tyr									
50	1		5										
55	<210>	43											

	<211	1> :	120													
5	<212	2> I	PRT													
J	<213	3> N	Mus r	nuscu	ılus											
10	<400	)> 4	<del>1</del> 3													
	Met	Gln	Val	Gln	Leu	Gln	Gln	Ser	Gly	Ala	Glu	Leu	Val	Arg	Pro	Gly
15	1				5					10					15	
	Ala	Ser	Val	Lys	Leu	Ser	Cys	Thr	Ala	Ser	Gly	Phe	Asn	Ile	Lys	Asp
20				20					25					30		
25	Asp	Tyr	Val	His	Trp	Val	Lys	Gln	Arg	Pro	Glu	Gln	Gly	Leu	Glu	Trp
			35					40					45			
30																
	Ile	Gly	Arg	Ile	Asp	Pro	Ala	Asp	Gly	Lys	Thr	Lys	Tyr	Ala	Pro	Lys
		50					55					60				
35																
	Phe	Gln	Asp	Lys	Ala	Thr	Met	Thr	Ser	Asp	Thr	Ser	Ser	Asn	Thr	Ala
40	65					70					75					80
45	Tyr	Leu	G1n	Leu	Ser	Ser	Leu	Thr	Ser	Glu	Asp	Thr	Ala	Val	Tyr	Tyr
43					85					90					95	
50	Cys	Val	Arg	Trp	Arg	Ile	Tyr	Tyr	Gly	Leu	Met	Asp	Tyr	Trp	Gly	Gln
				100					105					110		

	Gly Th	r Ser Val	Thr Val S	Ser Ser				
5		115		120				
	<210>	44						
10	⟨211⟩	5						
	⟨212⟩	PRT						
<i>15</i>	⟨213⟩	Mus musc	ılus				·	
20	<400>	44						
20	Asp As	p Tyr Val	His					
	1		5					
25								
	<210>	45						
30	<211>	17						
	<212>	PRT						
35	<213>	Mus muscu	ılus					
	<400>	45						
40	Arg Ile	e Asp Pro	Ala Asp G	Gly Lys Thr	Lys Tyr	Ala Pro	Lys Phe Gl	ln
	1		5		10		15	
45	Asp							
50						÷		
	<210>	46						
55	<211>	10						

	<21	2>	PRT													
5	<21	3>	Homo	sap	iens											
	<40	0>	46													
10	Trp	Arg	Ile	Tyr	Tyr	Gly	Leu	Met	Asp	Tyr						
	1				5					10						
15																
	<21	0> -	47													
20	<21	1>	123								٠					
	<21	2> 1	PRT													
	<21	3> 1	Mus 1	musci	ulus											
25																
	<400	0> 4	47													
30	Met	Gln	Val	Gln	Leu	Gln	Gln	Ser	Gly	Pro	Glu	Leu	Val	Lys	Pro	Gly
	1				5					10					15	
35												-				
	Ala	Ser	Val		Met	Ser	Cys	Lys		Ser	Gly	Tyr	Thr		Thr	His
				20					25					30		
40			_		_					_						_
	Phe	Val		His	Trp	Val	Lys		Asn	Pro	Gly	Gln		Leu	Glu	Trp
45			35					40					45			
		01	TD.	T.1	T.1	D	Tr.			0.1	TI.	<b>T</b>	T.		0.1	,
50	11e		lyr	He	11e	Pro		Asn	Asp	Gly	inr		iyr	Asn	Glu	Lys
		50					55					60				
55	Dh.a	I	C1	T v	۸1۵	Thr	Lou	Thr	Son	Acr	I we	Sor	Son	S~~	Th⊷	۸1.
55	1 116	ьyS	ara	⊥yS	ula	TIIT	Leu	1117	OCT.	ush	∟y S	OGT.	OGT.	OGI.	Thr	VIS

Tyr Met Glu Leu Ser Ser Leu Thr Ser Glu Asp Ser Ala Val Tyr Tyr Cys Ala Arg Gly Asn Arg Tyr Asp Val Gly Ser Tyr Ala Met Asp Tyr Trp Gly Gln Gly Thr Ser Val Thr Val Ser Ser <210> <211> <212> PRT <213> Mus musculus <400> 48 His Phe Val Leu His <210> <211> <212> PRT <213> Mus musculus <400> 49

	Tyr Ile Ile	Pro	Tyr	Asn	Asp	Gly	Thr	Lys	Tyr	Asn	Glu	Lys	Phe	Lys
5	1		5					10					15	
10	Gly													
15	<210> 50	÷												
20 .	<211> 13 <212> PRT <213> Mus n	nuscu	ılus											
25	<400> 50													
30	Gly Asn Arg	Tyr	Asp 5	Val	Gly	Ser	Tyr	Ala 10	Met	Asp	Tyr			
35	<210> 51 <211> 117													
40	<212> PRT <213> Mus m	uscu	lus											
45	<400> 51 Met Gln Val	Gln	Leu	Gln	Gln	Ser	Gly	Ala	Glu	Leu	Val	Lys	Pro	Gly
50	1		5					10					15	
55	Ala Ser Val	Lys 20	Leu	Ser	Cys	Thr	Val	Ser	G1y	Phe	Asn	Ile 30	Gln	Asp

5	Asn	Tyr	Met	His	Trp	Val	Lys	Gln	Arg	Pro	Glu	Gln	Gly	Leu	Glu	Trp
			35					40					45			
10	Ile	G1y	Arg	Ile	Asp	Pro	Ala	Asn	Gly	Asn	Thr	Arg	Tyr	Asp	Pro	Lys
		50					55					60				
15																
	Phe	Gln	Gly	Lys	Ala	Thr	Ile	Thr	Ala	Asp	Ile	Ser	Ser	Asn	Thr	Thr
20	65					70					75					80
20																
	Cys	Leu	Gln	Leu	Ser	Ser	Leu	Thr	Ser	Glu	Asp	Thr	Ala	Val	Tyr	Tyr
25					85					90					95	
30	Cys	Ala	Ser	Pro	Tyr	Tyr	Pro	Leu	Gly	Cys	Trp	Gly	Gln	Gly	Thr	Leu
				100					105					110		
35																
	Val	Thr	Val	Ser	Ala											
			115													
40																
	<210	)> {	52													
45	<211	i> !	5													
	<212	2> 1	PRT				٠						-			
50	<213	3> 1	Mus 1	nusci	ılus											
50																
	<400	)> ;	52													
55	Asp	Asn	Tyr	Met	His											

1 5 5 <210> 53 <211> 17 <212> PRT <213> Mus musculus 15 <400> 53 Arg Ile Asp Pro Ala Asn Gly Asn Thr Arg Tyr Asp Pro Lys Phe Gln 20 **5** . 1 10 15 25 Gly 30 <210> 54 <211> 7 35 <212> PRT <213> Mus musculus 40 <400> 54 Pro Tyr Tyr Pro Leu Gly Cys 45 1 5 50 <210> 55 <211> 116

<212> PRT

<213> Mus musculus

-																
5	<400	0> {	55													
	Met	Gln	Val	G1n	Leu	Gln	Gln	Ser	Gly	Pro	Glu	Leu	Val	Lys	Pro	G1y
10	1				5					10					15	
15	Ala	Ser	Val	Lys 20	Ile	Ser	Cys	Lys	Thr 25	Ser	Gly	Tyr	Thr	Phe	Thr	Glu
20	Asn	Thr		Tyr	Trp	Val	Lys		Ser	His	Gly	Lys		Leu	Glu	Trp
25			35					40					45			
	Ile	Gly	Ser	Ile	Thr	Thr	Tyr	Asn	Gln	Lys	Phe	Lys	Asp	Lys	Ala	Thr
30		50					55					60				
	Leu	Thr	Ile	Asp	Lys	Ser	Ser	Ser	Ser	Ala	Tyr	Met	Glu	Leu	Arg	Ser
35	65					70					75					80
40	Leu	Thr	Ser	Glu		Ser	Ala	Val	Tyr		Cys	Ala	Arg	Ser		Gly
					85					90					95	
45	Arg	Gly	Lys	Pro	Tyr	Tyr	Phe	Asp	Ser	Trp	Gly	Gln	Gly	Thr	Thr	Leu
50				100					105					110		
	Thr	Val	Ser	Ser												
55			115													

5	₹2102	90								
	<211>	5								
	<212>	PRT								
10	<213>	Mus mus	culus							
15	<400>	56								
	Glu As:	n Thr Ile	e Tyr							
20	1		5							
	<210>	57								
25	<211>	11								
	<212>	PRT								
30	<213>	Mus muse	culus							
35	<400>	57								
	Ser Ile	e Thr Thi	r Tyr	Asn	Gln	Lys	Phe	Lys	Asp	
	1		5					10		
40										
	<210>	58								
45	<211>	12								
	<212>	PRT								
50	<213>	Mus musc	culus							
	<400>	58								
55	Ser Gly	y Gly Arg	g Gly	Lys	Pro	Tyr	Tyr	Phe	Asp	Ser

	1	5	10
5	. (010)		
	<210> 59		
	<211> 117		
10	<212> PRT		
	<213> Mus muscu	lus	
15			
	<400> 59		
	Met Gln Val Gln	Leu Gln Gln Ser Gl	ly Ser Glu Leu Val Lys Pro Gly
20	1	5	10 15
25	Ala Ser Val Lys	Leu Ser Cys Thr Al	la Ser Gly Phe Asn Ile Lys Asp
	20	25	5 30
20			
30	Asn Tyr Met His	Trp Ile Lys Gln Aı	rg Pro Glu Gln Gly Leu Glu Trp
	35	40	45
35	•		
	Tle Glv Arg Tle	Asp Pro Gly Asp G	ly Asn Ser Arg Tyr Asp Pro Lys
40	50	55	60
	30	33	
	DI 01 01 I	A1 (7) T1 (7) A	1. A. Thu Can Can Am The Ale
45	Phe Gln Gly Lys		la Asp Thr Ser Ser Asn Thr Ala
	65	70	75 80
50	·		
50	Tyr Leu Gln Leu	Ser Ser Leu Thr S	er Glu Asp Thr Ala Val Tyr Tyr
		85	90 95

	Cys Ala Ser Pr	o Tyr Tyr Pr	o Leu Gly Tyr	Trp Gly Gln	Gly Thr Leu
5	10	0	105		110
·					
	Val Thr Val Se	r Ala			
10	115		•		
15	<210> 60				
	<211> 5				
20	<212> PRT				
20	<213> Mus mus	culus			
25	<400> 60				
	Asp Asn Tyr Met	t His			
30	1	5			
35	<210> 61				
55	<211> 17				
	<212> PRT				
40	<213> Mus musc	culus			
45	<400> 61				
	Arg Ile Asp Pro	Gly Asn Gly	Asn Ser Arg	Tyr Asp Pro	Lys Phe Gln
50	1	5	10		15
50					
	Gly				
55	-				

5	(210) 62
	<211> 7
	<212> PRT
10	<213> Mus musculus
15	<400> 62
	Pro Tyr Tyr Pro Leu Gly Tyr
20	_1
	⟨210⟩ 63
25	<211> 114
	<212> PRT
30	<213> Mus musculus
0.5	<400> 63
35	Met Gln Val Gln Leu Gln Gln Ser Gly Ala Glu Leu Val Arg Pro Gly
	1 5 10 15
40	
	Ala Ser Val Lys Leu Ser Cys Thr Val Ser Gly Phe Asn Ile Lys Asp
45	20 25 30
50	Asp Tyr Ile His Trp Val Lys Gln Arg Pro Glu Gln Gly Leu Glu Trp
50	35 40 45
55	Ile Gly Arg Ile Asp Pro Thr Asn Gly Asn Pro Ala Tyr Ala Pro Lys

	50	)				55					60				
5	Phe G1	n Asn	Ive	Ala	Thr	ΤΊρ	Thr	Ala	Asn	Thr	Sar	Ser	Tlo	Thr	Δ1a
	65	qea ii.	Lys	Ala	70	116	1111	Ala	кър	75	Set	261	116	1111	80
10	65				70					10					80
	Tyr Le	u Gln	Leu	Asn	Ser	Leu	Thr	Ser	Glu	Asp	Thr	Ala	Val	Tyr	Tyr
15				85					90					95	
20	Cys Th	r Gly	Ser	Phe	Ala	Tyr	Trp	G1y	Gln	Gly	Thr	Leu	Val	Thr	Val
20			100					105					110		
25	Ser Al	a													
30															·
	<210>	64													
	<211>	5													
35	<212>	PRT													
	<213>	Mus n	แนรดเ	ılus											
40															
	<400>	64													
45	Asp As	p Tyr	Ile	His											
	1			5											
50	<210>	65													
	<211>	17													
55	(212)	PRT													

	<213>	Mus m	uscu	ılus											
5	<400>	65													
	Arg Il		Pro	Thr	Asn	Gl v	Asn	Pro	Ala	Tvr	Ala	Pro	Lvs	Phe	Gln
10	1	- ·p		5		,			10	- , _			-,-	15	
15	Asp														
00															
20	<210>	66													
	<211>	4													
25	<212>	PRT													
	<213>	Mus m	uscu	lus											
30															
	<400>	66													
25	Ser Ph	e Ala ′	Tyr											-	
35	1														
40	<210>	67													
	<211>	114													
45	<212>	PRT													
	<213>	Mus m	uscu	lus											
50	<400>	67													
	Met Gl	n Val (	Gln	Len	Gln	G1n	Ser	Glv	Ala	Glu	Len	Val	Arg	Pro	Glv

55 1

5	Ala	Ser	Val		Leu	Ser	Cys	Thr		Ser	Gly	Phe	Asn		Lys	Asp
				20					25					30		
10	Asp	Tyr	Val	His	Trp	Val	Lys	Gln	Arg	Pro	Glu	G1n	Gly	Leu	Glu	Trp
			35					40					45			
15						_			~ 1			0.1	<b></b>	4.7		
	Ile		Arg	lle	His	Pro	Ala	Asn	Gly	Asn	Pro		lyr	Ala	Pro	Lys
20		50					55					60				
	Phe	Gln	Asp	Lys	Ala	Thr	Ile	Ile	Ile	Gly	Thr	Ala	Ser	Asn	Thr	Thr
25	65					70					75					80
30	Tyr	Leu	Gln	Leu	Ser	Ser	Leu	Thr	Ser	Glu	Asp	Thr	Ala	Val	Tyr	Tyr
					85					90				•	95	
35	Cva	Λla	G1v	Pro	Pho	Δla	Tyr	Trn	G1v	G1n	Glv	Thr	Len	Val	Thr	Val
	Cys	пта	dly	100		MIG	1 9 1	пр	105	OIII	OI,	1111	Вса	110	1111	
40				100					100							
	Ser	Ala														
45																
	<210	)> (	68													
50	<21	1>	5													
	<21	2> ]	PRT													
55	<21	3> ]	Mus	musc	ulus											

5	<400>	68													
	Asp As	р Туг	· Val	His											
	1			5											
10															
	<210>	69													
15	<211>	17													
	<212>	PRT													
00	<213>	Mus	muscu	ulus											
20															
	<400>	69													
25	Arg Il	e His	Pro	Ala	Asn	G1y	Asn	Pro	Gln	Tyr	Ala	Pro	Lys	Phe	Gln
	1			5					10					15	
30															
	Asp														
35															
	<210>	70													
40	<211>	4													
	<212>	PRT													
45	⟨213⟩	Mus	muscu	ılus											
	<400>	70													
50	Pro Ph	e Ala	Tyr												
	1														

	<210	)>	71													
5	<21	1>	116													
	<212	2> ]	PRT													
	<213	3> 1	Mus	musci	ulus											
10																
	<400	)> ′	71													
15	Met	Glu	Val	Gln	Leu	Gln	Glu	Ser	Gly	Pro	G1y	Leu	Val	Lys	Pro	Ser
	1				5					10					15	
20																
20	Gln	Ser	Leu	Ser	Leu	Thr	Cys	Ser	Val	Thr	Gly	Tyr	Ser	Ile	Thr	Ser
				20					25					30		
25																
	Asn	Tyr	Tyr	Trp	Asn	Trp	Ile	Arg	Gln	Phe	Pro	Gly	Asn	Lys	Leu	Glu
30			35					40					<b>4</b> 5			
										-						
<i>35</i>	Trp	Met	Gly	Tyr	Ile	Asn	Tyr	Asp	Gly	Ser	Asn	Asn	Tyr	Asn	Pro	Ser
00		50					55					60				
40	Leu	Lys	Asn	Arg	Ile	Ser	Ile	Ser	Arg	Asp	Thr	Ser	Lys	Asn	G1n	Phe
	65					70					75					80
45																
	Phe	Leu	Lys	Leu	Asn	Ser	Val	Thr	Thr	Glu	Asp	Thr	Ala	Thr	Tyr	Tyr
50					85					90					95	
00																
	Cys	Ala	Arg	Gly	Gly	Ala	Phe	Thr	Tyr	Trp	Gly	Gln	Gly	Thr	Leu	Val
55				100					105					110		

5	Thr Va	l Ser Ala												
		115												
10	<210>	72												
	<211>	6												
15	<212>	PRT												
	<213>	Mus musc	ulus											
20														
20	<400>	72												
	Ser As	n Tyr Tyr	Trp	Asn										
25	1		5											
30	<210>	73												
	<211>	16												
	<212>	PRT												
35	<213>	Mus musc	ılus											
40	<400>	73												
	Tyr Ile	e Asn Tyr	Asp	Gly	Ser	Asn	Asn	Tyr	Asn	Pro	Ser	Leu	Lys	Asn
45	1		5					10					15	
	<210>	74												
50	<211>	6												
	<212>	PRT												
<i>55</i>	<213>	Mus musci	ılus											

5	<400>	> 7	74														
	Gly G	31y	Ala	Phe	Thr	Tyr											
	1				5												
10																	
	<210>	7	'5														
15	<211>	1	14														
	<212>	· F	PRT														
20	<213>	· M	lus n	nusci	ılus												
20																	
	<400>	. 7	5														
25	Met G	ln	Val	G1n	Leu	Gln	Gln	Ser	Gly	Pro	G1u	Leu	Val	Lys	Pro	Gly	
	1				5					10					15		
30																	
	Ala S	er	Val	Lys	Ile	Ser	Cys	Lys	Ala	Ser	Gly	Tyr	Thr	Ile	Thr	Asp	
05				20					25					30			
35																	
	Asn L	ys	Met	Asp	Trp	Val	Lys	Gln	Ser	His	Gly	Lys	Ser	Leu	Glu	Trp	
40			35					40					45				
45	Ile G	ly	Tyr	Ile	Ser	Pro	Asn	Asn	Gly	Asp	Ile	Gly	Tyr	Asn	Arg	Lys	
	5	0					55					60					
50																	
50	Phe A	rg	Asn	Lys	Ala	Thr	Leu	Thr	Val	Asp	Lys	Ser	Ser	Ser	Thr	Ala	
	65					70					75					80	
55																	

Tyr Met Glu Leu His Ser Leu Thr Ser Glu Asp Ser Ala Val Tyr Tyr 90 95 85 5 Cys Ala Arg His Arg Ala Tyr Trp Gly Gln Gly Thr Leu Val Thr Val 10 110 100 105 Ser Ala 15 20 <210> 76 <211> 5 25 <212> PRT <213> Mus musculus 30 <400> 76 Asp Asn Lys Met Asp 35 5 <210> 77 40 <211> 17 <212> PRT 45 Mus musculus <213> 50 <400> 77 Tyr Ile Ser Pro Asn Asn Gly Asp Ile Gly Tyr Asn Arg Lys Phe Arg

1

55

5

10

5	Asn														
10	<210>	78													
	<211>	4													
15	<212>	PRT												-	
	<213>	Mus	nusc	ulus											
20															
20	<400>	78													
	His Ar	g Ala	Tyr												
25	1														
30	<210>	79													
	<211>	121													
35	<212>	PRT													
55	<213>	Musn	nusci	ulus											
	(100)	<b>5</b> 0													
40	<400>	79	<b>C</b> 1	T	W. 1	<b>61</b>	C	C1	C1	C1	T	W - 1	T	D	01-
	Met Asp	o Val	GIn		val	GIU	Ser	GIA		GIY	Leu	vai	Lys		GT?
45	1			5					10					15	
	Gly Son	c Lou	Luc	Lou	Sor	Cvc	Δla	Λla	Sor	G1 w	Pho	ፐኬሎ	Pho	Sor	The
50	Gly Se	Leu	20	Leu	261	Cys	пта	25	261	OIÀ	1 116	TIIT	30	261	1111
			۷۷					20					30		

Tyr Ala Met Ser Trp Val Arg Gln Thr Pro Glu Lys Arg Leu Glu Trp

			35					40					45			
5	Val	Ala	Tyr	Ile	Ser	Asn	Gly	Gly	Ala	Asn	Thr	Tyr	Tyr	Pro	Asp	Ser
		50					55					60				
10																
	Val	Lys	G1y	Arg	Phe	Thr	Ile	Ser	Arg	Asp	Asn	Ala	Lys	Asn	Thr	Leu
15	65					70					75					80
20	Tyr	Leu	<b>Gl</b> n	Met	Ser	Ser	Leu	Arg	Ser	Glu	Asp	Thr	Ala	Leu	Tyr	Tyr
20					85					90					95	
25	Cys	Ala	Arg	Gly	Gly	Tyr	Arg	Tyr	Pro	Tyr	Ala	Met	Asp	Tyr	Trp	Gly
				100					105					110		
30																
	Gln	Gly		Ser	Val	Thr	Val	Ser	Ser							-
35			115					120								
	<210	3 <0	80													
40	<21	1> !	5													
	<21	2> ]	PRT													
45	<213	3> 1	Mus ı	musc	ulus											
	<40	0> 8	80													
50	Thr	Tyr	Ala	Met	Ser											
	1				5											

	<210>	81										
5	<211>	17										
	<212>	PRT										•
	<213>	Mus muscu	ılus									
10												
	<400>	81										
15	Tyr Ile	Ser Asn	Gly Gly	Ala Asn	Thr	Tyr	Tyr	Pro	Asp	Ser	Val	Lys
	1		5			10					15	
20												
	Gly											
25												
	<210> 8	82										
30	⟨211⟩	11										
	<212> I	PRT										
35	<213> N	Mus muscu	lus									
33			•									
	<400> 8	32										
40	Gly Gly	Tyr Arg	Tyr Pro	Tyr Ala	Met	Asp	Tyr					
	1		5			10						
45												
50												

#### Claims

15

20

30

35

40

45

50

- 1. A bispecific antibody that substitutes for the effect of a functional protein.
- A bispecific antibody that has an activity of functionally substituting for a ligand of a heteromolecule-comprising receptor.
  - 3. The antibody according to claim 2, wherein said heteromolecule-comprising receptor is a dimer.
- 10 4. The antibody according to claim 2, wherein said receptor is a cytokine receptor.
  - 5. The antibody according to claim 4, wherein said cytokine receptor is an interferon receptor.
  - 6. The antibody according to claim 5, wherein said interferon receptor is a type I interferon receptor.
  - 7. The antibody according to claim 6, wherein said type I interferon receptor comprises an AR1 chain and an AR2 chain.
  - **8.** The antibody according to claim 7, wherein said antibody functionally substitutes for an interferon which is a ligand of a type I interferon receptor.
  - 9. The antibody according to claim 8, wherein said antibody comprises the variable region of an anti-AR1 chain antibody and the variable region of an anti-AR2 chain antibody.
- 10. The antibody according to claim 9, wherein said antibody comprises an anti-AR1 chain antibody variable region comprising the amino acid sequence of (a) below and an anti-AR2 chain antibody variable region comprising the amino acid sequence of any of the following (b1) to (b10):
  - (a) the H chain variable region amino acid sequence described in SEQ ID NO: 1 and the L chain variable region amino acid sequence described in SEQ ID NO:2;
  - (b1) the H chain variable region amino acid sequence described in SEQ ID NO: 7 and the L chain variable region amino acid sequence described in SEQ ID NO: 8;
  - (b2) the H chain variable region amino acid sequence described in SEQ ID NO: 9 and the L chain variable region amino acid sequence described in SEQ ID NO: 10;
  - (b3) the H chain variable region amino acid sequence described in SEQ ID NO: 19 and the L chain variable region amino acid sequence described in SEQ ID NO: 20;
  - (b4) the H chain variable region amino acid sequence described in SEQ ID NO: 13 and the L chain variable region amino acid sequence described in SEQ ID NO: 14;
  - (b5) the H chain variable region amino acid sequence described in SEQ ID NO: 23 and the L chain variable region amino acid sequence described in SEQ ID NO: 24;
  - (b6) the H chain variable region amino acid sequence described in SEQ ID NO: 5 and the L chain variable region amino acid sequence described in SEQ ID NO: 6;
  - (b7) the H chain variable region amino acid sequence described in SEQ ID NO: 17 and the L chain variable region amino acid sequence described in SEQ ID NO: 18;
  - (b8) the H chain variable region amino acid sequence described in SEQ ID NO: 15 and the L chain variable region amino acid sequence described in SEQ ID NO: 16;
  - (b9) the H chain variable region amino acid sequence described in SEQ ID NO: 21 and the L chain variable region amino acid sequence described in SEQ ID NO: 22;
  - (b10) the H chain variable region amino acid sequence described in SEQ ID NO: 11 and the L chain variable region amino acid sequence described in SEQ ID NO: 12.
  - 11. The antibody according to claim 9, wherein said antibody comprises an anti-AR1 chain antibody variable region comprising the amino acid sequence of (a) below or an anti-AR2 chain antibody variable region comprising the amino acid sequence of any of the following (b1) to (b3):
    - (a) the H chain variable region amino acid sequence described in SEQ ID NO: 3 and the L chain variable region amino acid sequence described in SEQ ID NO: 4;
    - (b1) the H chain variable region amino acid sequence described in SEQ ID NO: 25 and the L chain variable region amino acid sequence described in SEQ ID NO: 26;

- (b2) the H chain variable region amino acid sequence described in SEQ ID NO: 9 and the L chain variable region amino acid sequence described in SEQ ID NO: 10;
- (b3) the H chain variable region amino acid sequence described in SEQ ID NO: 21 and the L chain variable region amino acid sequence described in SEQ ID NO: 22.

5

- 12. A composition comprising the antibody according to any one of claims 2 to 11 and a pharmaceutically acceptable carrier.
- **13.** The composition according to claim 12, wherein said composition is a pharmaceutical composition used for preventing and/or treating viral disease, malignant neoplasm, or immune disease.
  - **14.** The composition according to claim 13, wherein said viral disease is a disease that arises and/or progresses as a result of hepatitis C virus infection.
- 15. The composition according to claim 14, wherein the disease that arises and/or progresses as a result of hepatitis C virus infection is acute or chronic hepatitis C, cirrhosis, or liver cancer.
  - **16.** The composition according to claim 13, wherein said viral disease is a disease that arises and/or progresses as a result of hepatitis B virus infection.

20

50

- 17. The composition according to claim 16, wherein the disease that arises and/or progresses as a result of hepatitis B virus infection is acute or chronic hepatitis B, cirrhosis, or liver cancer.
- 18. The composition according to claim 13, wherein the malignant neoplasm is chronic myelocytic leukemia, malignant melanoma, multiple myeloma, renal cancer, gliosarcoma, medulloblastoma, astrocytoma, hairy cell leukemia, AIDS-related Kaposi's sarcoma, skin T lymphoma, or non-Hodgkin's lymphoma.
  - 19. The composition according to claim 13, wherein the immune disease is multiple sclerosis.
- 20. A method for preventing and/or treating viral disease, malignant neoplasm, or immune disease, comprising the step of administering the antibody according to any one of claims 2 to 11, or the composition according to any one of claims 12 to 19.
- **21.** Use of the antibody according to any one of claims 2 to 11 for producing the composition according to any one of claims 12 to 19.
  - 22. A kit used in the method of preventing and/or treating diseases according to claim 20, wherein said kit comprises at least the antibody according to any one of claims 2 to 11, or the composition according to claim 12.
- **23.** An antibody recognizing both an enzyme and a substrate thereof, wherein said antibody is a bispecific antibody which functionally substitutes for a cofactor that enhances the enzymatic reaction.
  - 24. The antibody according to claim 23, wherein said enzyme is a proteolytic enzyme.
- **25.** The antibody according to claim 24, wherein said proteolytic enzyme, substrate, and cofactor are blood coagulation/ fibrinolysis associated factors.
  - 26. The antibody according to claim 25, wherein the enzyme of a blood coagulation/fibrinolysis associated factor is blood coagulation factor IX and/or activated blood coagulation factor IX; the substrate is blood coagulation factor X; and the cofactor is blood coagulation factor VIII and/or activated blood coagulation factor VIII.
  - 27. The antibody according to any one of claims 23 to 26, wherein said antibody comprises a complementarity determining region comprising the amino acid sequence of anti-blood coagulation factor IX/IXa antibody CDR3 of the following (a1) or (a2) or a complementarity determining region functionally equivalent thereto, and a complementarity determining region comprising the amino acid sequence of anti-blood coagulation factor X antibody CDR3 described in any one of the following (b1) to (b9) or a complementarity determining region functionally equivalent thereto:
    - (a1) H chain CDR3 amino acid sequence described in SEQ ID NO: 42;

```
(a2) H chain CDR3 amino acid sequence described in SEQ ID NO: 46;
(b1) H chain CDR3 amino acid sequence described in SEQ ID NO: 50;
(b2) H chain CDR3 amino acid sequence described in SEQ ID NO: 54;
(b3) H chain CDR3 amino acid sequence described in SEQ ID NO: 58;
(b4) H chain CDR3 amino acid sequence described in SEQ ID NO: 62;
(b5) H chain CDR3 amino acid sequence described in SEQ ID NO: 66;
(b6) H chain CDR3 amino acid sequence described in SEQ ID NO: 70;
(b7) H chain CDR3 amino acid sequence described in SEQ ID NO: 74;
(b8) H chain CDR3 amino acid sequence described in SEQ ID NO: 78;
(b9) H chain CDR3 amino acid sequence described in SEQ ID NO: 82.
```

15

20

25

35

45

50

28. The antibody according to any one of claims 23 to 26, wherein said antibody comprises a complementarity determining region comprising the amino acid sequences of anti-blood coagulation factor IX/IXa antibody CDR of the following (a1) or (a2) or a complementarity determining region functionally equivalent thereto, and a complementarity determining region comprising the amino acid sequence of anti-blood coagulation factor X antibody CDR described in any one of the following (b1) to (b9) or a complementarity determining region functionally equivalent thereto:

```
(a1) H chain CDR 1, 2, and 3 amino acid sequences described in SEQ ID NOs: 40, 41, and 42, respectively; (a2) H chain CDR 1, 2, and 3 amino acid sequences described in SEQ ID NOs: 44, 45, and 46, respectively; (b1) H chain CDR 1, 2, and 3 amino acid sequences described in SEQ ID NOs: 48, 49, and 50, respectively; (b2) H chain CDR 1, 2, and 3 amino acid sequences described in SEQ ID NOs: 52, 53, and 54, respectively; (b3) H chain CDR 1, 2, and 3 amino acid sequences described in SEQ ID NOs: 56, 57, and 58, respectively; (b4) H chain CDR 1, 2, and 3 amino acid sequences described in SEQ ID NOs: 60, 61, and 62, respectively; (b5) H chain CDR 1, 2, and 3 amino acid sequences described in SEQ ID NOs: 64, 65, and 66, respectively; (b6) H chain CDR 1, 2, and 3 amino acid sequences described in SEQ ID NOs: 68, 69, and 70, respectively; (b7) H chain CDR 1, 2, and 3 amino acid sequences described in SEQ ID NOs: 72, 73, and 74, respectively; (b8) H chain CDR 1, 2, and 3 amino acid sequences described in SEQ ID NOs: 76, 77, and 78, respectively; (b9) H chain CDR 1, 2, and 3 amino acid sequences described in SEQ ID NOs: 80, 81, and 82; respectively.
```

- 29. A composition comprising the antibody according to any one of claims 23 to 28 and a pharmaceutically acceptable carrier.
  - **30.** The composition according to claim 29, wherein said composition is a pharmaceutical composition used for preventing and/or treating bleeding, disorder accompanied by bleeding, or disorder caused by bleeding.
  - 31. The composition according to claim 30, wherein the bleeding, disorder accompanied by bleeding, or disorder caused by bleeding is a disorder that arises and/or progresses as a result of an activity decrease or deficiency of blood coagulation factor VIII and/or activated blood coagulation factor VIII.
- **32.** The composition according to claim 31, wherein the disorder that arises and/or progresses as a result of an activity decrease or deficiency of blood coagulation factor VIII and/or activated blood coagulation factor VIII is hemophilia A.
  - **33.** The composition according to claim 31, wherein the disorder that arises and/or progresses as a result of an activity decrease or deficiency of blood coagulation factor VIII and/or activated blood coagulation factor VIII is a disorder in which an inhibitor against blood coagulation factor VIII and/or activated blood coagulation factor VIII is generated.
  - **34.** The composition according to claim 31, wherein the disorder that arises and/or progresses as a result of an activity decrease or deficiency of blood coagulation factor VIII and/or activated blood coagulation factor VIII is acquired hemophilia.
  - **35.** The composition according to claim 31, wherein the disorder that arises and/or progresses as a result of an activity decrease of blood coagulation factor VIII and/or activated blood coagulation factor VIII is von Willerbrand's disease.
- 36. A method for preventing and/or treating bleeding, disorder accompanied by bleeding, or disorder caused by bleeding, wherein said method comprises the step of administering the antibody according to any one of claims 23 to 28, or the composition according to any one of claims 29 to 35.
  - 37. Use of the antibody according to any one of claims 23 to 28 for preparing the composition according to any one of

claims 29 to 35.

	38.	A kit used in the method of preventing and/or treating disorders according to claim 36, wherein said kit comprises at least the antibody according to any one of claims 23 to 28 or the composition according to claim 29.
5		at least the antibody according to any one of claims 23 to 26 of the composition according to claim 29.
10		
15		
15		
20		
25		
30		
00		
35		
40		
45		
50		
55		
55		

FIG. 1




FIG. 2




FIG. 3




FIG. 4




FIG. 5




FIG. 6




FIG. 7





FIG. 8








FIG. 10




FIG. 11




FIG. 12





FIG. 13



## INTERNATIONAL SEARCH REPORT

International application No.
PCT/JP03/13123

A. CLASSIFICATION OF SUBJECT MATTER Int.Cl <sup>7</sup> Cl2N15/09, C07K16/18, A6: A61P35/00, A61P37/00	LK39/395, A61P7/00, A61P3	31/12,							
According to International Patent Classification (IPC) or to both	national classification and IPC								
B. FIELDS SEARCHED									
Minimum documentation searched (classification system followed by classification symbols) Int.Cl <sup>7</sup> C12N15/09, C07K16/18, A61K39/395, A61P7/00, A61P31/12, A61P35/00, A61P37/00									
Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched									
Electronic data base consulted during the international search (na JSTPlus (JOIS), MEDLINE (STN), WPI (	ume of data base and, where practicable, sea DIALOG), BIOSIS (DIALOG)	rch terms used)							
C. DOCUMENTS CONSIDERED TO BE RELEVANT									
Category* Citation of document, with indication, where	appropriate, of the relevant passages	Relevant to claim No.							
X FRANCOIS, C. et al., Constru Y antibody reacting with the A of the human IL-2 receptor. No.10, pages 4610 to 4619(19)	alpha- and beta-chains , J.Immunol., Vol.150,	1-4 5-19,21,22 23-35,37,38							
Y bispecific antibody molecul	LU, D. et al., Di-diabody: a novel tetravalent bispecific antibody molecule by design., J.Immunol.Methods, Vol.279, Nos.1 to 2, pages 219 to 232(2003 August)								
Y approach to production of b	LU, D. et al., Fab-scFv fusion protein: an efficient approach to production of bispecific antibody fragments., J.Immunol.Methods, Vol.267, No.2, pages 213 to 226(2002)								
X Further documents are listed in the continuation of Box C.	See patent family annex.								
* Special categories of cited documents:  "A" document defining the general state of the art which is not considered to be of particular relevance earlier document but published on or after the international filing date document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified) document referring to an oral disclosure, use, exhibition or other means  "P" document published prior to the international filing date but later than the priority date claimed  Date of the actual completion of the international search  10 November, 2003 (10.11.03)	"T" later document published after the interpriority date and not in conflict with the understand the principle or theory und document of particular relevance; the considered novel or cannot be considered novel or cannot be considered novel or cannot be considered to repeat the considered to involve an inventive sterp combined with one or more other such combination being obvious to a person document member of the same patent.  Date of mailing of the international sear 25 November, 2003	ne application but cited to erlying the invention claimed invention cannot be red to involve an inventive claimed invention cannot be to when the document is a documents, such a skilled in the art family							
Name and mailing address of the ISA/	Authorized officer								
Japanese Patent Office	Telephone No.								

Form PCT/ISA/210 (second sheet) (July 1998)

## INTERNATIONAL SEARCH REPORT

International application No.
PCT/JP03/13123

		T
ategory*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim N
Y	KIM, S.H. et al., Mammalian type I interferon receptors consists of two subunits: IFNaR1 and IFNaR2, Gene, Vol.196, Nos.1 to 2, pages 279 to 286(1997)	2-19,21,22
X A	SEGAL, D.M. et al., Introduction: bispecific antibodies., J.Immunol.Methods, Vol.248, Nos.1 to 2, pages 1 to 6(2001)	1 2-19,21-35, 37,38
X A	CARTER P., Bispecific human IgG by design., J.Immunol.Methods, Vol.248, Nos.1 to 2, pages 7 to 15(2001)	1 2-19,21-35, 37,38
		-

Form PCT/ISA/210 (continuation of second sheet) (July 1998)

## INTERNATIONAL SEARCH REPORT

International application No.
PCT/JP03/13123

Box I Observations where certain claims were found unsearchable (Continuation of item 1 of first sheet)
This international search report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:
1. X Claims Nos.: 20, 36  because they relate to subject matter not required to be searched by this Authority, namely:  They pertain to methods for treatment of the human body by therapy.
2. Claims Nos.:  because they relate to parts of the international application that do not comply with the prescribed requirements to such an extent that no meaningful international search can be carried out, specifically:
3. Claims Nos.:  because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).
Box II Observations where unity of invention is lacking (Continuation of item 3 of first sheet)
This International Searching Authority found multiple inventions in this international application, as follows:  Claims have: (1) inventions relating to "a bispecific antibody having an activity of substituting for the ligand function of a receptor containing heteromolecules" as set forth in claims 2 to 19, 21 and 22; and (2) inventions relating to "a bispecific antibody recognizing both of an enzyme and its substrate" as set forth in claims 23 to 35, 37 and 38.  These groups of inventions are common to each other in nothing but being a bispecific antibody (double specific antibody). As reported by the following documents 1 and 2, however, double specific antibodies had been publicly known before the application and thus cannot be (continued to extra sheet)
1. As all required additional search fees were timely paid by the applicant, this international search report covers all searchable claims.
2. X As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3. As only some of the required additional search fees were timely paid by the applicant, this international search report covers only those claims for which fees were paid, specifically claims Nos.:
4. No required additional search fees were timely paid by the applicant. Consequently, this international search report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:
Remark on Protest  The additional search fees were accompanied by the applicant's protest  No protest accompanied the payment of additional search fees.

Form PCT/ISA/210 (continuation of first sheet (1)) (July 1998)

#### INTERNATIONAL SEARCH REPORT

International application No.

PCT/JP03/13123

Continuation of Box No. II of continuation of first sheet(1)

considered as a special technical feature in accordance with PCT Rule 13.2. Thus, these groups of inventions are not considered as being so linked as to form a single general inventive concept. Such being the case, claims of the present case have 2 groups of inventions.

claims of the present case have 2 groups of inventions.

Document 1: J. Immunol., Vol.150, No.10, pp.4610-4619 (1993)

Document 2: J. Immunol Methods, Vol.248, No.1-2, pp.1-6 (2001)

Form PCT/ISA/210 (extra sheet) (July 1998)